A comparison of derivatisation procedures for the detection of multiple analytes in systematic forensic toxicology by Al-Ahmadi, Tareq Mohmmed
A  Comparison  of  Derivatisation  Procedures  for  the 
Detection  of  Multiple  Analytes  in  Systematic 
Forensic  Toxicology 
Thesis  submitted  in  Accordance  with  the 
Requirements  of  the  University  of  Glasgow  for 
the  Degree  of  Doctor  of  Philosophy 
by 
Tareq  Mohmmed  AL-Ahmadi 
BA  pp  Sc 
Department  of  Forensic  Medicine  and  Science 
August  2007 
Copyright  ©Tareq  AL-Ahmadi  2007 I 
Dedication 
For 
My  father  who  died  in  1997  (1418H),  whose  wish  it  was  to  see  me  graduate,  for  my 
mother  who  has  helped  me  and  supported  me  by  asking  God  to  help  me,  for  my  wife  and 
my  daughter  Rafeef  who  helped  me  a  lot,  also  to  my  uncle  Abdarahman  who  has  supported 
me  and  helped  me,  and  for  all  my  family. H 
Acknowledgements 
First,  I  would  like  to  thank  God  who  helped  me  and  supported  me  during  my  studies. 
I  would  like  to  thank  the  University  of  Glasgow  which  gave  me  the  chance  to  study  in  this 
field. 
I  would  like  to  thank  Dr  Anderson  for  his  support  and  guidance  as  supervisor  and  for 
giving  me  help  and  encouragement  to  continue  and  write  my  thesis. 
I  would  like  to  thank  Professor  John  S.  Oliver  and  Dr  John  Clark  who  reminded  me  of 
some  Arabic  words. 
I  would  like  to  thank  Dr  Fiona  Wylie  who  has  helped  me  fix  the  instruments  and  given  me 
support  and  advice  during  my  studies. 
Thanks  are  also  extended  to  the  staff  and  students  in  the  Department,  particularly  Dr  Hazel 
Torrance  who  helped  me  and  supported  me  a  lot,  and  Eleanor  and  Colin,  who  helped  me 
collect  the  samples. 
I  would  like  to  thank  my  brothers  and  my  family  for  their  assistance. 
Finally  I  would  like  to  thank  my  Government  for  supporting  me  financially  and  advising 
me  during  my  studies. Contents 
Contents 
Dedication  ....................................................................................................................... 
ii 
Summary 
.......................................................................................................................  vii 
List  of  Figures  ..................................................................................................................  a 
List  of  Tables  ...............................................................................................................  aiiF 
List  of  Abbreviations 
.....................................................................................................  av 
1  Introduction 
.............................................................................................................. 
1 
1.1  Toxicology 
......................................................................................................... 
1 
1.2  Systematic  Toxicological  Analysis  (STA) 
.......................................................... 
2 
1.3  Aims  and  Objectives 
........................................................................................... 
3 
2  Gas  Chromatography  -Mass  Spectrometry 
.......................................................... 
5 
2.1  Introduction 
........................................................................................................ 
5 
2.2  Chromatography:  Overview 
................................................................................ 
7 
2.2.1  Retention  time 
............................................................................................ 
8 
2.2.2  Distribution  constant  (Kn) 
........................................................................... 
8 
2.2.3  Column 
....................................................................................................... 
9 
2.2.4  Detectors 
.................................................................................................... 
9 
2.3  Gas  Chromatography 
........................................................................................ 
10 
2.3.1  Introduction 
.............................................................................................. 
10 
2.3.2  Injection  system:  ....................................................................................... 
10 
2.3.3  GC  Column: 
............................................................................................. 
11 
2.4  Mass  Spectrometry 
........................................................................................... 
13 
2.4.1  Introduction 
.............................................................................................. 
13 
2.4.2  Sample  inlet: 
............................................................................................. 
14 
2.4.3  Ion  Source: 
............................................................................................... 
14 
2.4.4  Mass  analyser:  .......................................................................................... 
17 
2.4.5  Detector: 
................................................................................................... 
18 
3  Drugs  of  Abuse:  Pharmacokinetics  and  Drug  Metabolism  ..................................  19 
3.1  Introduction 
...................................................................................................... 
19 
3.2  Introduction  to  some  pharmacological  concepts  ................................................ 
19 
3.2.1  Drug  metabolism  ...................................................................................... 
21 
3.2.2  Clearance 
.................................................................................................. 
23 
3.2.3  Plasma  half  -  life  (T%): 
.............................................................................. 
24 
3.3  Amphetamine  type  stimulants  ........................................................................... 
25 
3.4  Methamphetamine  ............................................................................................ 
26 
3.5  Cocaine 
............................................................................................................ 
27 
3.6  Opioids 
............................................................................................................. 
29 
3.7  Cannabis 
........................................................................................................... 
32 
4  Comparison  of  Derivatisation  Procedures 
............................................................  34 
4.1  Introduction  and  Aims 
...................................................................................... 
34 
4.2  Chemistry  of  Derivatisation  Reactions 
.............................................................. 
35 
4.2.1  Introduction 
.............................................................................................. 
3  5 
4.2.2  Silylation 
.................................................................................................. 
37 
4.2.3  Acylation 
.................................................................................................. 
39 
4.2.4  Alkylation 
................................................................................................. 
41 
4.2.5  Methylation  (esterification) 
....................................................................... 
42 Contents 
4.3  Microwave  assisted  derivatisation 
..................................................................... 
43 
4.4  Experimental  Section 
........................................................................................ 
43 
4.4.1  Reagents  and  materials  ............................................................................. 
43 
4.4.2  Drug  standards  and  internal  standards  ....................................................... 
45 
4.4.3  Derivatisation  procedures  .......................................................................... 
47 
4.4.4  Microwave  heating 
................................................................................... 
48 
4.4.5  Instrumental  methods  ................................................................................ 
48 
4.5  Results  and  Discussion 
..................................................................................... 
49 
4.5.1  Microwave  assisted  derivatisation  procedures  ........................................... 
49 
4.5.2  GC-MS  analysis  of  derivatives  of  model  compounds  ................................ 
53 
4.5.3  PFPA/PFP-OH  Derivatives: 
...................................................................... 
54 
4.5.4  PFPA/TMS-diazomethane  Derivatives: 
..................................................... 
64 
4.5.5  TBDMS  Derivatives: 
................................................................................ 
72 
4.6  Conclusions 
...................................................................................................... 
84 
5  Study  of  a  Unified  Method  ..................................................................................... 
86 
5.1  Introduction 
...................................................................................................... 
86 
5.2  Method  Validation  -  Introduction 
..................................................................... 
89 
5.3  General  Experimental  Section 
........................................................................... 
90 
5.3.1  Introduction 
.............................................................................................. 
90 
5.3.2  Preparation  of  drug  mixtures  ..................................................................... 
91 
5.3.3  Preparation  of  drug  mixtures  in  blood 
....................................................... 
92 
5.3.4  Preparation  of  buffer  solution  .................................................................... 
93 
5.3.5  Extraction  method:  SPE  on  StrataTm  X 
...................................................... 
93 
5.3.6  Derivatisation  ........................................................................................... 
93 
5.3.7  GC-MS  analysis  ........................................................................................ 
93 
5.3.8  Validation  parameters  ............................................................................... 
94 
5.3.9  Application  to  case  samples  ...................................................................... 
94 
5.4  Method  Validation  for  Drug  Derivatisation  with  PFPA-PFPOH 
....................... 
94 
5.4.1  Introduction 
.............................................................................................. 
94 
5.4.2  Linearity 
................................................................................................... 
94 
5.4.3  Intra-Day  variation  .................................................................................... 
98 
5.4.4  Inter-Day  variation  .................................................................................... 
99 
5.4.5  Recovery 
................................................................................................ 
101 
5.4.6  Limit  of  Detection  (LOD) 
....................................................................... 
102 
5.4.7  Limit  of  Quantitation  (LOQ) 
................................................................... 
103 
5.4.8  Application  to  real  case  samples  ............................................................. 
104 
5.4.9  Discussion 
.............................................................................................. 
107 
5.4.10  Conclusion 
.............................................................................................. 
111 
5.5  Method  validation  for  drug  derivatisation  with  PFPA  and  TMS-diazomethaneI  11 
5.5.1  Introduction 
............................................................................................ 
111 
5.5.2  Linearity 
................................................................................................. 
111 
5.5.3  Intra  -day  variation  ................................................................................. 
114 
5.5.4  Inter  -  day  variation  ................................................................................ 
115 
5.5.5  Recovery 
................................................................................................ 
117 
5.5.6  Limit  of  Detection  and  Limit  of  Quantification 
.......................................  118 
5.5.7  Application  to  real  case  samples  .............................................................  119 
5.5.8  Discussion 
.............................................................................................. 
122 
5.5.9  Conclusion 
.............................................................................................. 
124 
5.6  Method  validation  for  drug  derivatisation  with  MTBSTFA 
............................. 
124 
5.6.1  Introduction 
............................................................................................  124 
5.6.2  Linearity 
.................................................................................................  124 
5.6.3  Intra  -Day  Variation 
...............................................................................  126 Contents  vi 
5.6.4  Inter-Day  Variation 
.................................................................................... 
128 
5.6.5  Recovery 
.................................................................................................... 
129 
5.6.6  Limits  of  Detection  and  Quantification 
..................................................... 
130 
5.6.7  Application  to  real  cases  ............................................................................ 
130 
5.6.8  Discussion 
.................................................................................................. 
131 
5.6.9  Conclusion 
................................................................................................. 
133 
5.7  General  Discussion  and  Conclusions 
................................................................. 
133 
6  Gamma-Hydroxybutyric  Acid  and  Beta-Hydroxybutyric  Acid  .......................... 
137 
6.1  Introduction 
........................................................................................................ 
137 
6.2  GHB  and  BHB  in  the  body 
................................................................................ 
139 
6.2.1  Chemistry,  synthesis  and  pharmacokinetics  of  GHB 
................................. 
139 
6.2.2  Chemistry  and  pharmacokinetics  of  BHB 
.................................................. 
142 
6.2.3  Toxicity 
...................................................................................................... 
144 
6.2.4  Methods  of  Analysis  of  GHB  and  BHB  ..................................................... 
145 
6.2.5  Aims 
........................................................................................................... 
146 
6.3  Experimental  Section 
......................................................................................... 
146 
6.3.1  Chemicals  and  reagents  .............................................................................. 
146 
6.3.2  Standards 
.................................................................................................... 
147 
6.3.3  Preparation  of  standard  solutions  of  GHB 
................................................. 
147 
6.3.4  Preparation  of  standard  solutions  of  BHB  ................................................. 
148 
6.3.5  Extraction  method  based  on  SPE  clean  screen  .......................................... 
148 
6.3.6  Method  validation  for  GHB 
....................................................................... 
155 
6.3.7  Method  validation  for  BHB  ....................................................................... 
157 
6.4  Application  to  Case  Samples  ............................................................................. 
160 
6.5  Discussion 
.......................................................................................................... 
166 
6.6  Conclusion 
......................................................................................................... 
167 
7  Benzodiazepines  ....................................................................................................... 
168 
7.1  Introduction 
........................................................................................................ 
168 
7.2  Chemistry 
........................................................................................................... 
169 
7.3  Pharmacokinetics  of  benzodiazepines  ................................................................ 
171 
7.4  Methods  of  analysis  of  benzodiazepines  ............................................................ 
173 
7.5  Aims 
................................................................................................................... 
173 
7.6  Derivatisation  procedures  ................................................................................... 
174 
7.6.1  Reagents 
..................................................................................................... 
174 
7.6.2  Drug  standards  and  internal  standards  .......................................................  174 
7.6.3  Preparation  of  drug  mixtures  and  internal  standard  solutions  ....................  174 
7.6.4  Method  and  Results 
....................................................................................  175 
7.6.5  Discussion  ..................................................................................................  185 
7.7  Conclusion  .........................................................................................................  187 
8  Conclusions  and  Further  Work  ..............................................................................  189 
8.1  Conclusions 
........................................................................................................  189 
8.2  Further  work  .......................................................................................................  190 
9  References  .................................................................................................................  191 
Appendix  1:  Publication  in  support  of  this  thesis  .........................................................  241 Summary  vii 
Summary 
Forensic  Systematic  Toxicological  Analysis  (STA)  deals  with  the  chemical  analysis  of 
biological  samples  in  a  logical  sequence  designed  to  detect  a  wide  range  of  exogenous 
materials,  including  drugs  and  other  chemical  substances.  The  ideal  approach  would  be  to 
detect  qualitatively  and  quantitatively  all  substances  of  interest  in  a  single  method 
involving  a  single  extraction  procedure  and  a  single  end-step  analytical  technique.  In 
recent  years  solid  phase  extraction  based  on  modified  silica  sorbents  has  become  the  most 
widely-used  extraction  procedure  in  forensic  toxicology.  More  recently,  new  polymeric 
sorbents  with  different  selectivities  have  become  available  which  promise  to  provide  the 
single  extraction  technique  required  for  STA.  Also,  one  of  the  principal  end-step 
analytical  techniques  used  for  STA  is  gas  chromatography-mass  spectrometry,  which  is 
applicable  to  volatile  and  thermally-stable  materials  but  which  can  be  extended  to  cover  a 
significantly  wider  range  of  toxicologically-relevant  materials  by  use  of  chemical 
derivatisation  procedures  during  sample  preparation.  The  aim  of  this  thesis  was  to 
investigate  both  the  extraction  and  end-step  components  of  STA. 
The  introductory  section  reviews  the  background  to  forensic  toxicology  and  systematic 
toxicological  analysis,  whether  dealing  with  the  analysis  of  an  individual  drug  or  with  a 
group  of  drugs  within  the  same  class,  and  introduces  details  about  the  blood  matrix  -  the 
most  commonly  used  sample  type  in  forensic  toxicology.  Subsequently,  some  of  the 
background  theory  of  Gas  Chromatography-Mass  Spectrometry  used  in  this  project  is 
examined  including  the  historical  development  of  chromatography.  The  detectors  which 
are  available,  such  as  the  mass  spectrometer  in  combination  with  gas  chromatography  and 
the  ionization  methods  used  are  also  described.  The  background  to  drugs  of  abuse,  which 
form  an  important  group  of  drugs  within  STA,  is  discussed,  including  their  chemistry  and 
pharmacology  and  information  on  the  main  classes  of  drugs  of  abuse  analysed  in  this  thesis 
and  their  metabolism  is  given.  Lastly,  derivatisation  methods  are  reviewed,  including  the 
different  types  of  derivatisation  used  in  this  project. 
Three  different  derivatisation  procedures  were  evaluated  for  their  general  applicability  to 
STA,  involving  (a)  acylation  with  pentafluoropropionyl  anhydride  (PFPA)  and 
pentafluoropropanol  (PFP-OH),  (b)  acylation/esterification  (methylation)  with 
pentafluoropropionyl  anhydride  (PFPA)  and  a  novel  methylating  agent 
trimethylsilyldiazomethane  (TMS-diazomethane),  used  as  a  chromatographic Summary  viii 
derivatisation  reagent  for  the  first  time  in  this  study,  and  (c)  silylation  with  tertiary- 
butyldimethylsilyl-trifluoroacetamide  (MTBSTFA).  Model  compounds  were  selected  for 
the  evaluation  process  including  a  primary  amine  (amphetamine),  a  secondary  amine 
(methamphetamine),  alicyclic  and  aromatic  hydroxy  compounds  (morphine, 
tetrahydrocannabinol),  and  carboxylic  acids  (benzoylecgonine,  11-nor 
tetrahydrocannabinol-9-carboxylic  acid).  Microwave  assisted  derivatisation  was  evaluated 
as  a  replacement  for  conventional  heating  on  a  hotplate.  Effective  conditions  for  rapid 
derivatisation  required  only  one  minute  in  the  microwave  oven  instead  of  30  minutes  in  a 
heating  block. 
For  method  (a)  derivatisation  was  successful  for  all  of  the  test  compounds  and  mass  spectra 
were  obtained  for  each  of  them.  These  derivatives  gave  good  gas  chromatographic 
behaviour,  in  terms  of  peak  shape  and  thermal  stability,  and  the  mass  spectra  had 
prominent  molecular  ions  and  also  prominent  diagnostic  fragment  ions  at  high  mass, 
suitable  for  use  as  qualifier  ions  in  selected  ion  monitoring  GC-MS.  For  method  (b),  the 
novel  methylating  agent  trimethylsilyl-diazomethane  was  used  to  convert  carboxylic  acids 
into  the  corresponding  methyl  esters.  This  reaction  was  found  to  proceed  rapidly  and 
quantitatively  at  room  temperature  and  holds  potential  for  future  use  in  toxicology  to 
replace  diazomethane,  a  hazardous  and  toxic  material.  The  products  of  acylation  of 
alcohol  remained  unchanged  from  method  (a).  However,  the  primary  amine 
(amphetamine)  and  secondary  amine  (methamphetamine)  gave  less  satisfactory  results  in 
terms  of  poor  method  linearity.  The  acylated/methylated  products  gave  good  gas 
chromatography  and  had  mass  spectra  which  are  suitable  for  both  identification  and 
quantification  by  GC-MS-SIM.  Method  (c)  gave  derivatives  with  all  test  compounds 
except  the  secondary  amine,  methamphetamine,  and  the  alcohol,  morphine.  The  gas 
chromatographic  behaviour  of  these  derivatives  was  good  and  the  mass  spectra  had 
prominent  ions  suitable  for  GC-MS-SIM,  often  characterised  by  prominent  M-57  ions  due 
to  the  loss  of  the  butyl  substituent  in  the  silyl  derivatives. 
The  extraction  of  multiple  drugs  from  blood  was  evaluated  using  the  novel  polymeric  SPE 
sorbent  Strata-X.  The  same  test  compounds  were  used  to  assess  the  extraction  step  in 
terms  of  recovery  and  variation  (within  day  and  between  days).  The  extracts  were 
analysed  by  GC-MS-SIM  using  each  of  the  three  types  of  derivative.  Recoveries  of  the 
test  compounds  were  in  the  range  of  50-100  percent  depending  on  the  analyte  and  its 
concentration  in  blood.  All  calibration  curves  were  linear  and  had  correlation  coefficients Summary  IX 
higher  than  0.99.  Within  day  variations  and  between  day  variations  were  in  the  range  of 
2-22%  relative  standard  deviation.  Limits  of  detection  and  quantitation  were  measured  for 
the  model  compounds  and  were  found  to  be  in  the  ranges  0.4-7.3  ng/ml  and  1.1-24.4  ng/ml 
respectively.  The  full  method,  combining  extraction  with  each  of  the  derivatisation 
reactions  was  finally  evaluated  for  the  presence  of  interferences  with  real  case  blood 
samples. 
A  particular  application  of  extraction  and  derivatisation  was  investigated  in  which  two 
isomers  of  hydroxybutyric  acid  (gamma-hydroxy  butyric  acid,  GHB,  and  beta- 
hydroxybutyric  acid,  BHB)  were  analysed  in  small  (0.2  ml)  whole  blood  samples.  GHB  is 
of  interest  as  an  abused  drug  which  has  been  implicated  in  drug  assisted  assault  while  BHB 
is  of  interest  in  alcohol  related  deaths  as  a  potential  marker  of  fatal  alcoholic  ketoacidosis. 
Both  compounds  were  extracted  with  Clean  Screen  GHB  solid  phase  extraction  cartridges 
with  recoveries  in  the  range  44-89%  depending  on  the  analyte  concentration.  The  extracts 
were  analysed  by  GC-MS-SIM  after  derivatisation  with  bistrimethylsilyl- 
trifluoroacetamide.  Calibration  curves  were  linear,  with  correlation  coefficients  above 
0.99.  Limits  of  detection  and  quantification  were  acceptable  for  the  intended  application, 
being  in  the  range  of  0.1-4  mg/L  depending  on  the  analyte.  The  method  was  applied  to 
authentic  case  samples  from  alcoholics  and  non-alcoholics.  It  was  noted  that  when  alcohol 
levels  were  high,  the  BHB  levels  were  also  high.  When  BHB  levels  were  high,  there  was 
some  indication  that  the  GHB  levels  were  affected,  in  that  the  higher  the  BHB  levels,  the 
lower  the  GHB  levels.  However  this  did  not  reach  statistical  significance. 
Benzodiazepines  form  one  class  of  drugs  which  is  commonly  encountered  in  STA  and 
which  often  requires  derivatisation  prior  to  GC-MS  analysis.  The  three  derivatisation 
procedures  were  evaluated  using  four  test  compounds  comprising  diazepam  plus  its  three 
metabolites  nordiazepam,  temazepam  and  oxazepam.  The  hydroxylated  metabolites 
(temazepam  and  oxazepam)  formed  derivatives  readily  with  all  three  reagent  mixtures  but 
nordiazepam  (secondary  aromatic  amine)  did  not  react  except  with  MTBSTFA. 
Based  on  the  work  of  this  study  it  is  concluded  that  a  method  is  possible  for  STA  based  on 
a  polymeric  sorbent,  to  give  a  general  extract,  followed  by  a  generalised  derivatisation 
procedure  such  as  acylation,  with  PFPA/PFP-OH  prior  to  GC-MS. List  of  Figures 
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I  Introduction 
1.1  Toxicology 
Page  1 
Toxicology  is  the  study  of  poisons  which  affect  the  function  of  the  body  and  can 
cause  deatht131.  Forensic  toxicology  is  part  of  general  toxicology  in  which  the 
results  of  toxicological  analysis  are  used  in  legal  proceedings.  It  is  a  branch  of 
science  that  incorporates  many  areas  of  knowledge  including  pharmacology, 
analytical  and  organic  chemistry,  physiology  and  pathology.  Traditionally,  the 
forensic  toxicology  laboratory  analyses  biological  specimens  for  the  presence  of 
alcohol,  drugs  and  other  toxic  compounds  as  part  of  post-mortem  investigations[49] 
However,  the  field  now  also  includes  samples  from  living  subjects,  such  as  clinical 
cases,  workplace  drug  testing  and  road  traffic  cases"o,  111,  The  toxicology  laboratory 
performs  qualitative  and  quantitative  chemical  analysis  of  tissues  and  body  fluids 
to  determine  the  presence  or  absence  of  drugs  and  other  toxic  substances  [12-19]. 
Drugs  and  poisons  can  be  classified  according  to  the  method  used  for  extraction. 
Seven  major  groups  are  usually  considered:  gases,  volatile  substances,  drugs, 
metals,  pesticides,  anions  and  miscellaneous  substances  (Figure  1-1).  20,211 
Poisons 
Group  3.  Drugs 
Group  5.  Pesticides, 
Group7.  Miscellaneous  substances 
Group  2.  Volatile  substances 
Group  4.  Metals 
Group  6.  Anions 
.f 
Figure  1-1:  -The  seven  major  groups  of  poisons. 
Samples  submitted  to  the  toxicology  laboratory  for  analytical  tests  can  include 
blood,  urine,  stomach  contents,  tissues  from  all  body  organs,  hair,  nails,  and,  from Chapter  One  Page  2 
living  subjects,  oral  fluid.  Blood  consists  of  plasma  (55%  by  volume)  and  cells 
(45%  by  volume)  [221  There  are  three  types  of  cells:  the  white  blood  cells,  which  are 
part  of  the  immune  response  against  bacteria  and  other  invading  organisms,  red 
blood  cells,  which  transport  oxygen  and  carbon  dioxide,  and  platelets,  which  are 
important  for  normal  blood  clotting  (haemostasis)1221  In  general,  the  blood  has 
many  functions  as  it  delivers  nutrients  from  the  digestive  system,  transports  oxygen 
from  the  lungs  to  all  of  the  cells  in  the  body,  transports  waste  from  the  body  to  the 
excretory  organs,  and  carries  hormones  from  the  endocrine  glands  to  target  tissues 
to  regulate  body  temperature  and  fluid  balance,  amongst  others.  [231  Blood  is 
considered  very  important  in  forensic  toxicology  as  it  can  indicate  the  amount  of 
drug  in  the  system  at  time  of  death  and  blood  concentrations  of  drugs  and  poisons 
can  in  principle  be  interpreted  in  terms  of  their  probable  toxicity  hazard  by 
comparing  them  with  published  or  in-house  data  for  clinical  subjects  and  post- 
mortem  cases.  161  The  amount  of  blood  in  the  body  is  usually  five  litres  (about  7% 
of  body  weight)  and  the  normal  pH  of  blood  is  slightly  alkaline,  ranging  between 
7.3-7.4.  The  toxicology  laboratory  routinely  receives  blood  samples  of  more  than  5 
ml  in  volume.  However,  sometimes  only  small  volumes  of  blood  are  available,  as 
with  live  patients,  especially  infants  and  children,  or  conversely  from  much 
decomposed  bodies:  this  makes  it  difficult  to  do  a  full  toxicological  screen. 
1.2  Systematic  Toxicological  Analysis  (STA) 
Forensic  systematic  toxicological  analysis  is  essentially  a  logical  sequence  of 
analytical  methods  which  are  applied  to  samples  in  order  to  detect  and  (usually) 
quantify  a  wide  range  of  exogenous  materials,  including  drugs  and  other  chemical 
substances.  11124291  This  is  in  contrast  to  an  analytical  method  which  targets  a 
specific  substance,  such  as  alcohol  or  carbon  monoxide.  STA  is  an  important  part  of 
forensic  toxicology  since,  in  many  cases;  no  information  is  available  concerning 
which  poisons  may  be  present.  The  International  Association  of  Forensic 
Toxicologists  (TIAFT)  has  a  specialist  committee  on  STA.  125'  30-331 
Until  recently,  gas  chromatography  -  mass  spectrometry  (GC-MS)  was  considered 
the  most  useful  technique  for  identifying  and  quantifying  poisons,  including  drugs  of 
abuse.  However,  in  the  last  few  years,  LC-MS-MS  has  become  more  widely 
available,  more  reliable  and  less  expensive  than  previously  and  in  future  may  replace Chapter  One  Page  3 
GC-MS  as  the  analytical  method  of  choice.  0"'  Nevertheless,  many  laboratories 
still  depend  on  GC-MS  as  their  gold  standard  technique,  lacking  equipment  for  LC- 
MS-MS.  There  remains  a  lot  of  interest  and  a  great  deal  to  be  obtained  by  extending 
the  capabilities  of  GC-MS  in  STA  as  far  as  possible  as  it  provides  higher 
chromatographic  resolution  than  is  currently  available  by  liquid  chromatography,  is 
often  more  sensitive  than  LC-MS-MS  and  is  more  useful  for  screening  for  unknowns 
because  of  its  library  search  capabilities.  147-571 
The  limitations  of  GC-MS  frequently  result  from  thermal  instability  of  analytes 
resulting  in  turn  from  their  chemical  structures.  Some  drugs  contain  polar  functional 
groups  which  are  thermally  unstable  and  which  will  interact  with  the  column  or 
injection  port,  affecting  peak  shape  and  sensitivity.  The  most  common  approach  to 
overcoming  this  problem  is  to  modify  the  analytes  chemically,  usually  referred  to  as 
chemical  derivatisation.  1581  Derivatisation  improves  separation  and  reduces  tailing 
by  increasing  volatility,  reducing  polarity  and  increasing  thermal  stability. 
Depending  on  the  functional  group  present,  different  derivatising  mechanisms  can 
be  used,  namely,  silylation,  acylation  and  alkylation,  including  methylation 
(esterification).  For  the  analysis  of  drugs  of  abuse,  individual  extraction  and 
derivatising  procedures  are  required  because  different  drugs  need  to  be  derivatised  in 
different  ways  depending  on  the  functional  groups  present.  This  is  a  major 
disadvantage  because  of  the  time  required  to  identify  and  quantify  a  wide  range  of 
drugs.  If  a  unified  approach  to  the  toxicological  analysis  could  be  developed  which 
allows  the  detection  of  a  wide  range  of  substances  of  medicolegal  interest  in  a 
minimum  number  of  chromatographic  analyses,  this  would  be  greatly  advantageous 
in  terms  of  time  saved.  1591 
1.3  Aims  and  Objectives 
The  aim  of  this  project  was  to  investigate  the  possibility  of  creating  a  unified 
analytical  approach  to  toxicological  screening.  Different  derivatising  agents  would 
be  investigated  using  selected  drugs  of  abuse  with  different  functional  group 
chemistry  as  model  compounds.  Based  on  the  results  of  the  evaluation  of 
derivatisation  chemistries,  a  method  for  the  simultaneous  detection  and  quantitation 
of  multiple  drugs  and  metabolites  using  only  1  ml  of  sample  would  be  developed Chapter  One  Page  4 
and  validated.  The  derivatives  would  also  be  evaluated  for  their  use  with 
benzodiazepines  commonly  encountered  in  forensic  toxicology. 
A  particular  application  of  derivatisation  chemistry  would  also  be  investigated. 
Gamma-hydroxybutyrate  (GHB)  and  beta-hydroxybutyrate  (BHB)  are  endogenous 
to  the  human  body  and  there  is  a  relationship  between  GHB  and  BHB.  When  BHB 
concentrations  are  elevated,  it  can  significantly  inhibit  the  metabolism  of  GHB.  [601 
GHB  has  been  abused  recreationally  for  relaxation  effects  [61]  and  also  has  reputedly 
been  used  for  drug  facilitated  sexual  assault  because  of  its  sedative  and  amnesic 
effects  at  high  doses.  [62-651  BHB  is  one  of  the  "ketone  bodies"  present  in  the  body, 
the  others  being  acetone  and  acetoacetate.  When  blood  alcohol  concentrations  in 
the  body  are  high,  this  will  increase  the  production  of  BHB.  This  in  turn  increases 
the  blood  pH,  causing  death  as  a  result  of  ketoacidosis.  By  measuring  BHB  in 
blood  the  forensic  pathologist  can  obtain  additional  information  to  assist  in 
assigning  the  cause  of  death  in  known  alcohol  abusers.  The  aim  of  this  part  of  the 
project  was  to  investigate  and  validate  methods  for  the  simultaneous  determination 
of  GHB  and  BHB  in  small  blood  samples,  with  particular  emphasis  on  short 
processing  times. Chapter  Two  Page  5 
2  Gas  Chromatography  -  Mass  Spectrometry 
2.1  Introduction 
Gas  chromatography-mass  spectrometry  (GC-MS,  Figure  2-1)  is  an  instrumental  technique 
used  in  analytical  chemistry  which  can  separate,  identify  and  quantify  chemical  substances 
in  samples  containing  complex  mixtures  of  substances,  such  as  those  extracted  from 
biological  specimens  used  in  forensic  toxicology.  l"01  GC-MS  dynamically  combines  two 
techniques:  gas  chromatography  (GC)  which  can  separate  the  chemical  mixtures  into  their 
separate  chemical  components  and  mass  spectrometry  (MS)  which  can  identify  and 
quantify  the  chemicals.  It  is  a  sensitive  technique  which  has  the  ability  to  detect  low 
concentrations  of  analytes.  The  use  of  chromatographic  techniques  to  introduce  samples 
dynamically  to  the  mass  spectrometer  (as  opposed  to  an  off-line  method  of  trapping 
materials  eluting  from  the  GC  column  and  introducing  them  on  a  sample  probe)  first 
appeared  in  the  1960's,  when  all  gas  chromatography  was  performed  using  packed 
columns.  The  initial  problem  that  needed  to  be  solved  was  to  remove  the  carrier  gas,  which 
for  packed  columns  had  a  flow  rate  of  30  ml/min,  which  would  destroy  the  vacuum  needed 
for  efficient  mass  spectrometry.  The  Ryhage  jet  separator  achieved  this  but  the  problem 
subsequently  disappeared  when  capillary  columns  became  routinely  available,  as  the 
pumping  system  used  to  maintain  the  vacuum  in  the  mass  spectrometer  could  easily  cope 
with  their  flow  rate  of  1-2  ml/min.  [71-91] 
Gas  chromatographic  analysis  is,  however,  restricted  to  a  fairly  narrow  range  of 
compounds  which: 
"  are  relatively  volatile,  having  boiling  points  generally  below  400°C.  Substances 
with  very  high  boiling  points  are  usually  not  amenable  to  assay  by  GC-MS. 
"  Have  low  molecular  weights,  generally  below  500  Daltons. 
"  Are  relatively  non-polar  compounds.  GC  columns  often  have,  or  develop, 
undesirable  active  sites  that  interact  with  polar  compounds, 
"  Are  thermally  stable:  The  bulk  of  GC  analysis  relies  on  the  injection  of  samples 
into  a  vaporising  inlet  and  thermally  unstable  compounds  are  liable  to  breakdown  at Chapter  Two  Page  6 
such  temperatures,  often  resulting  in  inlets  contaminated  with  non-volatile  matrix 
products. 
Despite  its  great  capabilities,  GC-MS  has  some  disadvantages:  most  analyses  are  time 
consuming  and  involve  labour-intensive  steps.  [71,80,821 
The  separate  techniques  and  principal  applications  of  GC-MS  are  considered  to  be  very 
important  for  drugs  of  abuse,  and  because  of  that,  this  section  will  provide  details  about 
gas  chromatography  and  mass  spectrometry. 
Figure  2-1:  -  A  modem  instrument  for  Gas  Chromatography  -  Mass  Spectrometry Chapter  Two  Page  7 
2.2  Chromatography:  Overview 
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Figure  2-2:  -  Components  of  a  chromatograph 
Chromatography  is  a  separation  method  that  is  used  in  many  branches  of  science  (Figure  2- 
2).  It  was  invented  by  the  Russian  botanist  Mikhail  Tswett.  166  '  801  He  used  the  word 
chromatography  to  describe  this  technique,  deriving  it  from  two  Greek  words,  chroma 
meaning  colour  and  graphy  meaning  to  write.  [66'  831 
Chromatography  basically  involves  the  separation  of  a  mixture  of  components  due  to 
differences  in  equilibrium  distribution  of  sample  components  between  two  different 
phases.  One  of  these  phases  is  a  mobile  phase  that  does  move  and  the  other  one  is  a 
stationary  phase  that  does  not  move.  All  chromatographic  separations  are  governed  by 
distribution  constant  (KD,  see  para  2.2.2) 
Chromatography  has  advantages  as  it  can  separate  very  complex  mixtures,  cope  with  very 
small  sample  volumes,  separated  components  can  be  collected  individually  and  analyses 
can  be  highly  accurate  and  precise.  1801  It  is  used  for  determining  concentrations  where  each 
chromatographic  peak  in  a  chromatogram  corresponds  to  a  separate  component  and 
therefore  the  area  of  each  peak  is  proportional  to  its  amount  (Figure  2-3).  [71.80]  There  are 
general  factors  which  will  increase  resolution,  which  describes  the  degree  with  which 
adjacent  peaks  are  separated:  longer  column  lengths,  smaller  column  diameters,  decreased 
flow  rates,  uniform  stationary  phase  particle  size  (packing  material  in  packed  column 
chromatography),  decreased  sample  size,  selection  of  the  correct  stationary  and  mobile 
phases,  using  the  correct  pressure  and  using  gradient  elution.  There  are  terms  and  symbols Chapter  Two  Page  8 
which  are  very  important  for  chromatography  such  as  those  described  in  the  following 
'[71paragraphs.  ý  80,84] 
sample  injection  point 
A 
detector 
signal 
Figure  2-3:  -Chromatogram  nomenclature 
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2.2.1  Retention  time 
This  is  the  time  taken  after  sample  injection  for  an  analyte  peak  to  reach  the  detector  and  is 
denoted  by  the  symbol  t,  [661 
2.2.2  Distribution  constant  (KD) 
The  distribution  constant  KD  is  equal  to  the  ratio  of  the  concentrations  of  the  solute  C  in 
stationary  phase  CS  divided  by  concentration  in  the  mobile  phases  CM  (Figure  2-4). 
KD  =C  s/  CM 
Figure  2-4:  -  Distribution  Constant 
The  value  of  KD  should  remain  constant  across  a  wide  range  of  solute  concentrations 
where  difference  KD  to  affect  on  the  migration  rates  of  solutes  through  a  Column  [80,83,  Bad Chapter  Two, 
2.2.3  Column 
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When  selecting  an  analytical  column,  the  basic  choices  to  be  made  are  in  the  stationary 
phase,  column  diameter,  length  and  the  thickness  of  stationary  phase  or  stationary  phase 
loading.  171,801  A  non  polar  stationary  phase  is  often  the  most  useful  in  analytical 
toxicology.  The  highest  resolution  is  afforded  by  the  narrowest  columns  with  the  thinnest 
stationary  phase.  Thin  film,  narrow  bore  columns  are  especially  good  for  separating 
mixtures  of  high-boiling-point  compounds  that  are  retained  too  strongly  on  thick  film 
columns.  Short  retention  times  provide  high-speed  analyses.  However,  thin  film,  narrow 
bore  columns  have  very  low  sample  capacity  and  require  high  sensitivity  detectors.  Thick 
film,  narrow  bore  columns  can  be  used  with  most  detectors  and  with  compounds  of  high 
volatility.  Retention  times  are  longer  than  on  thin-film  columns.  Thick-film,  wide-bore 
columns  are  required  for  use  with  thermal  conductivity  and  infrared  detectors.  These 
detectors  are  relatively  insensitive  and  require  relatively  large  sample  sizes  to  be  loaded  on 
the  column,  which  usually  requires  the  higher  sample  capacity  of  a  thick  film  column. 
Columns  used  in  gas  chromatography  are  further  discussed  in  section  2.3.3.172,80,851 
2.2.4  Detectors 
The  detector  can  provide  information  on  each  compound  as  it  elutes  from  the  column.  Its 
signals  are  proportionate  to  the  quantity  of  each  solute,  making  quantitative  analysis 
possible  (Figure  2-5).  1801 
Analyte  Internal 
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Standard 
chromatogram 
Standard  Ratio=  AJA, 
Sample  Ratio=  A/A, 
Analyte  concentration  =  Standard  Sample  ratio 
in  sample  concentration  x  Standani  ratio 
Figure  2-5:  -  Determination  of  analyte  concentration Chapter  Two  Page  10 
The  most  common  detector  is  the  flame  ionisation  detector  (FID)  but  there  are  many  other 
detectors  such  as  the  mass  selective  detector  (MSD),  the  nitrogen-phosphorus  detector 
(NPD),  the  electron  capture  detector  (ECD),  the  flame  photometric  detector  and  the 
thermal  conductivity  detector  (TCD).  A  common  detector  now  is  the  mass  spectrometer 
(MS),  which  will  be  explained  in  more  detail  in  Section  2.4  F2861 
2.3  Gas  Chromatography 
2.3.1  Introduction 
Gas  chromatography  is  one  of  the  most  widely  used  analytical  techniques  for  quantitative 
analysis.  172,871  Gases  are  used  in  gas  chromatography  as  the  mobile  phase  which  transports 
the  sample  components  through  the  column  to  the  detector.  Selection  of  the  best  carrier 
gas  is  important,  because  it  affects  both  the  column  separation  processes  and  detector 
performance.  The  carrier  gas  which  is  used  should  be  inert  chemically  with  respect  to  the 
column  materials  and  sample  components  as  well  as  being  dry  and  free  of  oxygen.  The 
carrier  gas  should  be  of  high  purity  because  impurities  such  as  oxygen  and  water  can 
chemically  attack  the  liquid  phase  in  the  column  and  ultimately  destroy  the  column.  Gases 
with  the  smallest  diffusion  coefficients  such  as  hydrogen  (H2)  and  helium  (He)  which  are 
widely  used  will  give  better  separation  efficiencies  than  higher  molecular  weight  gases 
such  as  nitrogen  (N2),  carbon  dioxide  (C02)  and  argon  (Ar).  180'  881  The  ratio  of  viscosity  to 
diffusion  coefficient  should  be  a  minimum  for  rapid  analysis.  The  choice  of  gas  is  often 
dictated  by  the  type  of  detector.  Generally,  gas  chromatography  consists  of  three  major 
components:  an  injection  system,  a  chromatographic  column  and  a  detector.  189-911. 
2.3.2  Injection  system: 
The  sample  injection  port  is  connected  to  the  top  of  the  column  and  should  be  hot  enough 
to  vaporize  the  sample  rapidly.  The  most  common  introduction  techniques  are  split  and 
splitless  injection  modes.  Split  injection  can  be  considered  to  be  the  oldest  and  simplest 
technique  (Figure  2-6).  This  procedure  involves  injection  of  approximately  1µl  of  the 
sample  into  a  heated  injection  port  and  usually  1-2%  of  the  vapour  enters  the  column  with 
the  rest  being  lost  to  the  waste  outlet.  There  are  advantages  to  split  injections  as  the 
sample  amount  introduced  to  the  column  is  very  small,  flow  rate  up  to  the  split  point  is 
fast,  there  is  no  need  to  dilute  the  sample  and  the  samples  can  be  introduced  by  putting  a Chapter  Two  Page  11 
plug  of  deactivated  glass  wool  in  the  inlet  liner  to  trap  non  volatile  compounds.  One 
disadvantage  is  that  trace  analysis  is  limited.  [721 
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Figure  2-6:  -  Split  Injection  Mode.  Figure  2-7:  -  Splitless  Injection  Mode. 
In  splitless  injection  (Figure  2-7),  the  injector  is  kept  hot  enough  to  vaporize  the  specimen 
and  solvent,  but  the  column  temperature  remains  below  the  boiling  point  of  the  analyte.  It 
uses  the  same  hardware  as  split  injection,  but  the  split  valve  is  closed  when  the  sample  is 
injected.  The  sample  is diluted  with  a  volatile  solvent  and  I  to  51il  is  injected  in  the  heated 
injection  port.  The  big  advantage  of  splitless  injection  is  the  improved  sensitivity  over 
spilt  injection  and  it  is  commonly  used  in  trace  analysis.  There  are  some  disadvantages, 
for  Split 
, 
it  is  time-consuming  as  each  chromatographic  analysis  starts  with  a  cold  column 
and  uses  a  temperature  programme,  and  also  the  sample  must  be  diluted  with  a  volatile 
solvent.  172,80,921. 
2.3.3  GC  Column: 
Often  the  columns  are  coiled  to  allow  housing  within  a  fan-assisted  thermostatically 
controlled  oven.  Two  types  of  column  are  currently  used  in  GC.  Firstly,  capillary  columns 
(open  tubular  columns,  Figure  2-8)  which  do  not  contain  any  packing  material  and  are 
usually  now  constructed  from  fused  silica  with  a  polyimide  protective  coating.  Fused 
silica  capillary  columns  are  extremely  inert  as  the  column  wall  is  constructed  of  very  high 
purity  silica  (<lppm  metals).  Resistance  to  flow  is  very  low  therefore  long  lengths,  coiled, 
up  to  100m  are  possible.  Internal  diameters  are  in  the  range  0.1-0.7  mm,  with  a  very  thin 
layer  (0.1-5µm)  of  a  liquid  or  solid  stationary  phase  coated  or  chemically  bonded  to  the 
surface  of  the  inner  wall.  They  can  be  used  with  both  spilt  and  splitless  injection  systems. 
The  sample  volume  capacity  of  a  narrow  bore  column  is  <  0.1  µl,  and  the  thinner  the 
J--  220°C 
ý-ý 
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coating  the  greater  the  efficiency,  but  the  lower  the  sample  capacity  before  overloading 
causes  peak  tailing  and  deterioration  of  resolution.  By  contrast,  megabore  columns  having 
an  internal  diameter  of  0.5mm  or  more  can  accommodate  sample  volumes  up  to  lOµ1. 
They  are,  however,  less  efficient,  but  have  the  highest  sample  capacity,  so  special  injection 
techniques  are  not  needed.  The  preferred  carrier  gas  for  capillary  columns  is  helium  or 
hydrogen.  There  are  many  advantages  of  capillary  columns,  such  as  they  have  very  high 
efficiencies  and  resolving  powers  for  complex  mixtures  of  up  to  100  or  more  components 
and  solutes  elute  at  lower  temperatures  than  with  corresponding  packed  column.  However, 
capillary  columns  are  expensive.  [80,931 
Figure  2-8:  -  Capillary  Column  (open  tubular) 
They  can  be  further  subdivided  according  to  the  method  of  supporting  the  stationary  phase 
(Figure  2-9). 
[721 
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Figure  2-9:  -  Types  of  Stationary  Phase*rr4 Chapter  Two  Page  13 
1-  Wall  coated  open  tubular  (WCOT)  columns: 
These  feature  a  0.1-5  µm  thick  film  of  stationary  liquid  on  the  inner  wall  of  the  column  and 
they  provide  the  highest  resolution  of  all  gas  chromatographic  columns-1721  Tubing  internal 
diameters  commonly  manufactured  commercially  are  0.1,0.2,0.3,0.32  and  0.53mm. 
Lengths  typically  vary  from  10  to  50  meters.  Thin  films  provide  high  resolution  and  fast 
analysis,  but  they  have  limited  sample  capacity.  Thicker  films  have  higher  sample 
capacity  but  show  lower  resolution  and  are  typically  used  for  only  very  volatile 
compounds.  They  also  having  the  advantage  that  direct  injection  techniques  without 
splitting  may  be  used.  1801 
2-  Support  coated  open-tubular  (SCOT)  columns: 
This  type  of  column  has  solid  particles  coated  with  the  stationary  liquid  phase  and  attached 
to  the  inner  wall.  SCOT  columns  can  hold  more  liquid  phase  and  have  a  higher  sample 
capacity  than  the  thin  films  common  to  the  early  WCOT  columns  but  SCOT  columns  are 
less  efficient.  SCOT  columns  are  not  available  in  fused  silica.  1801 
3-  Porous  layer  open-tubular  (PLOT)  columns: 
These  contain  a  porous  layer  of  a  solid  adsorbent  such  as  alumina  or  molecular  sieve. 
PLOT  columns  are  well  suited  for  the  analysis  of  light  fixed  gases  and  other  volatile 
compounds.  PLOT  columns  represent  a  small  proportion  (<5%)  of  capillary  columns  in 
use.  1801 
2.4  Mass  Spectrometry 
2.4.1  Introduction 
The  general  method  of  operation  of  a  mass  spectrometer  is  to  create  ions  under  vacuum 
then  separate  the  ions  based  on  their  mass-to-charge  (m/z)  ratios  and  measure  the  quantity 
of  ions  of  each  mass-to-charge  ratio.  1941  In  1919  Francis  Aston  produced  the  first  mass 
spectrometer  as  an  instrument  for  determining  the  mass  of  an  atom.  He  examined  positive 
ions  from  neon  and  found  that  there  were  two  types  of  ion  present,  with  relative  isotopic 
masses  of  20  and  21.  He  had  found  a  way  of  separating  and  identifying  isotopes.  Since Chapter  Two  Page  14 
then,  the  method  has  been  developed  so  that  it  is  now  a  very  valuable  tool  for  analysing 
atoms  and  molecules  of  gases,  liquids  and  solids  (Figure  2-10). 
Inlet 
I---N  Ion  Source  Detector  Mass  Analyser 
Vacuum  system 
Figure  2-10:  -  Components  of  a  mass  spectrometer 
Computer 
Mass  spectrometry  (MS)  is  a  technique  in  which  materials  are  ionized  and  dissociated  into 
fragments  characteristic  of  the  molecules  or  elements  present  in  the  sample.  The  numbers 
of  ions  at  each  m/z  value  provide  information  for  qualitative  and  quantitative  analysis.  It  is 
considered  to  be  the  most  powerful  detector  for  gas  chromatography  because  the 
spectrometer  is  sensitive  to  low  concentrations  of  analyte  [801 
2.4.2  Sample  inlet: 
When  the  sample  is  not  a  gas  or  a  volatile  liquid,  it  has  to  be  heated  to  produce  a  vapour 
before  it  can  be  introduced  into  the  mass  spectrometer.  The  exceptional  sensitivity  of  the 
instrument  means  that  only  picograms  of  sample  are  required. 
2.4.3  Ion  Source: 
Once  inside,  the  vaporized  sample  is  ionized  by  bombardment  with  high  energy  electrons. 
The  bombarding  electrons  scatter  electrons  from  the  atoms  or  molecules  in  the  sample, 
creating  positively  charged  ions  (Figure  2-11,  Figure  2-12,  Figure  2-13): 
M+e  -->  M+'  +  2e 
Sample  high  -  energy  electron  molecular  ion 
These  positive  ions  are  expelled  from  the  ion  source  into  the  mass  analyser  by  the  ion 
repeller  plate,  which  is  another  metal  plate  carrying  a  slight  positive  charge.  1951  There  are 
two  common  ionization  methods  used  in  GC-MS. Chapter  Two  Page  15 
2.4.3.1  Electron  Impact  (EI)  ionization 
The  EI  mass  spectrum  is  obtained  by  the  impact  of  a  beam  of  electrons,  usually  generated 
from  a  tungsten  filament,  with  the  sample  molecules  in  the  gas  phase,  under  vacuum.  It  is 
the  oldest  and  best-characterized  of  all  the  ionization  methods  and  it  is  usually  considered 
to  be  a  "hard"  ionization  method  as  sufficient  energy  is  transmitted  to  the  sample 
molecules  to  produce  fragmentation  in  addition  to  simple  ionisation.  It  can  be  used  for 
GC-MS  systems  and  direct  inlet  techniques.  EI  is  best  suited  to  relatively  non-polar, 
volatile  samples.  An  EI  mass  spectrum  usually  contains  the  molecular  ion,  M,  and  many 
fragment  ions,  making  EI  useful  for  structure  characterization.  A  beam  of  electrons  passes 
through  the  gas-phase  sample.  An  electron  that  collides  with  a  neutral  analyte  molecule 
gives  a  positively  charged  radical  ion  M.  The  ionization  process  can  produce  a  molecular 
ion,  which  will  have  the  same  molecular  weight  and  elemental  composition  as  the  starting 
molecule.  The  ionization  potential  is  the  energy  required  to  produce  a  molecular  ion. 
Most  mass  spectrometers  use  electrons  with  energy  of  70  electron  volts  for  EI,  which  is 
higher  than  the  ionisation  potential  for  most  atoms  or  molecules  and  which  results  in  the 
formation  of  energetic  molecular  ions  containing  enough  excess  energy  to  break  internal 
bonds  within  the  molecule  and  produce  fragment  ions.  Decreasing  the  electron  energy  can 
reduce  fragmentation  but  it  also  reduces  the  number  of  ions  formed.  The  useful  mass 
range  for  EI  is  generally  up  to  1,000  Daltons.  [93'  961 
2.4.3.2  Chemical  Ionization  (CI) 
This  is  known  as  a  "soft"  ionization  method  because  the  analyte  is  ionized  without  the 
transfer  of  excessive  energy  to  the  resultant  ions  and  few  fragments  are  produced.  CI  uses 
ion-molecule  reactions  to  produce  ions  from  the  analyte  and  often  a  CI  mass  spectrum 
contains  a  protonated  molecule,  [M+H]+,  referred  to  as  a  pseudo-molecular  ion.  The 
chemical  ionization  uses  a  reagent  gas  such  as  methane,  isobutane  or  ammonia  at  a 
relatively  high  pressure,  which  is  ionized  first  by  electron  impact  because  of  the  large 
number  of  molecules  of  the  gas  which  are  present  in  the  source.  The  high  reagent  gas 
pressure  results  in  ion-molecule  reactions  between  the  reagent  gas  ions  and  uncharged 
reagent  gas  molecules.  Some  of  the  products  of  these  ion-molecule  reactions  can  react 
with  the  analyte  molecules  to  produce  analyte  ions.  The  results  depend  on  reagent  gas 
type,  reagent  gas  pressure  or  reaction  time,  and  the  nature  of  the  sample.  Because  less 
fragmentation  occurs  in  CI  than  with  EI  ionisation,  a  fragment  pattern  is  obtained  which  is Chapter  Two  Page  16 
not  informative  or  reproducible  enough  for  a  library  search.  The  mass  range  for  CI  is  up  to 
1,000  Daltons.  CI  is  better  suited  than  EI  to  more  polar  compounds.  The  sample  is  heated 
to  generate  gas  phase  molecules  which  undergo  proton  transfer  reactions  with  the  CI 
gas.  [93,971 
Figure  2-11:  -Ion  source  (electron  impact) 
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Figure  2-13:  -Acceleration  of  ions  from  the  ion  source Chapter  Two  Page  17 
2.4.4  Mass  analyser: 
The  original  method  of  separating  ions  according  to  their  mass-to-charge  ratios  used  a 
magnetic  field  or  a  combination  of  magnetic  and  electrostatic  fields.  More  recently, 
alternative  methods  have  become  more  common  and  these  include  the  quadrupole,  time  of 
flight  and  ion  trap  mass  analysers.  The  work  carried  out  for  this  thesis  used  a  quadrupole 
instrument. 
In  the  original  magnetic  sector  mass  spectrometer,  the  positive  ions  formed  are  accelerated 
by  an  electric  field  of  several  thousand  volts.  The  ions  then  enter  a  strong  magnetic  field, 
which  deflects  them  by  different  amounts.  The  amount  of  deflection  depends  on  firstly  the 
mass  of  the  ion  -  meaning  lighter  ions  are  deflected  more  than  heavier  ones,  and  secondly 
the  charge  on  the  ion  -  meaning  ions  with  two  or  more  positive  charges  are  deflected  more 
than  ions  with  only  one  positive  charge.  These  two  factors  are  combined  into  the 
mass/charge  ratio  (m/z)  (Figure  2-14). 
electromagnet 
1 
Figure  2-14:  -  Magnetic  sector  analyser 
When  the  magnetic  field  is  correct  for  a  particular  m/z  value,  ions  with  this  m/z  ratio  are 
deflected  to  the  collector  and  recorded.  By  continuously  varying  ("sweeping")  the 
magnetic  field,  each  separated  positive  ion  beam  can  be  focused  on  the  collector  in 
sequential  order  of  mass/charge  ratio,  to  build  up  the  mass  spectrum. 
The  quadrupole  mass  analyser  is  based  on  a  quadrupole  field  created  between  four 
electrodes  (the  quadrupoles).  Ions  transit  the  quadrupole  field  at  a  velocity  dependent  on 
their  mass,  since  each  ion  gains  the  same  momentum  during  acceleration  from  the  ion 
source.  To  enable  the  ions  to  transit  the  quadrupole  region,  the  quadrupole  field  is  switched 
in  an  alternating  manner  (at  approximately  radio  frequency),  otherwise  the  ions  would 
simply  collide  with  the  quadrupole  of  opposite  charge.  The  mass  spectrum  is  recorded  for Chapter  Two  page  18 
the  desired  range  of  m/z  values  by  sweeping  through  a  range  of  frequencies  in  the 
alternating  quadrupole  field.  Major  advantages  of  this  type  of  analyser  over  the 
conventional  magnetic  sector  include  their  smaller  size,  lower  cost,  lower  operating 
voltages  and  ease  of  computer  control. 
The  time  of  flight  mass  analyser  has  recently  come  to  the  fore  in  the  field  of  proteomics, 
for  the  analysis  of  peptides.  As  mentioned  earlier,  ions  leave  the  ion  source  at  velocities 
dependent  on  their  masses,  i.  e.  they  are  travelling  at  different  speeds.  It  follows  that  the 
time  taken  for  them  to  reach  the  detector,  if  they  travel  in  a  straight  line,  can  be  used  to 
measure  the  m/z  ratio.  Literally  this  is  the  time  of  flight  between  source  and  detector.  The 
start  time  of  the  flight  must  be  precisely  known  also  and  this  is  obtained  by  using  a  pulsed 
ionisation  process,  usually  involving  a  laser. 
2.4.5  Detector: 
Ions  impinging  on  a  detector  surface  contain  a  significant  amount  of  energy  and  this  is 
used  to  generate  a  more  easily  recorded  material,  usually  electrons  or  photons,  which  are 
detected  using  an  electron-  or  photo-multiplier.  Both  of  these  multipliers  can  enormously 
amplify  the  signal  created  by  the  ions  themselves.  This  amplified  signal  is  converted  into 
digital  form  with  a  high  frequency  analogue-to-digital  converter  and  relayed  to  the 
computer  data  acquisition  system. Chapter  Three  Page  19 
3  Drugs  of  Abuse:  Pharmacokinetics  and  Drug 
Metabolism 
3.1  Introduction 
Model  compounds  were  chosen  for  this  study  from  amongst  the  major  groups  of  abused 
drugs,  including  the  amphetamines,  cocaine,  opioids  and  cannabinoids.  The  following 
sections  review  some  basic  concepts  in  pharmacology  and  some  background  information 
on  these  drug  groups. 
3.2  Introduction  to  some  pharmacological  concepts 
Generally,  the  toxicological  study  of  chemicals  or  drugs  requires  a  basic  knowledge  of  how 
they  affect  the  biological  system  (pharmacodynamics)  and  how  the  biological  system 
absorbs  and  disposes  of  them  (pharmacokinetics).  The  field  of  pharmacodynamics  is  one 
of  the  most  important  in  pharmacology  science  which  involves  studying  the  behaviour  of 
substances  in  the  blood,  whether  the  effects  are  desired  effects  or  toxic  side-effects.  [99-1021 
The  people  who  take  drugs  may  experience  changes  in  mood  and  emotion,  increase  in 
body  temperature,  muscle  tension,  teeth  clenching,  nausea,  anxiety,  rapid  eye  movement, 
chills,  sweating,  faintness  and  blurred  vision.  However,  the  most  serious  health  risks  are 
depression,  sleep  problems,  increase  in  heart  rate  and  blood  pressure,  brain  damage, 
muscle  breakdown,  liver  damage,  kidney  failure,  heart  failure  and  psychological  problems. 
People  who  need  drug  treatment  have  become  addicted  to  drugs  and  have  lost  the  ability  to 
choose  between  using  and  not  using  the  substance.  Drug  use  becomes  the  only  way  that 
they  feel  normal.  This  is  a  very  involved  process,  and  we  do  not  know  exactly  what  each 
drug  does.  For  example,  alcohol  is  a  drug  and  one  of  its  effects  is  to  dehydrate  protoplasm. 
This  prevents  the  cell  wall  from  operating  properly.  This  happens  in  every  cell  in  the 
body,  but  it  has  its  most  noticeable  effect  on  the  central  nervous  system  where  it  suppresses 
the  higher  cortical  centres  in  the  brain.  This  reduces  a  subject's  normal  ability  to  perceive 
the  environment.  There  are  many  drugs  of  abuse  but  the  more  important  ones  will  be 
discussed  below  as  these  were  the  model  compounds  used  in  this  study.  1103,1°41  There  are 
also  terms  which  are  very  important  for  pharmacokinetics  such  as  those  described  in  the 
following  paragraphs. Chapter  Three  Page  20 
Pharmacokinetics  includes  absorption  of  the  substances  into  the  body,  which  describes 
how  are  the  drugs  absorbed  through  the  skin,  the  intestine  and  the  oral  mucosa, 
distribution,  which  describes  how  the  substances  spread  through  the  organism  and 
elimination,  which  describes  how  the  substances  are  metabolised  and  excreted  (Figure 
3-1). 
Figure  3-1:  -  Pharmacokinetic  characteristics  of  an  orally  absorbed  drug  11051 
Drugs  can  enter  the  body  by  several  different  routes  including  orally  -  by  mouth,  injection, 
or  inhalation  and  by  skin  absorption.  The  transport  of  drugs  across  the  plasma  membrane 
of  cells  is  one  of  the  most  important  factors  involved  in  delivery  of  drugs  or  other 
substances  to  the  target  organ.  The  cell  is  the  basic  building  block  of  the  body  tissues. 
Each  cell  has  a  wall  that  protects  the  cell  from  harm,  a  nucleus  which  is  the  core  of  the  cell 
and  it  also  has  a  variety  of  other  specialized  parts  with  specialized  functions  called 
organelles.  The  nucleus  contains  deoxyribonucleic  acid  or  DNA  which  determines  how 
the  cell  is  made  and  how  it  works.  Drugs  enter  cells  through  the  cell  membrane,  which  is  a 
phospholipids  bilayer  that  is  non-polar  and  so  is  hydrophobic.  Most  importantly,  for  the 
effective  use  of  most  drugs,  non-polar  molecules  can  cross  cell  membranes  but  less  lipid 
soluble  (lipophobic)  molecules  do  not  penetrate  the  lipid  membrane  and  must  enter  cells  by 
a  different  route,  either  by  active  transport  or  diffusion  through  specialised  channels. 
When  a  weakly  acidic  or  basic  drug  is  administered  to  the  body,  the  drug  will  ionise  to  a 
greater  or  lesser  extent  depending  on  the  pK.  and  the  pH  of  the  body  fluid  in  which  it  is 
dissolved.  t1061  Therefore  the  degree  of  ionization  of  a  drug  is  most  often  determined  by  the 
relationship  between  its  pK.  and  the  pH  of  its  environment  (as  demonstrated  in  Equation  3- 
1  below).  The  pH  of  the  body  varies  widely  but  the  most  important  biological  solution  is 
the  blood,  which  normally  has  a  pH  of  7.4.  The  relationship  between  pK.  and  the  ratio  of Chapter  Three  Page  21 
acid-base  concentration  to  pH  is  expressed  by  the  Henderson-Hasselbach  equation 
(Equations  3-2  and  3-3  as  shown  below).  1106-11°1 
pH  =  pKa  -  log  non  -  protonated  species 
protonated  species 
Equation  3-1 
For  acids:  pH  =  pKa  +  log  [ionized]/  [un-ionized]  Equation  3-2 
For  bases  :  pH  =pKa  +  log  [un-ionized]/  [ionized]  Equation  3-3 
This  equation  is  useful  in  determining  how  much  drug  will  be  found  on  either  side  of  a 
membrane  that  separates  two  compartments  that  differ  in  pH.  1101,1111  Examples  of  this 
include  the  absorption  of  drugs  through  the  gastric  mucosa  (actually  a  series  of  membranes 
and  layers)  into  blood.  The  pH  of  gastric  juice  is  acidic  (typically  pH  3)  and  so  basic  drugs 
will  be  ionised  (protonated)  and  therefore  will  be  poorly  absorbed  from  the  stomach.  By 
contrast,  acidic  drugs  such  as  aspirin  or  ibuprofen  will  be  largely  non-ionised  and  will  be 
more  readily  absorbed  through  the  gastric  mucosa.  However,  this  situation  is  altered  if  an 
antacid  is  also  administered,  which  increases  the  gastric  pH.  If  the  pH  is  increased  by  one 
unit,  the  percentage  of  a  basic  drug  which  is  ionised  will  decrease  by  a  factor  of  10,  which 
will  affect  its  absorption  from  the  stomach.  Another  common  example  is  the  effect  of 
urine  pH  on  the  excretion  of  drugs.  Basic  drugs  are  more  rapidly  excreted  through  the 
kidney  when  the  urine  pH  is  acidic  than  when  it  is  basic. 
3.2.1  Drug  metabolism 
Drugs  and  other  substances  are  usually  metabolized  by  phase  one  reactions,  which  involve 
oxidation,  reduction  and  hydrolysis  processes  which  modify  the  molecule  by  changing  the 
nature  of  a  functional  group  or  by  adding  a  functional  group.  These  can  involve 
hydroxylation,  oxidation  and  dealkylation  routes  of  metabolism  and  may  be  considered 
degradation  reactions.  Phase  two  metabolism  involves  the  production  of  compounds 
(conjugates)  and  may  be  considered  conjugation  reactions.  Conjugation  reactions  often 
involve  the  addition  of  sulphuric  acid  or  glucuronic  acid  to  an  existing  functional  group 
forming  sulphates  and  glucuronides.  However,  other  acids  may  be  involved  such  as  glycine Chapter  Three  Page  22 
and  glutamine  conjugates.  1'°5'  1121  Phase  two  metabolism  produces  substances  which  are 
easily  eliminated  from  the  body  through  the  kidney  into  the  urine  (Figure  3-2,  and  Figure 
3-3). 
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3.2.2  Clearance 
Clearance  is  a  term  that  defines  the  ability  of  the  body  to  remove  a  drug  from  one  part  of 
the  body  e.  g.  kidneys,  liver.  1'°51  the  most  common  definitions  are  the  two  expressions 
shown  below  in  Equations  3-4  and  3-5: 
CL  =  dose  /  AUC  Equation  3401051 
CL  =  KO  /Css  Equation  3-511051 Chapter  Three  Page  24 
Where  CL  is  the  clearance  in  ml/min,  dose  is  the  actual  dose  absorbed  by  the  body,  AUC  is 
the  area  under  the  plasma  drug  concentration  versus  time  curve,  Ko  is  the  infusion  rate  of 
the  drug  in  a  controlled  clinical  setting,  delivering  the  drug  intravenously,  and  Css  is  the 
steady  state  plasma  concentration  of  the  drug  under  these  controlled  conditions. 
Clearance  will  vary  depending  on  the  physiological  state  of  the  organs  such  that  organ 
disease  and  organ  damage  may  reduce  clearance.  11051  The  concept  of  clearance  is  also 
extremely  useful  in  clinical  pharmacokinetics  because  clearance  of  a  given  drug  is  usually 
constant  over  the  range  of  concentrations  encountered  clinically.  This  is  true  because 
systems  for  elimination  of  drugs  are  not  usually  saturated  and  the  absolute  rate  of 
elimination  of  the  drug  is  essentially  a  linear  function  of  its  concentration  in  plasma.  1113,114] 
3.2.3  Plasma  half  -  life  (Tyj: 
This  is  the  most  commonly  used  pharmacokinetic  term  in  court.  1'°51  It  defines  the  ability  of 
the  body  to  eliminate  a  drug  from  circulation  in  plasma  and  reflects  how  often  a  drug  needs 
to  be  administered.  The  plasma  half  -  life  defines  the  time  required  for  the  body  to  remove 
50%  of  the  drug  from  plasma  after  absorption  and  distribution  are  complete.  The  half  -  life 
is  usually  in  hours,  although  some  drugs  have  a  half  -  life  of  minutes  or  weeks.  The  half  - 
life  is  calculated  from  the  slope  of  the  terminal  region  of  the  plasma  drug  concentration 
versus  time  curve  from  Equation  3-6: 
Half  -  life  =  0.693  /ß  Equation  3-6 
Where  ß  is  the  slope  of  the  terminal  part  of  the  plasma  concentration  versus  time  curve. 
The  half  -  life  of  a  drug  is  dependent  on  its  volume  of  distribution  and  its  clearance.  11051 
The  half  -  life  is  useful  in  estimating  the  concentration  of  drug  at  an  earlier  time  by  back 
calculation,  for  example,  a  drug  with  a  half  -life  of  12  h  and  a  blood  concentration  of  2.0 
mg/L  will  be  expected  to  have  a  concentration  of  1.0  mg  /L  12  h  later.  This  will  reduce  to 
0.5  mg/L  at  24  h  and  0.125  mg/L  after  two  days. Chapter  Three  Page  25 
3.3  Amphetamine  type  stimulants 
CH2 
CH3 
I 
CH-NH2 
Figure  3-4:  -  Chemical  structure  of  amphetamine  (C,  1-113N,  MW  135,  pK.  9.9). 
Amphetamine  (Figure  3-4)  is  used  as  a  central  nervous  system  stimulant  in  the  treatment  of 
certain  conditions,  such  as  attention  deficit  hyperactivity  disorder,  depression  and 
narcolepsy  and  is  abused  illegally  as  a  stimulant.  It  is  a  synthetic  phenethylamine 
derivative  available  since  1935111s-1171.  It  appears  as  crystal,  chunks  and  fine  to  coarse 
powders,  off-  white  to  yellow  in  colour,  and  is  supplied  loose  or  in  capsules  and  tablets  of 
various  sizes  and  colours.  The  drug  may  be  sniffed,  smoked,  injected  or  taken  orally  in 
tablet  or  capsule  form.  It  is  also  a  metabolite  of  a  number  of  other  drugs,  including 
fenethylline,  fenproporex  and  methamphetamine.  The  half-life  of  Amphetamine  varies 
from  a  few  hours  to  more  than  day  depending  on  the  value  of  the  urine  pH,  where  the  half- 
life  is  normally  5-8  hours  but  decreases  to  3-6  hours  with  low  urine  pH  and  increases  to  9- 
16  hours  with  high  urine  pH.  Y1051  Amphetamine  is  largely  excreted  unchanged  but  a 
percentage  is  also  inactivated  during  metabolism,  being  deaminated  to  phenylacetone 
which  is  subsequently  oxidized  to  benzoic  acid  and  excreted  as  conjugates  (Figure  3-5). 
However,  a  small  amount  is  converted  by  oxidation  to  norephedrine  and  this  compound 
and  its  parent  are  hydroxylated  on  the  benzene  ring  in  the  pars  position.  Following  a 
single  oral  dose  of  10  mg  of  d-amphetamine  sulphate  in  a  66  kg  adult,  the  blood 
concentration  reached  a  peak  of  about  0.035  mg/L  at  2  hours  and  declined  with  a  half-  life 
of  11-13  hours.  Urine  amphetamine  concentrations  are  usually  less  than  4.5  mg/L  in  adults 
given  a  single  20  mg  oral  dose,  while  a  patient  taking  30  mg  daily  on  a  chronic  basis  had 
urine  concentrations  of  1.1-18  mg/L  and  amphetamine  abusers  often  have  urine 
117  concentrations  in  the  range  of  10-100  mg/Lt"u°ý Chapter  Three  Page  26 
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Figure  3-5:  -  Metabolic  pathways  for  Amphetaminen'83 
3.4  Methamphetamine 
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Figure  3-6:  -  Chemical  structure  of  methamphetamine  (C,  oH15N,  MW  149,  pK,  10). 
Methamphetamine  (Figure  3-6)  is  an  alkaloid  similar  in  structure  to  amphetamine  but  with 
an  N-methyl  substituent.  It  was  first  synthesized  in  1919  and  is  a  powerful  central  nervous 
system  stimulant.  This  stimulant  can  be  swallowed,  snorted,  smoked  or  dissolved  in  water 
and  injected.  Generally  it  affects  heart  rate,  body  temperature,  blood  pressure,  appetite, 
attention  and  mood.  Methamphetamine  users  feel  a  short  yet  intense  rush  when  the  drug  is 
initially  administered.  Methamphetamine  hydrochloride  is  a  salt  commonly  known  as 
meth  or  speed.  The  smokeable  form  of  the  drug  is  called  LA  or,  because  of  its  clear, 
chunky  crystals  which  resemble  frozen  water,  ice,  crystal,  64  glasses  or  quartz.  A  single 
oral  methamphetamine  dose  of  0.125  mg/Kg  (8.75  mg/70  Kg)  given  to  6  adults  produced 
an  average  peak  plasma  concentration  of  0.020  mg/L  at  3.6  hours.  The  plasma  elimination 
half-life  averaged  10  hours  (range  6-15  hours)  for  24  subjects.  Methamphetamine 
undergoes  some  N-demethylation  to  amphetamine,  its  major  active  metabolite  (Figure 
3-7).  During  normal  physiological  conditions,  up  to  45%  of  a  dose  is  eliminated  unchanged 
in  the  24  hour  urine,  and  about  4-7  %  is  excreted  as  amphetamine.  In  acidic  urine,  up  to Chapter  Three  Page  27 
76%  is  found  in  urine  as  unchanged  drug  and  7%  as  amphetamine  in  24  hours,  whereas  in 
alkaline  urine  the  corresponding  values  are  2%  and  less  than  0.1%  respectively.  [62,121,1221 
CH3 
-CH-  NH 
metamphetamine  i CH3 
CH3 
CHZ-CH-NHZ  10 
amphetamine 
CH3 
i  CH  -C-  NH2 
1 
OH 
norephedrine 
1/ 
deamination,  p-hydroxylation  and  conjugation 
Figure  3-7:  -  Metabolic  pathways  for  MethamphetamineL"81 
3.5  Cocaine 
Figure  3-8:  -  Chemical  structure  of  Cocaine  (C17H21NO4,  MW  303,  pKa  8.6) 
Cocaine  (Figure  3-8)  is  isolated  from  Erythroxylon  coca  which  has  been  grown  in 
numerous  countries  around  the  world  but  mostly  in  South  America.  There  are  more  than 
250  varieties  of  coca  plants  but  only  three  are  widely  used  in  the  illegal  cocaine  drug  trade. 
These  are  Huanuca  coca,  grown  in  Bolivia  and  Peru,  Amazonian  coca,  grown  in  the 
Amazon  river  basin  and  Colombian  coca  grown  primarily  in  Colombia.  [48,1231  The 
properties  of  cocaine  include  a  molecular  weight  of  303  and  a  pK,  of  8.6  and  it  is 
considered  to  be  a  powerful  stimulant.  The  routes  of  administration  include  chewing, 
snorting,  injecting  and  smoking.  It  can  be  absorbed  into  the  body  through  any  mucous 
membrane.  The  chewing  of  powdered  coca  leaves  containing  17-48  mg of  cocaine  by  6 
volunteers  produced  peak  plasma  cocaine  concentrations  in  the  range  0.011-0.149  mg/L 
within  0.4-2  hours.  11181  The  half-  life  of  cocaine  ranges  from  40  min  to  4h  depending  on 
how  the  elimination  phase  is  estimated.  11051  There  are  short  term  effects  on  the  user, 
including  increased  energy,  decreased  appetite,  mental  alertness,  increased  heart  rate  and Chapter  Three  Page  28 
blood  pressure,  constricted  blood  vessels  and  increased  temperature.  11241  There  are  also 
long  term  effects  such  as  addiction,  irritability  and  mood  disturbances,  restlessness, 
paranoia  and  auditory  hallucination.  [124,125]  Cocaine  is  considered  a  powerfully  addictive 
drug.  80  to  90  %  of  cocaine  is  metabolised  to  ecgonine  methyl  ester  by  enzymatic 
hydrolysis  and  to  benzoylecgonine  by  spontaneous  hydrolysis  at  physiological  and  alkaline 
pH.  11251  Rapid  enzymatic  hydrolysis  by  plasma  and  liver  esterases  yields  ecgonine  methyl 
126-1281 
ester.  Other  metabolites  include  norcocaine  (Figure  3-8)E 
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Figure  3-9:  -  Metabolic  pathways  for  Cocaine11  . 
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3.6  Opioids 
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Figure  3-10:  -Chemical  structure  of  Morphine  (C,  yHj9N03,  MW  285,  pKa  9.85  and  7.87) 
showed  with  its  heterocyclic  rings  distinguished. 
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The  opioids  are  a  large  family  of  drugs  and  are  the  most  important  therapeutic  components 
in  the  treatment  of  moderate  to  severe  pain.  1t051  Opiates"  are  drugs  directly  derived  from 
the  opium  poppy  and  include  opium,  morphine  and  codeine.  Opium  is  a  very  ancient  drug 
which  has  been  used  as  an  analgesic  for  many  thousands  of  years.  The  term  opioid  refers 
to  all  natural  and  synthetic  drugs  with  morphine-like  properties  and  so  includes  a  wider 
range  of  drugs  than  the  opiates.  Morphine  (Figure  3-10),  hydromorphone,  meperidine, 
heroin  and  fentanyl  are  agonists  at  opioid  receptors  and,  as  they  are  very  lipid  soluble,  are 
rapidly  and  extensively  distributed  to  tissues.  Synthetic  opioids  like  fentanyl,  or  semi- 
synthetic  opioids  such  as  hydromorphone,  have  higher  lipid  solubilities  than  morphine 
which  allows  them  to  cross  the  blood  brain  barrier  quickly,  leading  to  a  more  rapid  onset  of 
their  effects.  Due  to  the  diversity  of  their  chemical  structures,  the  metabolism  of  opioids 
varies  significantly  between  members  (Figure  3-11).  [b05.1301 
Morphine  is  essentially  completely  metabolized  by  glucuronidation  at  the  3-  and  6- 
positions,  whereas  methadone  is  dealkylated  leading  to  a  product  which  readily  forms  a 
cyclic  structure.  Dealkylation  pathways  are  also  important  for  drugs  with  larger 
substituents  on  the  N-atom,  e.  g.  buprenorphine,  butorphanol  and  pentazocine.  1105' 
Morphine  has  the  following  properties:  molecular  weight  285,  pKa  values  9.85  and  7.87. 
It  is  an  alkaloid  narcotic  drug  extracted  from  opium  and  is  a  highly  addictive  analgesic 
which  can  be  administered  by  several  routes  i.  e.  injected,  smoked,  sniffed  or 
swallowed.  1105,118.1311  The  trade  names  for  morphine  are  Roxinal,  MS  contain,  or 
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morphine  sulphate.  The  common  street  name  for  morphine  is  Morph.  [1321  There  are  many 
symptoms  of  overdose  which  include  cold  clammy  skin,  flaccid  muscles,  fluid  in  the  lungs, 
lowered  blood  pressure,  pinpoint  or  dilated  pupils,  sleepiness,  stupor,  coma,  slowed 
breathing  and  slow  pulse  rate. 
The  plasma  half  -life  for  a  lot  of  the  common  opioids  is  relatively  short;  for  instance, 
morphine  which  has  a  half-life  only  a  few  hours.  11051  Morphine  is  rapidly  excreted  through 
the  kidneys  into  the  urine  as  glucuronides,  with  up  to  85%  of  the  dose  recovered  in  urine 
within  24  hours.  Only  small  amounts  (2-10%)  are  excreted  unchanged.  1'°51 
The  formation  of  glucuronide  conjugates  is  an  important  feature  of  the  pharmacokinetics 
and  toxicology  of  morphine.  Laboratories  will  often  measure  morphine  as  total  morphine, 
which  includes  free  morphine  and  the  sum  of  the  two  glucuronide  conjugates.  This  is  due 
to  the  greater  ease  associated  with  measuring  these  higher  concentrations  of  total 
morphine,  since  morphine  levels  are  often  undetectable  after  several  hours1133"135ß 
However,  since  LC-MS  became  available,  individual  glucuronides  are  measured  without 
hydrolysis.  This  is  important  since  morphine-6-glucuronide  is  pharmacologically  more 
active  than  morphine  itself  [1361 Chapter  Three  Page  31 
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3.7  Cannabis 
C5Hr 
Figure  3-12:  -  Chemical  Structure  of  delta-9-tetrahydrocannabinol,  THC  (C21H30O2,  MW  314, 
p1,10.6) 
Cannabis  is  a  green  or  grey  mixture  of  dried  leaves  of  the  hemp  plant  Cannabis  sativa. 
There  are  three  drugs  derived  from  the  cannabis  plant  -  herbal  cannabis,  hashish  and 
hashish  oil.  1137,138]  There  are  over  200  slang  terms  for  cannabis  including  boom,  Mary 
Jane,  gangster,  cannabis  and  chronic.  However,  the  names  maryuana  or  marihuana  are 
not  used  in  UK  legislation,  which  uses  the  name  cannabis  exclusively.  The  drug  is  usually 
smoked  as  cannabis  cigarettes.  The  main  active  drug  substance  in  cannabis  is  THC  (delta  - 
9-tetrahydrocannabinol,  Figure  3-12)  Although  most  of  the  THC  in  cannabis  plants  is 
concentrated  in  the  resin,  all  parts  of  the  plant,  apart  from  the  seeds  and  roots,  have  been 
found  to  contain  THC.  1105,118,1391 
After  inhaling  cannabis  smoke  for  a  few  minutes,  the  bronchial  passages  relax  and  become 
enlarged  and  the  blood  vessels  in  the  eyes  expand,  making  the  eyes  look  red.  The  heart 
rate,  normally  70  to  80  beats  per  minute,  may  increase  by  20  to  50  beats  per  minute  or,  in 
some  cases,  even  double-11183  This  effect  can  be  greater  if  other  drugs  are  taken  with 
cannabis.  The  whole  blood/plasma  concentration  ratio  for  THC  is  0.55.  Estimates  of  its 
elimination  half-life  have  ranged  from  20-57  hours  in  infrequent  users  and  from  3-13  days 
in  frequent  users.  The  elimination  plasma  half-life  of  11-carboxy-THC  averaged  33  hours 
in  infrequent  users  of  cannabis  and  40  hours  in  frequent  users.  11181  THC  is  metabolized  to 
two  monohydroxy  compounds,  11-hydroxy-THC  and  8-beta-hydroxy-THC  (Figure  3-13) 
which,  although  pharmacologically  active,  do  not  achieve  appreciable  plasma 
concentrations  and  probably  do  not  contribute  significantly  to  the  acute  effects  of  the  drug 
after  smoking.  1105  A  third  metabolite,  and  quantitatively  the  most  important,  11-nor-9- 
carboxy-delta-9-THC,  has  been  identified  and  is  believed  to  be  a  product  of  further 
oxidation  of  11-hydroxy-THC.  11401  About  70%  of  a  dose  of  THC  is  excreted  within  72 
hours  in  the  faeces  (40%)  and  urine  (30%).  11051  The  urinary  elimination  half-life  of  9- Chapter  Three  Page  33 
carboxy-THC  averaged  3  days  (range  0.8-9.8)  in  heavy  smokers  of  cannabis.  11051  Passive 
inhalation  of  cannabis  smoke  has  resulted  in  plasma  THC  levels  of  1-7pg4L  and  urine  9- 
carboxy-THC  levels  as  high  as  39pg/L,  as  measured  by  a  specific  assay.  [141,  lazy 
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4  Comparison  of  Derivatisation  Procedures 
4.1  Introduction  and  Aims 
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Systematic  forensic  toxicology  involves  a  logical  sequence  of  analytical  procedures 
designed  to  detect  a  wide  range  of  drugs  and  poisons  in  cases  for  which  there  is  no 
information  about  which  substances  might  be  present,  i.  e.  a  general  unknown.  Ideally,  all 
possible  substances  will  be  detected  but  inevitably  there  are  restrictions.  Conventional 
methods  used  for  the  purpose  have  included  UV  spectroscopy,  thin  layer  chromatography, 
gas  chromatography  and  high  pressure  liquid  chromatography,  usually  with  a  diode  array 
detector.  [11,143-157]  More  recently,  combined  techniques  involving  a  chromatographic 
technique  and  spectrometry  have  become  more  accessible  to  the  majority  of  forensic 
toxicology  laboratories  and  as  a  result  are  now  the  techniques  of  choice.  [36,39,54,158-1731 
One  of  the  main  requirements  in  systematic  toxicological  analysis  is  often  chemical 
derivatisation,  which  is  the  process  of  chemically  modifying  a  molecule  to  produce  a  new 
compound  which  has  properties  that  make  it  suitable  for  analysis.  [1521  Derivatives  are 
made  for  most  chromatographic  techniques  but  are  especially  important  for  analyses 
involving  GC-MS.  Historically  in  the  forensic  sciences  the  use  of  derivatising  agents  with 
GC-MS  has  been  largely  within  the  scope  of  the  forensic  toxicology  and  chromatography 
of  drugs  and  metabolites  in  biological  fluids  and  tissues.  [154,174,1751 
There  are  several  GC-MS  methods  for  the  determination  of  drugs  of  abuse  which  have 
been  published,  most  of  them  dealing  with  determination  of  individual  drugs  of  abuse  or 
else  with  groups  of  related  drugs.  Derivatising  procedures  for  systematic  forensic 
toxicological  analysis  have  included  the  silylation,  acylation  and  esterification  reactions 
described  below  in  Section  4.2.  [176-1833  However,  no  systematic  comparison  has  been  made 
of  the  different  derivatives  for  forensic  toxicology. 
The  ultimate  aim  of  this  work  was  to  create  a  unified  procedure  for  systematic 
toxicological  analysis  which  would  enable  a  wide  range  of  drugs  and  metabolites  to  be 
detected  in  a  minimum  number  of  analyses,  thereby  making  the  procedure  suitable  for  the 
complete  toxicological  analysis  of  small  samples.  The  intention  was  to  develop  a  simple, 
fast  method  based  on  solid  phase  extraction  of  acid,  neutral  and  basic  analyses  followed  by 
a  comprehensive  derivatisation  procedure  which  would  enable  the  extracts  to  be  analysed Chapter  Four  Page  35 
by  GC-MS.  The  study  described  in  this  chapter  is  concerned  with  the  end-step 
derivatisation  and  analysis,  which  required  to  be  set  up  before  extraction  procedures  could 
be  evaluated.  Drugs  were  subsequently  extracted  from  whole  blood  by  solid  phase 
extraction  followed  by  derivatisation  and  analysis  by  GC-MS-SIM,  and  that  study  is 
described  in  Chapter  5. 
The  present  study  describes  a  comparison  of  three  derivatisation  methods  involving 
silylation,  acylation  and  esterification  reactions  for  the  analysis  of  drugs  of  abuse.  Several 
existing  reagents  and  a  new  reagent,  trimethylsilyl-diazomethane  were  evaluated  to 
establish  which  would  be  most  suitable  for  a  unified  procedure.  In  addition,  the  literature 
records  that  derivatisation  is  more  rapid  when  microwave  irradiation  is  used  rather  than 
direct  thermal  heating,  reducing  the  incubation  time  from  more  than  thirty  minutes  to  one 
minute,  [184-190]  and  this  was  also  evaluated  in  the  present  study. 
Model  compounds  which  feature  each  of  the  functional  groups  commonly  found  in  target 
analytes  of  interest  in  forensic  toxicology  (amphetamine,  methamphetamine,  morphine, 
benzoylecgonine,  THC-OH  and  THC-COOH)  were  used  to  evaluate  the  reagents.  The 
justification  for  this  approach  is  that  functional  groups  usually  react  independently  and  are 
not  significantly  influenced  by  the  molecule  in  which  they  are  located. 
4.2  Chemistry  of  Derivatisation  Reactions 
4.2.1  Introduction 
Chemical  derivatisation  has  long  been  a  useful  adjunct  in  the  characterization  of  organic 
compounds  using  techniques  that  include  chromatography  and  spectroscopy. 
Derivatisation  is  the  process  of  chemically  modifying  a  compound  to  produce  a  new 
substance  which  has  properties  that  are  suitable  for  analysis  using  a  particular  technique, 
such  as  GC.  180'  191-194]  Volatility  and  thermal  stability  of  the  analytes  are  required  in  GC 
and  GC-MS  analysis.  Other  reasons  for  derivatisation  are  to  enable  analysis  of  functional 
groups,  to  provide  selective  detection,  to  produce  mass  shifts  in  mass  spectra,  to  modify 
fragmentation  and  to  improve  chemical  ionization.  E80,1951 
Derivatisation  prior  to  analysis  involves  an  additional  chemical  step  that  is  not  only  time 
consuming  but  also  introduces  potential  impurities,  uncertainties  about  the  completeness  of Chapter  Four  Page  36 
the  conversion  and  possible  interpretation  difficulties  associated  with  the  adopted  chemical 
reaction.  Many  drugs  are,  however,  derivatized  prior  to  undergoing  GC  analysis  to  confer 
volatility  to  the  analytes  and  improve  their  stability,  separation  and  chromatographic 
properties.  This  is  because  most  drugs,  both  licit  and  illicit,  are  organic  in  structure,  and 
their  analyses  by  chromatographic  methodology  often  can  be  facilitated  by  chemical 
derivatisation.  [80,174,191] 
Generally,  derivatisation  is  performed  to  convert  polar  N-H,  O-H  and  S-H  groups  into 
thermally  stable,  nonpolar  groups  and  derivatives  are  therefore  used  to  increase  sensitivity 
and  chromatographic  performance  for  specific  compounds  such  as  acids,  alcohols  and 
amines,  which  are  difficult  to  analyse  because  of  the  presence  of  reactive  hydrogen  atoms. 
When  attempting  to  analyse  these  types  of  compound,  they  can  react  with  the  surface  of 
the  injection  port  or  the  analytical  column  which  can  result  in  tailing  peaks  and  low 
response.  They  may  also  be  highly  soluble  in  the  sample  matrix,  causing  very  poor 
headspace  content  and  low  response. 
GC  derivatisation  methods  can  be  classified  into  4  groups  according  to  the  reagents  used 
and  reaction  achieved.  These  are  silylation,  acylation,  alkylation  and  esterification 
reactions.  Therefore  the  choice  of  a  derivatising  reagent  is  based  on  the  functional  group 
requiring  derivatisation,  the  presence  of  other  functional  groups  in  the  molecule,  and  the 
reason  for  performing  the  derivatisation.  The  chemical  structure  and  properties  of  the 
molecule  influence  the  reagent  choice.  In  choosing  a  suitable  derivatisation  reagent  certain 
criteria  must  be  used  as  guidelines.  A  good  reagent  produces  a  derivatisation  reaction  that 
is  95-100%  complete,  will  not  cause  any  rearrangements  or  structural  alterations  during 
formation  of  the  derivative,  does  not  contribute  to  loss  of  the  sample  during  reaction, 
produces  a  derivative  that  will  not  interact  with  the  analytical  (GC  or  HPLC)  column,  and 
one  which  is  stable  with  respect  to  time  °$'I  The  main  requirements  for  a  successful 
derivatisation  reaction  are  that  a  single  derivative  should  be  formed  for  each  compound, 
the  derivatisation  reaction  should  be  simple  and  rapid  and  should  occur  under  mild 
conditions.  [196-2071 
The  following  Sections  review  the  derivatisation  reactions  used  in  this  study. Chapter  Four 
4.2.2  Silylation 
Page  37 
The  term  silyl  refers  to  derivatives  containing  silicon  and  usually,  but  not  exclusively, 
relates  to  the  trimethylsilyl  group,  (CH3)3Si.  Trimethylsilylation  involves  the  introduction 
of  the  trimethylsilyl  group  into  a  molecule  (Figure  4-1),  usually  in  substitution  for  an 
active  hydrogen  atom.  [194,208] 
OSI(CH3)3  OSi(CH3)3 
II 
RR  +  R-  C=  N-  Si(CH3)3  -ý  -A-Si(CH3)3  -I-  R-  C=  NH 
Figure  4-1:  -  Typical  silylation  reaction,  in  which  A  represents 
a  heteroatom  such  as  0  or  N. 
The  reagents  that  have  been  used  for  this  purpose  are  derivatives  of  trimethylsilane, 
(CH3)3SiH.  The  replacement  of  active  hydrogen  by  the  trimethylsilyl  group  reduces  the 
polarity  of  the  compound  and  decreases  the  possibilities  of  hydrogen  bonding  (Figure  4-2). 
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Figure  4-2:  -  Derivatisation  by  Silylation  Reaction Chapter  Four  Page  38 
The  advantages  of  volatility  and  stability  imparted  by  silylation  make  the  process  a  natural 
tool  for  gas-phase  purification  and  analysis[208-214].  The  derivative  is  simply  and 
conveniently  prepared.  In  many  case  the  reactants  are  mixed  at  room  temperature  and  the 
reaction  is  complete  in  a  few  minutes.  Nearly  all  functional  groups  which  present  a 
problem  in  gas  chromatographic  separation  (hydroxyl,  carboxylic  acid,  amine,  thiol, 
phosphate)  can  be  derivatized  by  silylation  reagents.  Even  sugars  and  polar  steroids  have 
successfully  been  derivatised  and  analysed  by  GC-MS.  Silylation  reagents  are  influenced 
by  both  the  solvent  system  and  the  addition  of  a  catalyst.  A  catalyst  such  as 
trimethylchlorosilane  or  pyridine  increases  the  reactivity  of  the  reagent.  [215] 
Silylation  has  some  disadvantages,  as  silylation  reagents  are  moisture  sensitive.  The 
reaction  must  therefore  be  performed  using  anhydrous  conditions.  TMS  derivatives  are 
more  sensitive  to  hydrolysis  than  other  derivatives  containing  more  sterically  crowded 
alkyl  substituents  on  the  silicon  atom  and  silylation  must  use  aprotic  organic  solvents.  [216- 
2271 
A  large  number  of  silylating  reagents  is  available  commercially  or  else  they  are  easily 
prepared,  including  N,  O-bis(trimethylsily)acetamide  (BSA),  N,  O-bis 
(trimethylsily)trifluoroacetamide  (BSTFA),  hexamethyldisilazane  (HMDS),  N-methyl-N- 
trimethylsilyl-trifluoroacetamide  (MSTFA),  N-tert-butyl-dimethylsilyl-N-methyl- 
trifluoracetamide  (MTBSTFA),  tert-butyl-dimethylchlorosilane  (TBDMCS),  N-tert-butyl- 
dimethylsilylimidazole  (TBDMSIM),  trimethylchlorosilane  (TMCS),  N-trimethylsilyl- 
diethylamine  (TMSDEA)  and  trimethylsilylimidazole  (TMSIM).  MSTFA  is  the  most 
volatile  TMS  amide  available. 
Typical  reaction  conditions  involve  heating  samples  with  a  silanising  reagent  on  a  hotplate 
at  60°C  for  30-60  minutes,  but  molecules  containing  sterically-hindered  hydroxyl  or  other 
groups  often  require  prolonged  exposure  at  high  temperatures.  Examples  in  forensic 
toxicology  include  buprenorphine,  which  has  a  sterically  hindered  alcohol  group  on  the 
side  chain  and  some  anabolic  steroids. 
Silyl  derivatives  have  been  widely  used  in  forensic  toxicology  and  STA  since  their 
introduction  in  the  1950's.  [144,205,211,228-2303  Formation  of  trimethylsilyl  derivatives  is 
commonly  used  before  the  GC-MS  analysis  of  drugs,  including  the  opiates,  cocaine 
metabolites  and  cannabinoids.  [2311  However,  trimethylsilylation  is  not  often  used  for Chapter  Four  Page  39 
amphetamines  because  incomplete  conversion  occurs  unless  suitable  catalysts  are  used 
such  as  ethanethiol  and  ammonium  iodide.  [2321 
In  the  present  study,  MTBSTFA  reagent  was  selected  for  evaluation  because  previous 
work  had  shown  that  methyl-tertiary-butylsilyl  derivative  mass  spectra  are  characterized  by 
abundant  ions  at  [M-57]+  which  are  good  for  identification  of  drugs  and  for  quantification. 
[228,233,2341  MTBSTFA  is  a  liquid  at  room  temperature,  and  so  can  often  be  used  for 
derivatisation  without  a  solvent.  It  is  sensitive  to  moisture  [2351 
. 
The  advantage  of  using 
MTBSTFA  is  enhanced  reactivity  including  its  ability  to  silylate  carboxyls,  hydroxyls, 
thiols  and  primary  and  secondary  amines,  short  reaction  times  often  at  room  temperature, 
and  simplified  work-up  owing  to  derivatisation  by-products  being  neutral  and  largely 
volatile,  so  providing  the  possibility  for  direct  injection  of  the  reaction  mixture  for  GC 
analysis.  [2081  During  the  course  of  the  work  for  this  study,  a  literature  publication  appeared 
on  the  analysis  of  benzodiazepines  in  biological  samples,  based  on  the  methyl-tertiary- 
butylsilyl  derivative,  in  which  the  authors  showed  that  MTBSTFA  forms  sensitive, 
reproducible  and  stable  derivatives  with  benzodiazepines  which  have  active  hydrogen 
atoms  in  either  a  secondary  amine  (for  example  desmethyl  diazepam)  or  in  a  hydroxyl 
group  (for  example,  Temazepam).  [2361  Tertiary-butyl  dimethylsilyl  derivatives  were  found 
to  be  preferable  to  trimethylsilyl  derivatives  because  stable  trimethylsilyl  derivatives  are 
formed  only  with  benzodiazepines  which  have  a  hydroxyl  group. 
4.2.3  Acylation 
Acylation,  an  alternative  to  silylation,  is  the  conversion  of  compounds  with  active 
hydrogen  atoms  such  as  OH,  SH  and  NH  into  esters,  thioesters  and  amides,  respectively 
(Figure  4-3).  A  classic  example  of  this  method  is  the  insertion  of  perfluoracyl  groups  into 
a  substance  to  enable  or  enhance  electron  capture  detection  (ECD)  [2371  and  negative  ion 
chemical  ionisation  (NICI)  mass  spectrometry.  1238,239]  Carbonyl  groups  adjacent  to 
halogenated  carbons  enhance  the  response  of  ECD.  A  further  benefit  of  acylation  is  the 
formation  of  fragmentation-directing  derivatives  for  GC-MS  analysis,  which  produce 
strong  ions  at  high  mass,  suitable  for  GC-MS  in  the  selected  ion  monitoring  mode. 
Acylation  reactions  can  be  performed  using  three  main  types  of  reagents:  acyl  halides,  acid 
anhydrides  or  reactive  acyl  derivatives  such  as  acylated  imidazoles.  Acyl  halides  and  acid 
anhydrides  (including  perfluoro  acid  derivatives)  readily  form  derivatives  of  alcohols, 
phenols  and  amines  which  are  both  stable  and  highly  volatile.  Acyl  imidazoles  (including Chapter  Four  Page  40 
perfluoracyl  imidazoles)  react  readily  with  hydroxyl  groups  and  secondary  or  tertiary 
amines  to  form  acyl  derivatives. 
RCOC1  +  R-OH  --30  RCOOR  +  HC1 
Figure  4-3:  -  Typical  acylation  reaction 
As  for  silylation  reagents,  the  acylation  reagents  can  be  used  for  highly  polar, 
multifunctional  compounds,  such  as  carbohydrates  and  amino  acids.  Acylation  is  normally 
carried  out  in  pyridine,  tetrahydrofuran  or  another  solvent  capable  of  accepting  the  acid  by- 
product.  The  tendency  of  acyl  derivatives  to  direct  the  fragmentation  patterns  of 
compounds  in  MS  applications  provides  helpful  information  on  the  structure  of  these 
materials.  Other  advantages  of  acylation  are  obtained  because  the  derivatives  are 
hydrolytically  stable  and  give  increased  sensitivity  and  selectivity  in  GC-MS  by  increasing 
the  molecular  weight.  Acylation  can  also  be  used  as  a  first  step  to  activate  carboxylic  acids 
prior  to  esterification,  which  was  used  in  the  present  study. 
However  there  are  disadvantages  with  acyl  derivatives  as  they  can  be  difficult  to  prepare 
and  reaction  products  (acid  by-products)  often  need  to  be  removed  before  analysis. 
Acylation  reagents  are  moisture  sensitive  and  are  hazardous  and  odorous.  There  are  many 
acylation  reagents  used,  such  as  perfluorinated  anhydrides,  including  trifluoroacetic 
anhydride  (TFA),  pentafluoropropionic  anhydride  (PFPA)  and  heptafluorobutyric 
anhydride  (HFBA),  fluoroacylimidazoles,  including  trifluoroacetylimidazole  (TFAI), 
pentafluoropropanoylimidazole  (PFPA),  and  heptafluorobutyrylimidazole  (HFBD,  N- 
methyl-bis-trifluoroacetamide  (MBTFA),  and  also  acid  chlorides  such  as 
pentafluorobenzoyl  chloride  (PFBCI)[24°,  241].  PFPA  is  one  of  the  most  commonly  used 
acylation  reagents,  as  derivatives  are  suitable  for  both  FID  and  ECD,  the  reagent  reacts 
with  alcohols,  amines  and  phenols  to  produce  stable  and  highly  volatile  derivatives.  The 
acid  by-product  should  be  removed,  via  a  stream  of  nitrogen,  before  injection  on  to  the 
column.  Bases,  such  as  triethylamine,  can  be  added  as  an  acid  receptor  and  promote 
reactivity. 
Typical  reaction  conditions  for  acylation  involve  heating  samples  with  an  acylating  reagent 
at  60°C  for  30-60  minutes.  The  reagent  can  be  used  directly  or  can  be  diluted  with  a 
suitable  solvent  such  as  ethyl  acetate.  If  necessary,  a  basic  catalyst  can  also  be  added[242, 
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Acyl  derivatives  have  been  used  widely  in  forensic  STA.  1229,230,242,243]  In  the  present 
study,  PFPA  was  selected  for  evaluation  because  of  previous  experience  within  Forensic 
Medicine  and  Science  of  its  use  for  a  range  of  drug  types  including  amphetamines, 
antidepressants  such  as  fluoxetine,  opioids  such  as  buprenorphine  and  acidic  drugs.  [228 
4.2.4  Alkylation 
Alkylation  involves  adding  an  alkyl  group  to  an  active  functional  group(Figure  4-4) 
containing  a  replaceable  hydrogen  atom,  such  as  those  contained  in  carboxylic  acids, 
alcohols,  thiols,  phenols,  primary  and  secondary  amines,  amides  and  sulfonamides.  [244-247] 
These  are  the  main  functional  groups  that  can  be  subjected  to  alkylation  reactions. 
R2-OH 
R1-AH  -  R1-A-R2  +  H2O 
catalyst 
Figure  4-4:  -  Typical  alkylation  reaction,  where  RI  and  R2  are  organic  groups 
and  A  represents  a  heteroatom 
Replacement  of  hydrogen  with  an  alkyl  group  is  important  because  the  derivative  has 
lower  polarity  relative  to  the  parent  substance.  Alkylation  of  weakly  acidic  groups  such  as 
alcohols  requires  strongly  basic  catalysts  such  as  sodium  or  potassium  methoxide.  [2441 
More  acidic  OH  groups  such  as  those  contained  in  phenols  and  carboxylic  acids  require 
less  basic  catalysts  and  can  even  be  Lewis  acids  such  as  hydrogen  chloride  or  boron 
trifluoride.  Alkylation  can  be  used  alone  to  form  esters,  ethers  and  amides  or  it  can  be 
used  in  conjunction  with  silylation  or  acylation,  as  in  the  present  study.  [246] 
Esterification  is  the  most  common  type  of  alkylation  and  is  used  to  derivatise  carboxylic 
acids  and  other  acidic  functional  groups.  Esterification  involves  the  condensation  of  the 
carboxyl  group  of  an  acid  and  the  hydroxyl  group  of  an  alcohol,  with  the  elimination  of 
water'  [244]  Results  are  best  in  the  presence  of  a  catalyst,  like  BF3  or  HCI,  which  is  then 
removed  with  the  water.  Alkyl  esters  have  excellent  stability  and  can  be  isolated  and 
stored  for  long  periods  of  time.  There  are  many  advantages  for  example,  the  wide  range  of 
alkylation  reagents  available,  reaction  conditions  can  vary  from  strongly  acidic  to  strongly 
basic,  some  reactions  can  be  done  in  aqueous  solutions  and  alkyl  derivatives  are  generally 
stable.  Some  disadvantages  are  that  the  reaction  is  limited  to  amines  and  acidic  hydroxyls, Chapter  Four  Page  42 
reaction  conditions  can  be  severe  and  the  reagents  are  often  toxic.  Typical  reaction 
conditions  for  esterification  involve  heating  the  acid  with  an  alcohol  and  catalyst  either 
under  reflux  (large  scale)  or  in  a  sealed  tube  at  60°C  for  30-60  minutes.  [244,247] 
There  are  many  alkylating  reagents  such  as  dimethylformamide  (DMF  -  dialkylacetals), 
tetrabutylammonium  hydroxide  (TBH),  BF3  in  methanol  or  butanol  and  pentafluorobenzyl 
bromide  (PFBBr)  (Figure  4-5).  (245,246,2481 
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Figure  4-5:  -  Pentafluorobenzyl  bromide  (left)  and  N,  N-Dimethylformamide  (right) 
In  the  present  study,  pentafluoropropanol  was  used  to  alkylate  (esterify)  carboxylic  acid 
groups  in  the  selected  model  compounds  (THC-COOH  and  benzoylecgonine)  with  the 
corresponding  acid  anhydride  (PFPA)  as  the  catalyst.  This  combination  has  previously 
been  used  in  forensic  toxicology  for  the  analysis  of  THC-COOH  [249,250]. 
4.2.5  Methylation  (esterification) 
Methylation  is  a  particular  form  of  the  alkylation  reaction  in  which  a  methyl  group  (CH3-) 
is  introduced  into  a  molecule.  A  specific  example  is  the  replacement  of  a  hydrogen  atom 
by  a  methyl  group.  It  is  widely  used  for  derivatisation  of  carboxylic  acids.  It  is  a  stable 
reaction,  the  reagents  are  easy  to  evaporate,  the  retention  time  of  the  product  is  usually 
well-defined,  a  good  mass  spectrum  is  obtained  and  the  reagents  are  readily  available  and 
inexpensive.  On  the  other  hand,  methylation  can  not  distinguish  benzoylecgonine  and 
cocaine. 
Conventional  reagents  for  methylation  include  boron  trifluoride  in  methanol, 
tetramethylammonium  hydroxide,  methyl  iodide  and  diazomethane?  51-2571  Diazomethane 
is  an  ideal  methylating  agent  in  that  it  reacts  quantitatively  at  room  temperature  and  is Chapter  Four  Page  43 
readily  volatile.  However,  it  is  hazardous  to  prepare  and  use  because  of  its  toxicity  and 
potential  for  detonation.  More  recently  an  alternative  reagent,  trimethylsilyl- 
diazomethane,  became  commercially  available  as  a  solution  in  hexane  for  applications  in 
organic  synthesis  and  this  was  evaluated  in  the  present  study.  [251,253,254,258-2601 
4.3  Microwave  assisted  derivatisation 
Microwaves  are  commonly  used  to  heat  things  containing  water  but  can  also  heat  organic 
molecules  as  in  microwave  assisted  derivatisation.  E189'  1901  Water  molecules  consist  of  two 
hydrogen  atoms  carrying  a  small  positive  charge  and  an  oxygen  atom  carrying  a  negative 
charge.  The  oscillating  electric  field  of  the  microwave  interacts  with  these  charged  atoms 
to  cause  the  molecule  to  twist.  This  rotation  causes  friction,  producing  heat. 
Technically,  in  a  microwave  oven  the  mains  voltage  is  stepped  up  by  a  transformer  and 
capacitor  to  around  3000V,  to  power  the  magnetron  and  generate  microwaves  which  are  in 
effect  high  -  frequency  radio  waves,  at  about  2.5GHz.  The  radiation  is  conducted  through 
the  waveguide  into  the  heating  chamber,  and  then  the  microwaves  are  reflected  from  the 
walls  and  door,  and  penetrate  the  material  in  the  oven  from  the  sides  and  above.  A 
turntable  rotates  the  target  slowly  to  give  even  exposure.  Some  ovens  achieve  this  by 
using  a  microwave  stirrer  instead. 
The  derivatisation  reactions  described  in  Section  4.2  are  normally  carried  out  using  a  dry- 
block  (oven)  for  a  period  of  typically  30  minutes  up  to  several  hours.  This  time  delay  is  a 
major  disadvantage  of  [187,188,261,2621  261,262  By  using  a  microwave  a  much  shorter 
time  has  been  found  to  be  needed  for  the  same  derivatisation,  e.  g.  1  minute  at  900 
Watts.  [184-186] 
4.4  Experimental  Section 
4.4.1  Reagents  and  materials 
a)  PFPA  (pentafluoropropionic  anhydride,  C6F10O3,  MW  460,  Figure  4-6)  was  supplied  by 
Fluka  Chemicals,  The  Old  Brickyard  New  Road,  Gillingham,  Dorset,  SP8  4JL,  England. Chapter  Four  Page  44 
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Figure  4-6:  -  Structure  of  PFPA  anhydride 
b)  PFP-OH  (2,2,3,3,3-pentafluoropropanol,  97%,  C3F5H3O,  MW  150,  Figure  4-7)  and 
TMS  (trimethylsilyl-diazomethane,  2.0  M  solution  in  hexane,  C4H10N2Si.  MW  114,  Figure 
4-8)  were  supplied  by  Sigma-Aldrich  Company  Ltd,  Fancy  Road,  Poole,  Dorset,  BH12 
40H,  England. 
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Figure  4-7:  -  Structure  of  PFP-OH  alcohol 
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Figure  4-8:  -  Structure  of  trimethylsilyl-diazomethane 
c)  MTBSTFA,  (N-Methyl-N-tert-butyldimethysilytrifluoroacetamide,  C9H18F3NOSi,  MW 
238,  Figure  4-9)  containing  1%  by  volume  of  TBDMCS  was  supplied  by  Perbio  Science 
UK  Limited,  Century  House,  Tattenhall,  Cheshire,  CH3  9RJ. Chapter  Four  Page  45 
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Figure  4-9:  -  Structure  of  MTBSTFA+1  %  TBDMCS 
(d)  ReactiVials®  (1  ml  and  3  ml  sizes)  for  microwave-assisted  derivatisation  were  obtained 
from  Perbio  Science  UK  Limited,  Century  House,  Tattenhall,  Cheshire,  CH3  9RJ.  These 
were  sealed  with  the  standard  ReactiVial  screw  cap  and  septum. 
4.4.2  Drug  standards  and  internal  standards 
Drug  standards  and  internal  standards  used  were  amphetamine,  amphetamine-d5  (Figure 
4-10),  methamphetamine,  methamphetamine-d5  Figure  4-11),  morphine,  morphine-d3 
(Figure  4-12),  benzoylecgonine,  benzoylecgonine-d3  (Figure  4-13),  A9- 
tetrahydrocannabinol  (THC-OH),  tetrahydrocannabinol-d3  (Figure  4-14)  and  11-nor-A9- 
tetrahydrocannabinol-9-carboxylic  acid  (THC-COOH,  Figure  4-15).  Stock  standard 
solutions  of  all  drugs  were  obtained  at  concentrations  of  0.1  mg/mL  in  methanol  from 
Sigma-Aldrich  Company  Ltd,  Fancy  Road,  Poole,  Dorset,  BH12  40H,  England.  THC- 
OH  and  THC-COOH  were  supplied  by  LGC  Promochem  Group  Company,  Queens  Road, 
Teddington,  TW11  OLY,  and  Middlesex.  Working  standards  were  prepared  at  10  µg/mL 
by  dilution  with  methanol.  Further  details  of  standard  solutions  are  given  in  Section  5.1. 
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Figure  4-10  :-  Amphetamine  and  Amphetamine-dg Chapter  Four  Page  46 
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Figure  4-12:  -  Morphine  and  Morphine-d3 
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Figure  4-13:  -  Benzoylecgonine  and  Benzoylecgonine-  d3 
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Figure  4-14:  -  THC-OH  and  THC-OH-d3 Chapter  Four  Page  47 
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Figure  4-15:  -THC-000H  and  THC-COOH-d3 
4.4.3  Derivatisation  procedures 
CDs 
During  the  initial  studies  of  derivatisation  reactions,  standards  were  reacted  individually 
rather  than  in  mixtures.  Aliquots  of  working  standard  solution  (10  µg/ml,  100  µl)  were 
pipetted  into  ReactiVials®  and  evaporated  to  dryness  under  a  stream  of  nitrogen,  without 
heating,  to  avoid  evaporation  of  amphetamines.  The  residues  were  then  dissolved  in  the 
three  selected  reagents  and  subjected  to  microwave  heating  as  described  in  Section  4.4.4. 
Reagents  were  evaluated  as  follows 
a)  Acylation/alkylation  was  carried  out  with  a  mixture  of  PFPA  and  PFP-OH.  Different 
ratios  of  PFPA  and  PFP-OH  were  prepared  (0.5:  1,1:  1  and  2:  1  v/v)  and  different 
volumes  of  reagent  mixture  were  reacted  with  the  standards  (50,100  and  150  µl).  In 
addition,  the  effect  of  adding  the  reagents  sequentially  instead  of  simultaneously  was 
tested. 
b)  Acylation/methylation  (esterification)  was  carried  out  with  PFPA/TMS-diazomethane. 
Different  volumes  of  PFPA  (50,100,150  µl)  and  TMS-diazomethane  (10,20,50  µl) 
were  tried  and  the  effect  of  adding  the  sequentially  was  tested. 
c)  Silylation  was  carried  out  with  MTBSTFA  containing  1%  TBDMCS.  Different 
volumes  of  reagent  were  tried  (20,30,50  µl). 
The  yield  of  derivatisation  reactions  was  indicated  by  the  peak  size  of  the  products  when 
measured  by  GC-MS.  Comparisons  were  carried  out  within  batches  of  samples  and  no 
internal  standards  were  used  except  for  morphine  and  benzoylecgonine  TBDMS. 
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4.4.4  Microwave  heating 
The  microwave  oven  used  in  this  study  was  a  Micro  Chef  Model  ST23W  manufactured  by 
Proline,  with  a  maximum  power  output  of  750Watts.  The  irradiation  intensity  and  length 
of  the  irradiation  time  is  dictated  by  the  power  level  chosen.  Vials  were  arranged  on  the 
glass  plate  in  the  oven  in  a  circle  as  shown  in  (Figure  4-16)  to  balance  their  exposure  to  the 
microwave  radiation. 
0  00  1 
00  0O 
Figure  4-16:  -  Microwave  Oven 
Different  power  settings  and  reaction  times  were  evaluated  to  establish  practical  conditions 
for  derivatisation.  In  addition,  different  types  of  reaction  vial  were  tested  to  identify  a 
suitable  type  for  use  in  the  microwave  oven,  as  initial  tests  found  that  some  types  of  screw 
cap  were  damaged  by  the  oven. 
4.4.5  Instrumental  methods 
After  heating  in  the  microwave  oven,  the  vials  containing  reaction  mixtures  were  then 
cooled  to  room  temperature  and,  except  for  those  derivatised  with  MTBSTFA  reagent, 
evaporated  to  dryness  under  a  stream  of  N2.  The  derivatised  extracts  were  reconstituted  in 
50µl  of  ethyl  acetate  prior  to  analysis  by  GC-MS.  MTBDMS  derivatives  were  injected  in 
the  reagent. 
GC-MS  was  carried  out  on  a  Thermo-Finnigan  trace  quadrupole  instrument  operated  in 
EI+  repetitive  full  scan  mode.  Operational  parameters  used  were  based  on  those  used  in 
the  Forensic  Medicine  and  Science  routine  laboratory,  many  of  which  were  the  standard 
default  settings  recommended  by  the  instrument  manufacturer.  Data  was  acquired  and Chapter  Four  Page  49 
processed  using  ExcaliberTM  software  from  Thermo-Finnigan.  It  was  equipped  with  a  fused 
silica  capillary  column  (HP-5,30m  x  0.32  mm  x  0.25  gm  film  thicknesses)  and  Supplied 
by  J&W  Scientific  (Agilent  Technologies).  Helium  was  used  as  the  carrier  gases  at  flow 
rate  of  1.2  ml/min.  1l  of  samples  were  injected  via  a  split-splitless  injection  mode  with  an 
injection  temperature  of  200  °C.  The  initial  column  temperature  was  100  °C  and  was 
programmed  to  300  °C  at  a  rate  of  10  °C/min.  The  spectrometer  was  used  in  the  EI  mode 
with  electron  energy  of  70  eV  and  source  temperature  200  T.  The  emission  current  was 
180µA  with  detector  voltage  350V,  as  shown  in  Table  4-1. 
Table  4-1:  -  Conditions  for  GC-MS 
Parameter  Setting 
Column  HP-5  column, 
0.25  gm  film 
J&W  Scientific 
30  mx0.32  mm  x 
thickness.  Supplied  by 
(Agilent  Technologies) 
Carrier  Gas  Helium,  1.2  ml/min 
Injector  Temperature  280  T 
Injection  volume  1  1, 
Injection  mode  split  -splitless,  purge  time  0.7  min 
Temperature  Programme  100  to  300  °C  at  10  °C  /minute 
Interface  temperature  200°C 
Electron  energy  70  eV 
Source  temperature  200°C 
Emission  current  180  A 
Detector  voltage  350V 
4.5  Results  and  Discussion 
4.5.9  Microwave  assisted  derivatisation  procedures 
Microwave  heating  instead  of  a  conventional  heating  block  was  used  to  assist 
derivatisation.  It  required  less  time  to  achieve  complete  derivatisation. 
Initial  tests  of  the  microwave  oven  indicated  that  the  conditions  applied  should  be  suitable 
for  the  vials  and  vial  caps,  particularly  the  power  setting  used.  During  trials  of  the 
procedure,  it  was  found  that  conventional  vial  caps  such  as  Bakelite  caps  (used  on  the 
standard  laboratory  %z-Drachm  and  1-Drachm  vials)  or  autosampler  caps  (used  on  screw- 
top  autosampler  vials)  may  melt  at  high  power  settings.  Metallic  crimp-top  vials  could  not 
be  used  in  a  microwave  oven.  This  problem  was  solved  by  using  resistant  ReactiVial® Chapter  Four  Page  50 
type  vials  and  caps,  although  these  are  relatively  expensive  and  require  to  be  re-used  rather 
than  being  treated  as  disposable. 
A  disadvantage  of  using  the  microwave  was  that  the  distribution  of  power  was  uneven  and 
the  arrangement  of  the  vials  on  the  glass  plate  in  the  oven  was  found  to  be  important. 
Regular  laboratory  test  tube  racks  manufactured  using  plastic-coated  wire  could  not  be 
used  because  the  plastic  coating  melted  in  the  oven.  However,  ReactiVials  are  of  heavy 
glass  construction  and  were  found  to  be  stable  in  the  oven  without  any  additional  support. 
It  was  found  to  be  convenient  to  arrange  the  vials  in  a  circle  shape  as  shown  in  (Figure 
4-16)  so  that  the  temperature  distribution  was  balanced,  which  would  help  the 
derivatisation  reaction.  [263-265] 
The  use  of  a  microwave  oven  instead  of  a  conventional  heating  block  gave  a  significant 
saving  of  time  in  the  derivatisation  step  since  tests  showed  that  derivatisation  reactions 
with  all  three  reagents  were  complete  in  1  minute  instead  of  30  minutes  (usually)  in  a 
heating  block.  However,  there  were  also  disadvantages  of  using  the  microwave  oven. 
One  disadvantage  was  that  expensive  vials  were  needed  with  caps  that  were  able  to  resist 
the  effects  of  the  oven.  Tests  carried  out  with  conventional  vials  such  as  those  used  in 
autosamplers  showed  that  the  caps  melted  or  were  damaged  leading  to  loss  of  reagents  by 
evaporation.  The  only  suitable  vials  which  were  found  were  ReactiVialsTM  which  are 
heavy-duty  vials  with  thick  bases  and  which  cost  several  pounds  each.  This  cost  would 
prevent  the  vials  being  disposed  of  after  use,  which  would  lead  to  the  risk  of  cross- 
contamination  in  forensic  toxicology  casework  and  which  would  be  unacceptable  unless  a 
quality-controlled  cleaning  system  was  introduced  by  which  vials  were  checked  before  use. 
Another  disadvantage  was  that  volatile  reagents  were  lost  due  to  evaporation,  even  when 
ReactiVials  were  used.  As  a  result,  relatively  large  volumes  of  PFPA  and  PFPOH  reagents 
was  required  so  that  the  reaction  mixture  did  not  dry  our  during  the  derivatisation  step. 
The  use  of  100  microlitres  of  this  reagent  mixture  per  sample  would  also  be  expensive  for 
routine  toxicology.  This  problem  might  be  solved  by  adding  a  "keeper"  solvent  with  a 
high  boiling  point,  which  has  been  done  in  the  past  when  volatile  analytes  such  as 
amphetamines  are  analysed,  to  prevent  losses  by  evaporation.  One  example  is  the  addition 
of  dimethylformamide  to  SPE  extracts  of  amphetamines  before  they  are  evaporated  to  a 
low  volume.  [2311 Chapter  Four  Page  51 
The  aim  of  the  investigation  was  to  optimise  the  time  for  complete  derivatisation  especially 
for  some  drugs  such  as  THC-COOH,  which  requires  the  derivatisation  of  two  functional 
groups.  The  temperature,  power  and  time  of  irradiation  were  investigated.  The  time  to 
derivatise  was  varied  from  1  to  5  minutes.  It  was  found  that  using  3  or  5  minutes  at  the 
high  power  setting  affected  the  integrity  of  the  caps  and  the  sample  was  lost.  The  optimum 
time  was  found  to  be  1  minute  at  the  high  power  setting  (750  Watts),  which  was  found  to 
be  sufficient  for  all  of  the  reactions  which  were  under  evaluation.  Longer  derivatisation 
time  periods  did  not  lead  to  higher  yields  of  derivatives,  based  on  the  peak  sizes  of  the 
products,  but  could  lead  to  evaporation  of  the  reagents.  These  settings  were  therefore 
retained  for  the  rest  of  the  study. 
Based  on  the  trails  of  different  reagent  mixture  compositions,  the  following  were  found  to 
be  the  optimum  amounts. 
a)  Acylation/alkylation: 
Acyl  derivatives  were  formed  using  100  µl  PFPA  and  50  µl  PFP-OH.  Better  results 
were  obtained when  these  reagents  were  added  individually  and  consecutively, 
beginning  with  PFPA,  which  reacts  with  alcohols  and  amines.  PFP-OH  added 
subsequently  reacts  with  carboxylic  acids.  Trials  were  carried  out  of  different  volumes 
of  the  reagents  as  it  was  important  to  know  the  effect  of  the  reagent  amount  on  the 
reaction.  Chromatograms  were  recorded  of.  the  derivatives  formed  by  the  test  drugs 
after  reaction  with  200µL  PFPA,  50  µL  PFP-OH  and  60  µL  ethyl  acetate,  which 
showed  that  all  the  drugs  reacted  well  except  THC-OH  and  THC-COOH  (Figure  4-17). Chapter  Four  Page  52 
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Figure  4-17:  -  TIC  Chromatograms  and  Mass  Spectra  for  test  drugs  following  reaction  with 
PFPA,  PFP-OH  and  ethyl  acetate. Chapter  Four 
b)  Acylation/methylation  (esterification): 
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Acyl  derivatives  were  formed  using  100  µl  PFPA  and  methylation  was  subsequently 
carried  out  using  20  µl  TMS-diazomethane  in  hexane  (2M  solution). 
c)  TBDMS  derivatives: 
These  were  prepared  using  30  gl  of  MTBSTFA  reagent  containing  1%  TBDMS,  which 
was  enough  to  dissolve  the  sample  for  derivatisation  in  the  microwave  without 
evaporation  to  dryness  during  the  heating  process. 
4.5.2  GC-MS  analysis  of  derivatives  of  model  compounds 
A  summary  of  the  products  obtained  using  the  three  derivatisation  reagents  with  each  of 
the  model  compounds  is  given  in  Table  4-2  The  derivatives  formed  by  the  deuterated 
internal  standards  are  similar  to  those  formed  by  the  unlabelled  compounds  and  have 
similar  retention  times,  which  were  only  1-2  seconds  less  than  those  of  the  unlabelled 
compounds.  The  chromatography  and  fragmentation  patterns  observed  in  their  mass 
spectra  are  discussed  in  detail  below. 
Table  4-2:  -  Results  of  derivatisation  reactions 
Model  Compound  Reagent  Product  Retention  Time 
Amphetamine  (AM)  PFPA/PFP-OH  AM-PFP  4.54 
PFPA/TMS- 
diazomethane 
AM-PFP  4.54 
MTBSTFA  AM-TBDMS  6.92 
Methamphetamine 
(METH) 
PFPA/PFP-OH  METH-PFP  5.73 
PFPA/TMS- 
diazomethane 
METH  -PFP  5.73 
MTBSTFA  None  formed  - 
Morphine  (MOR)  PFPA/PFP-OH  MOR-bis-PFP  13.98 
PFPA/TMS- 
diazomethane 
MOR-bis-PFP  13.98 
MTBSTFA  BZE-bis-TBDMS  14.76 
Benzoylecgonine 
(BZE) 
PFPA/PFP-OH  BZE-PFP  ester  12.36 
PFPA/TMS- 
diazomethane 
Cocaine  13.98 
MTBSTFA  BZE-TBDMS  ester  15.86 Chapter  Four  Page  54 
THC  PFPA/PFP-OH  THC-PFP  13.01 
PFPA/TMS-  THC-PFP  13.01 
diazomethane 
MTBSTFA  THC-TBDMS  15.86 
THC-COOH  PFPA/PFP-OH  THC-COOH-PFP  14.35 
PFP  ester 
PFPA/TMS-  THC-COOH-PFP  15.29 
diazomethane  methyl  ester 
MTBSTFA  THC-COOH-bis-  19.33 
TBDMS 
4.5.3  PFPAIPFP-OH  Derivatives: 
Derivatisation  was  successful  for  all  of  the  test  compounds  and  mass  spectra  were  obtained 
for  each  of  them.  These  derivatives  gave  good  gas  chromatographic  behaviour,  in  terms  of 
peak  shape  and  thermal  stability,  and  the  mass  spectra  had  prominent  molecular  ions  and 
also  prominent  diagnostic  fragment  ions  at  high  mass,  suitable  for  use  as  qualifier  ions  in 
selected  ion  monitoring  GC-MS.  The  ions  used  for  the  identification  and  quantification  are 
shown  in  Table  4-3. 
The  optimum  derivatisation  reagent  composition  was  regarded  as  the  one  which  produced 
a  good  chromatographic  peak  with  the  correct  fragmentation  pattern.  These  reagents  react 
with  alcohols,  amines  and  phenols  (Figure  4-18,  Figure  4-19,  Figure  4-22  and  Figure 
4-26).  PFPA  will  replace  the  proton  (H)  of  a  functional  group  with  -C3F50.  In  the  case  of 
benzoylecognine  and  THC-COOH,  which  contain  carboxylic  acid  groups  (Figure  4-24  and 
Figure  4-28)  the  reaction  will  be  with  PFP-OH  with  addition  of  -C3H2F5. 
Table  4-3:  -  Selected  Ions  used  for  GC/MS-SIM  with  PFPA-PFP-OH 
Target  analyte  Retention 
time 
(min) 
Qualifier  Ions 
(m/z) 
Internal  Standard  Selected 
Ions 
(m/z) 
Amphetamine  4.51  118  Amp-Ds  122 
Methamphetamine  5.71  204  Meth-D5  208 
Morphine  13.86  414  Mor-D3  417 
Benzoylecgonine  12.43  82  Bze-D3  85 
THC-OH  12.94  417  THC-OH-D3  420 Chapter  Four 
THC-COOH  14.35 
(a)  Amphetamine  and  Methamphetamine: 
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The  mass  spectra  of  amphetamine  and  methamphetamine  PFP  derivatives  are  shown  in 
Figures  4-17  and  4-18. 
Lo06pNV0lýlti  IýT  f.!  i  AY  "  Nl  !  Tt!! 
T:  10  01  ""!  1  MOW  AO  Iu11  ft  NAOlN.  001 
ýý 
III.  1 
M 
ý 
ý So 
ýs 
" 
a 
: 
a 
16 
1 
"q.  A 
LL1DA 
THC-COOH-D3 
CH3  0FF 
I  11  1I 
CH',  -CH-NH  C-C-C 
II FF 
m/z  281M+ 
a.  t  I 
Figure  4-18:  -  Mass  Spectrum  of  Amphetamine  -PFP 
The  molecular  ions  for  amphetamine  and  methamphetamine  PFP  derivatives  are  at  m/z  281 
and  m/z  295  respectively.  These  molecular  ions  fragment  as  shown  in  Figures  4-19  and  4- 
20.  Amphetamine  and  methamphetamine  PFP  derivatives  produce  base  peaks  at  ni/z  118 
and  m/z  204  repectively  and  correspond  to  the  fragments  [C6H5-CH2-C2H3]  +  for 
amphetamine  and  [CH  CH3  NCH3  C2OF5]+  for  methamphetamine.  PFP  derivatives  of  both 
amphetamine  and  methamphetamine  share  a  fragment  ion  at  m/z  119  which  corresponds  to 
the  loss  of  C3F5ONH  and  C4H3F5NO  for  amphetamine  and  methamphetamine  respectively. 
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Figure  4-19:  -  Mass  Spectrum  of  Methamphetamine  -PFP 
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Figure  4-20:  -  Fragmentation  of  Amphetamine  PFP  derivative 
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The  fragmentation  reactions  can  therefore  be  classified  according  to  where  the  cleavage 
occurs  in  the  molecule:  amphetamine  derivatives  show  a  typical  alpha  cleavage  reaction 
adjacent  to  the  carbon  holding  the  nitrogen  atom  (charge  retention  on  nitrogen)  as  well  as  a 
charge  migration  reaction  resulting  in  cleavage  between  the  carbon  atom  and  the  nitrogen 
atom  plus  loss  of  1  proton  Table  4-3: 
Table  4-3:  -  retention  and  migration  of  charge 
Compound  Reaction 
Charge  retention  Charge  migration 
AM  190  118 
AM-d5  194  122 
METH  204  118 
METH-d5  208  122 
Fragment  ions  at  m/z  118,122,204  and  208  were  selected  for  use  as  quantitation  ions  in 
subsequent  work. 
(b)  Morphine: 
The  mass  spectrum  of  morphine  is  shown  in  Figure  4-21.  Morphine  has  2  hydroxyl  groups 
and  so  will  react  with  PFPA  producing  a  molecular  ion  at  m/z  577.  This  ion  fragments  as 
shown  in  Figure  4-22.  Significant  reactions  involve  loss  of  the  pentafluoropropanoyl  ion 
from  the  phenolate  hydroxyl  group  and  of  the  pentafluoropropionyl  ion  from  the  alicyclic 
hydroxyl  group  to  give  the  base  peak  at  m/z  414.  This  fragment  ion  and  the  corresponding 
one  at  m/z  417  for  morphine-d3  were  used  as  quantitation  ions. Chapter  Four 
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(c)  Benzoylecgonine: 
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Benzoylecgonine  has  a  carboxylic  acid  group  which  reacts  with  PFP-OH  to  form  the 
corresponding  ester  with  a  molecular  ion  at  m/z  421  as  shown  in  Figure  4-24.  The 
molecular  ion  for  benzoylecgonine  fragments  as  shown  in  Figure  4-25.  The  base  peak  is  at 
m/z  82,  which  consists  of  part  of  the  ecgonine  ring  system,  and  the  intense  ion  at  m/z  300 
is  formed  by  loss  of  benzoic  acid.  Notably,  the  loss  of  the  pentafluoropropanol  fragment  is 
not  favoured  and  gives  a  relatively  weak  ion  at  m/z  272.  The  base  peak  ion  and  the 
corresponding  ion  in  benzoylecgonine-d3  at  m/z  85  were  used  as  quantitation  ions. 
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Figure  4-24:  -  Mass  spectrum  of  Benzoylecgonine  -PFP Chapter  Four 
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Figure  4-25:  -  Fragmentation  of  Benzoylecgonine  PFP  derivative 
(d)  THC-OH  and  THC-COOH 
THC-OH  has  a  phenolic  hydroxyl  group  so  will  react  with  PFPA  producing  a  PFP 
derivative  with  a  molecular  ion  at  m/z  460  as  shown  in  Figure  4-26,  which  is  also  the  base 
peak.  This  ion  fragments  as  shown  in  Figure4-27.  A  number  of  strong  ions  are  present  at 
high  mass,  which  are  useful  as  qualifier  ions Chapter  Four 
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Figure  4-26:  -  Mass  Spectrum  of  THC-OH-PFP 
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Figure4-27:  -Fragmentation  of  THC-OH  PFP  derivative 
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THC-COOH  also  has  a  carboxylic  acid  group  which  reacts  with  PFP-OH  and  PFPA  to 
produce  a  bis-PFP  derivative  with  a  molecular  ion  at  m/z  622  as  shown  in  Figure  4-28. 
The  molecular  ion  for  THC-COOH  will  fragment  as  shown  in  Figure  4-29.  The  base  peak 
ion  at  m/z  459  is  formed  by  loss  of  pentafluoropropanoate,  and  this  ion  together  with  the 
corresponding  ion  for  THC-COOH-d3  at  m/z  462  was  used  as  quantitation  ions. 
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Figure  4-28:  -  Mass  Spectrum  of  THC-COOH  -PFP  derivative Chapter  Four  Page  63 
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Figure  4-29:  -  Fragmentation  of  THC-COOH  PFP  derivative Chapter  Four 
4.5.4  PFPA/TMS-diazomethane  Derivatives: 
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The  second  derivatisation  procedure  investigated  used  PFPA  and  TMS-diazomethane. 
PFPA  does  not  react  with  carboxylic  acid  groups  but  the  novel  methylating  agent  TMS- 
diazomethane  was  added  in  order  to  convert  these  to  methyl  esters.  This  reaction  was 
found  to  proceed  rapidly  and  quantitatively  at  room  temperature  and  holds  potential  for 
future  use  in  toxicology  to  replace  diazomethane,  a  hazardous  and  toxic  material[252,255] 
Trimethylsilyl-diazomethane  potentially  provides  a  safer  alternative  to  diazomethane, 
which  is  prepared  in  small  batches  just  before  use  because  of  its  high  toxicity  and 
explosion  risk.  Diazomethane  is  an  almost  ideal  reagent  for  methylation  because  it  is  a 
gaseous  reagent  used  in  solution  which  reacts  with  carboxylic  acids  immediately  and  can 
even  be  used  with  aqueous  samples.  Trimethylsilyl-diazomethane  is  available 
commercially,  dissolved  in  hexane  or  ether  as  a  2M  solution,  and  so  avoids  the  hazards  and 
risks  of  preparing  diazomethane  in  the  laboratory.  The  present  study  found  that  a  small 
volume  of  the  reagent  (20  microlitres)  was  sufficient  to  methylate  the  test  compounds  used. 
However,  the  commercial  product  is  not  of  "derivatisation  grade"  as  are  other  reagents 
used  for  trace  analysis  and  it  contains  impurities  derived  from  its  manufacture.  The 
originally-published  method  for  this  involves  a  Grignard  rection  in  ether  or  hexane  and 
distillation  to  obtain  a  solution  of  trimethylsilyl-diazomethane.  [2661  Some  of  the  reaction 
bi-products  and  reagents  are  present  in  the  trimethylsilyl-diazomethane  solution  which  is 
obtained  and  these  may  potentially  cause  interference.  Interferences  due  to  the  reagent  in 
toxicological  analyses  were  assessed  in  the  second  phase  of  this  study  (Chapter  5). 
However,  the  reagent  has  also  been  advocated  for  the  analysis  of  acidic  pesticides  in 
wastewater.  [2551  Also,  the  reagent  was  used  for  the  analysis  of  acidic  metabolites  of  the 
riot  control  agent  2-chlorobenzylidene  malononitrile  (CS  gas)  in  post  mortem  liver 
samples.  [267]  In  the  present  study,  no  interference  was  found  in  the  GC-MS  analysis  of  the 
test  compounds. 
The  products  of  acylation  of  amines  and  alcohol  remained  unchanged  from  those  obtained 
with  PFPA/PFP-OH  but  the  acylated/methylated  products  also  gave  good  gas 
chromatography  and  had  mass  spectra  which  are  suitable  for  both  identification  and 
quantification  by  GC-MS-SIM.  The  ions  for  use  in  selected  ion  monitoring  are  given  in 
Table  4-4. Chapter  Four 
Table  4-4:  -  Selected  Ions  used  for  GC/MS-SIM  with  PFPA-TMS-Diazomethane 
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Target  analyte  Retention  time 
(min) 
Selected 
Ions  (m/z) 
Internal 
Standard 
Selected  Ions 
(m/z) 
Amphetamine  4.51  118  Amp-d5  122 
Methamphetamine  5.71  204  Meth-d5  208 
Morphine  13.86  414  Mor-d3  417 
Benzoylecgonine  12.43  82  Bze-d3  85 
THC-OH  12.94  417  THC-OH-d3  420 
THC-COOH  14.35  489  THC-COOH-d3  492 
Therefore,  in  this  reaction  PFPA  reacts  with  all  drugs  as  before  (Figure  4-18,  Figure  4-19, 
4-21  and  Figure  4-26)  except  benzoylecgonine  and  THC-COOH  which  contain  carboxylic 
acid  groups.  These  acid  groups  are  derivatised  with  TMS-diazomethane,  substituting  a 
proton  from  the  functional  group  with  a  methyl  group  (Figure  4-36,  Figure  4-38).  The  mass 
spectra  of  PFP  acyl  derivatives  of  AM,  METH,  MOR  and  THC  are  not  repeated  here  but 
specimen  chromatograms  are  given  in  Figure  4-30  to  Figure  4-35,  which  illustrate  the 
symmetrical  peak  shapes  obtained  with  this  reagent. Chapter  Four 
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Figure  4-30:  -  TIC  chromatogram  of  amphetamine  PFP  derivative 
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Figure  4-31:  -  TIC  chromatogram  of  methamphetamine  PFP  derivative 
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Figure  4-32:  -  TIC  Chromatogram  and  Mass  Spectrum  for  Morphine-PFP Chapter  Four  Page  67 
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Figure  4-33:  -  Selected  ion  chromatograms  for  benzoylecgonine  methyl  ester  (cocaine) 
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Figure  4-34:  -TIC  chromatogram  for  THC-OH  PFP  derivative 
Figure  4-35:  -  TIC  chromatogram  for  THC-COOH  PFP/methyl  ester  derivative Chapter  Four  Page  68 
The  molecular  ion  for  benzoylecognine  with  PFPA/TMS-  diazomethane  was  m/z  303,  i.  e. 
methylation  of  benzoylecgonine  produces  cocaine  as  shown  in  Figure  4-36.  This  is  a 
disadvantage  of  methylation  compared  to  other  derivatising  agents  as  the  product  cannot  be 
distinguished  from  cocaine  which  was  in  the  sample.  This  problem  could  be  overcome  by 
using  an  analogue  of  TMS-diazomethane  such  as  TMS-diazopropane.  TMS-diazoethane 
would  also  cause  a  problem  because  cocaethylene  may  also  be  present  in  blood  following 
simultaneous  administration  of  cocaine  and  ethanol,  which  is  a  common  practice. 
The  molecular  ion  fragments  as  shown  in  Figure  4-37.  The  mass  spectrum  has  a  base  peak 
at  m/z  182  and  with  elemental  composition  [C10H12NO2]+.  The  PFPA/TMS-diazomethane 
and  PFPA/PFP-OH  derivatives  of  benzoylecgnine  share  the  m/z  82  and  m/z  272  ions, 
which  have  elemental  composition  [C5H8N]  +  and  [C18H803]  +,  because  the  ester  group  is 
lost  when  each  of  these  ions  is  formed. 
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Figure  4-36:  -  Mass  Spectrum  Benzoylecgonine  PFP-TMS-diazomethane  derivative  (Cocaine) Chapter  Four  Page  69 
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Figure  4-37:  -  Fragmentation  for  benzoylecgonine  PFPITMS-  diazomethane  derivative 
(cocaine) Chapter  Four  Page  70 
The  molecular  ion  for  THC-COOH  with  PFPA/TMS-diazomethane  was  at  m/z  504  as 
shown  in  Figure  4-38.  This  ion  fragments  as  shown  in  Figure  4-39.  It  has  a  base  peak  at  m/z 
489  and  has  the  composition  [C24H2605F5 
Figure  4-38:  -  Mass  Spectrum  for  THC-COOH-PFP-TMS-diazomethane 
The  methyl  ester/PFP  derivative  and  PFP-OH  ester/PFP  derivative  share  a  common  ion  at 
m/z  489,  which  indicates  that  the  ester  substituent  is  lost,  as  this  removes  the  structural 
difference  between  the  two  derivatives. Chapter  Four  Page  71 
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Figure  4-39:  -  Fragmentation  for  THC-COOH-PFPITMS-  diazomethane Chapter  Four  Page  72 
4.5.5  TBDMS  Derivatives: 
The  third  derivatisation  method  investigated  was  using  MTBSTFA.  In  this  reaction 
analytes  react  with  (CH3)2SiC(CH3)3  from  MTBSTFA  reagent  to  produce  the  structures 
shown  in  (Figure  4-41,  Figure  4-43,  Figure  4-45,  Figure  4-47  and  Figure  4-49).  The 
advantage  of  this  reagent  is  its  ability  to  react  with  alcohols,  primary  amines,  phenols  and 
carboxylic  acid  groups  and  this  method  gave  derivatives  with  all  test  compounds  except 
the  secondary  amine,  methamphetamine,  despite  the  addition  of  a  catalyst, 
MTBDMCS,  Figure  4-40.  Gas  chromatographic  behaviour  of  these  derivatives  was  good, 
but  although  using  MTBSTFA  to  derivatise  morphine  produced  good  peak  shapes  and 
looked  to  be  sensitive,  these  results  were  for  a  standard  at  a  high  concentration.  At  a  low 
concentration,  it  was  difficult  to  detect  morphine.  The  mass  spectra  had  prominent  ions 
suitable  for  GC-MS-SIM,  often  showing  ions  due  to  the  loss  of  the  butyl  substituent  in  the 
silyl  derivatives.  Ions  for  use  in  selected  ion  monitoring  are  given  in  Table  4-5. 
Table  4-5:  -  Selected  Ions  used  for  GCIMS  with  MTBSTFA  derivatisation 
Target  analyte  Retention 
time(min) 
Selected 
Ions(m/z) 
Internal 
Standard 
Selected 
Ions 
(m/z) 
Amphetamine  6.92  158  Amp-D5  162 
Morphine  15.72  342  Mor-D3  345 
Benzoylecgonine  14.76  282  Bze-D3  285 
THC-OH  15.86  342  THC-OH-D3  345 
THC-COOH  19.33  515  THC-COOH-D3  518 
The  molecular  ions  for  amphetamine,  morphine,  benzoylecgonine,  THC-OH  and  THC- 
COOH  TBDMS  derivatives  were  at  m/z  249,  m/z  513,  m/z  403,  m/z  428  and  m/z  572 
respectively.  These  ions  fragment  as  shown  in  (Figure  4-42,  Figure  4-44,  Figure  4-46, 
Figure  4-48  and  Figure  4-50). Chapter  Four 
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Figure  4-40:  -  TIC  Chromatogram  for  Amphetamine  -TBDMS,  (A)  without  Catalyst  (B)  with 
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Figure  4-41:  -  Ion  Chromatogram  for  m/z  158  and  Mass  Spectrum  for  Amphetamine  -TBDMS Chapter  Four 
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Figure  4-42:  -  Fragmentation  of  Amphetamine  -TBDMS 
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+ 
Amphetamine  has  a  primary  amine  and  produces  a  base  peak  at  m/z  158  assigned  the 
fragment  composition  [C8H2OSiN]+.  This  ion  is  formed  by  the  characteristic  reaction  of 
amphetamines,  alpha  cleavage,  beside  the  carbon  holding  the  nitrogen  atom.  The  other 
high-mass  fragment  ion,  at  m/z  192,  is  formed  by  loss  of  the  tertiary  butyl  group  from  the 
derivative.  The  molecular  ion  at  m/z  249  is  not  visible  but  there  is  a  weak  ion  at  m/z  234 
due  to  loss  of  a  methyl  group. Chapter  Four  Page  76 
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Figure  4-43:  -  TIC  Chromatogram  and  Mass  Spectrum  for  Morphine-TBDMS  (also  containing 
the  internal  standard  Morphine-d3). Chapter  Four  Page  77 
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Figure  4-44:  -  Fragmentation  of  Morphine-bis-TBDMS  derivative 
The  mass  spectrum  of  morphine-bis-TBDMS  derivative  contains  strong  ions  at  m/z  399 
and  m/z  342.  Note  that  the  internal  standard,  present  in  the  GC  peak,  gives  analogous  ions 
3  mass  units  higher  at  m/z  502  and  m/z  345,  but  other  ion  doublets  are  not  clearly  visible, 
suggesting  that  other  fragments  have  lost  the  N-methyl  group  which  contains  the  deuterium 
atoms.  The  ion  at  m/z  499  is  formed  by  loss  of  the  silyl  group  on  the  phenolic  hydroxyl 
group  together  with  a  proton  transfer  to  the  ion  (a  similar  reaction  occurs  with 
diamorphine).  The  ion  at  m/z  442  is  then  formed  by  loss  of  the  tertiary  butyl  group  from 
the  initial  product.  This  is  suggested  by  the  absence  of  an  ion  corresponding  to  loss  of  the 
tertiary  butyl  group  from  the  molecular  ion,  which  would  have  appeared  at  m/z  456. Chapter  Four  Page  78 
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Figure  4-45:  -Ion  Chromatogram  m/z  282  and  Mass  Spectrum  for  Benzoylecgonine  TBDMS 
(also  containing  the  internal  standard  Benzoylecgonine-d3) Chapter  Four  Page  79 
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Figure  4-46:.  Fragmentation  of  Benzoylecgonine  -TBDMS 
Benzoylecgonine  has  a  carboxylic  acid  group  and  forms  an  MTBDMS  ester.  The  base 
peak  in  the  mass  spectrum  is  at  m/z  282  and  is  assigned  to  the  fragment  [C14H22O4Si]+ 
. 
It  is 
formed  by  loss  of  the  benzoyl  group,  as  in  cocaine,  which  produces  the  ion  at  m/z  182  in 
the  mass  spectrum  of  cocaine.  The  loss  of  the  tertiary  butyl  group  occurs  directly  from  the 
molecular  ion  to  give  the  fragment  at  m/z  346.  The  presence  of  the  internal  standard  helps 
in  identifying  the  fragmentation  reactions  by  providing  a  parallel  series  of  ions  for  those 
fragments  which  retain  the  deuterium,  which  is  held  by  the  N-methyl  group. Chapter  Four  Page  80 
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M+  428 
I 
Figure  4-48:  -  Fragmentation  of  THC-OH-TBDMS 
I 
The  molecular  ion  of  THC-OH  TBDMS  derivative  is  too  small  to  be  visible  in  the  mass 
spectrum.  High  mass  fragment  ions  are  present  at  m/z  399  and  m/z  342,  corresponding  to 
the  loss  of  C2H5  and  then  C4H9  fragments.  This  sequence  is  indicated  by  the  absence  of  a 
strong  M-57  ion,  which  would  have  appeared  at  m/z  371.  The  source  of  the  C2H5  fragment 
is  suggested  in  Figure  4-48  but  is  not  known  with  certainty.  The  source  of  the  C4H9 
fragment  could  either  be  the  tertiary  butyl  group  or  else  the  side-chain,  as  there  is  a  loss  of 
57  in  the  mass  spectrum  of  THC  which  comes  from  the  side  chain.  [1921  However,  if  the 
fragment  came  from  the  side  chain  this  would  result  in  the  loss  of  deuterium  from  the 
internal  standard,  as  the  deuterium  is  on  the  end  carbon  of  the  side  chain.  The  mass 
spectrum  clearly  shows  that  this  does  not  happen  as  there  is  an  ion  at  m/z  345  for  the 
internal  standard. Chapter  Four 
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Figure  4-50:  -  Fragmentation  of  THC-COOH-TBDMS 
Benzoylecogonine  and  THC-COOH  have  carboxylic  acid  groups  and  base  peaks  at  m/z 
282  and  m/z  515  and  are  assigned  to  the  fragments  [C14H22O4Si]+  and  [C29H47O4Si2]+. 
THC-OH  has  a  hydroxyl  group  and  a  base  peak  at  m/z  342  assigned  to  the  fragment 
[C21H30SiO2]  +. Chapter  Four  Page  84 
4.6  Conclusions 
Several  conclusions  were  drawn  from  this  study,  which  was  the  initial  step  in  the 
development  of  a  method  for  use  in  systematic  forensic  toxicology. 
1.  PFPA/PFP-OH  derivatisation: 
This  reagent  produced  derivatives  with  all  of  the  test  compounds,  including  the  secondary 
amine  (methamphetamine)  and  the  two  carboxylic  acids  (benzoylecgonine  and  THC- 
COOH).  The  derivatives  gave  good  gas  chromatographic  properties  in  terms  of  peak  shape 
and  had  mass  spectra  with  strong  ions  which  were  suitable  for  selected  ion  monitoring 
either  as  the  quantification  ion  or  else  as  qualifier  ions.  The  reagent  is  volatile  which 
allows  it  to  be  evaporated  before  GC-MS  analysis,  which  would  help  to  preserve  the  GC 
column,  injector  liner  and  mass  spectrometer  source  from  contamination. 
It  was  concluded  that  this  reagent  had  a  potentially  wide  range  of  applications  in  STA  and 
it  was  investigated  further  in  phase  2  of  this  study. 
2.  PFPA/trimethylsilyl-diazomethane  derivatisation: 
Comments  on  trimethylsilyl-  diazomethane  as  a  reagent  are  given  above.  When  used  as  a 
derivatising  agent  in  combination  with  PFPA,  all  of  the  test  compounds  gave  derivatives 
with  good  chromatographic  and  mass  spectrometric  properties.  The  mass  spectra  of 
amines  and  alcohols  were  identical  to  those  obtained  with  PFPA  and  PFP-OH  described 
above.  Methyl  esters  were  easily  formed  from  benzoylecgonine  and  THC-COOH  and 
these  derivatives  had  good  mass  spectra  with  suitable  ions  for  selected  ion  monitoring. 
The  only  potential  disadvantages  with  this  reagent  was  that  benzoylecgonine  was 
converted  to  cocaine  and  so  could  not  be  distinguished  from  it  and  there  is  a  risk  of 
interference  in  GC-MS  analysis  due  to  the  impurities  in  the  TMS-diazomethane  reagent 
mentioned  above.  It  was  concluded  that  trimethylsilyl-diazomethane  is  a  useful  reagent  for 
forensic  toxicology  but  care  must  be  taken  to  check  for  potential  interference  from  the 
reagent  during  method  validation. Chapter  Four 
3.  MTBSTFA  derivatisation: 
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This  reagent  gave  good  derivatives  with  all  of  the  test  compounds  except 
methamphetamine  where  secondary  amines  not  react  very  well  with  MTBSTFA. 
Chromatographic  and  mass  spectrometric  properties  were  good.  However,  although 
morphine  with  MTBSTFA  derivatision  had  a  good  peak  shape  and  the  presence  of  strong 
ions  gave  the  potential  for  sensitive  detection  by  GC-MS,  it  was  found  that  low 
concentration  standards  were  not  well  detected  in  practice.  This  reagent  had  previously 
been  used  for  analysis  of  carboxylic  acids  in  urine  of  racing  greyhounds  and  was  effective 
in  identifying  unknown  acids  because  the  mass  spectra  had  strong  ions  at  m/z  values 
corresponding  to  loss  of  the  tertiary  butyl  group  from  the  molecular  ion,  thereby  allowing 
the  molecular  weight  to  be  obtained.  [2281  The  reagent  was  also  found  to  be  effective  in  a 
subsequent  part  of  this  research  project  for  the  analysis  of  benzodiazepines  (Chapter  7). 
The  conclusion  from  this  study  is  that  conventional  heating  would  be  preferable  to 
microwave  heating  as  the  time  saved  is  usually  less  important  than  the  overall  cost  of  a 
routine  analysis,  especially  if  large  numbers  of  samples  are  being  analysed.  This  might  be 
different  under  different  circumstances,  for  example  in  emergency  toxicology  in  hospital, 
where  rapid  turn-around  is  potentially  life  saving.  Each  of  the  reagents  used  in  this  study 
showed  some  advantages  and  all  three  of  them  were  considered  to  have  potential  use  in 
forensic  STA.  In  phase  2  of  the  study,  the  reagents  were  applied  to  the  derivatisation  of 
extracts  of  the  test  compounds  from  whole  blood. Chapter  Five  Page  86 
5  Study  of  a  Unified  Method 
5.1  Introduction 
Methods  of  analysis  generally  have  the  steps  shown  in  Figure  5-1  consisting  of  sample 
preparation  followed  by  extraction  of  the  substances  of  interest,  derivatisation  if  required 
and  then  the  end  step  analysis. 
Sample  pre-treatment  pH,  protein  precipitation,  homogenisation, 
dialysis,  digestion,  hydrolysis  of  conjugates 
4. 
Extraction  and  clean-up  Liquid-liquid  extraction,  solid  phase 
extraction,  heads  ace  analysis 
4. 
Chemical  derivatisation  if  required  Formation  of  esters,  ethers,  oximes  etc 
4. 
End-step  Analysis  Spectrometric  and  chromatographic 
methods 
Figure  5-1  :-  Components  of  an  analytical  method 
As  mentioned  previously,  the  ultimate  aim  of  this  work  was  to  create  a  unified  procedure 
for  systematic  toxicological  analysis  which  would  enable  a  wide  range  of  drugs  and 
metabolites  to  be  detected  in  a  minimum  number  of  analyses,  thereby  making  the 
procedure  suitable  for  the  complete  toxicological  analysis  of  small  samples.  The  usual 
way  of  developing  a  new  method  is  to  start  at  the  end  step,  so  that  knowledge  is  gained 
about  the  possibility  of  detecting  extracted  analytes  with  instrumental  techniques.  This 
part  of  the  method  is  carried  out  with  standards  of  the  substances  of  interest.  Similarly, 
derivatisation  methods  can  be  tested  using  reference  standards  without  the  need  to  extract 
them  from  a  biological  material  such  as  blood.  When  the  end  detection  method  is 
available,  it  can  be  used  to  test  extraction  procedures. Chapter  Five  Page  87 
The  previous  Section  described  the  investigation  of  the  derivatisation  and  GC-MS  analysis 
steps.  This  section  deals  with  the  extraction  step  for  selected  drugs  in  whole  blood,  with 
the  aim  being  to  develop  a  general  extraction  procedure  which  would  work  with  most  types 
of  drug. 
Solid  Phase  Extraction  (SPE)  is  an  extraction  method  that  uses  a  solid  phase  and  a  liquid 
phase  to  isolate  one  or  many  type  of  analyte  from  a  solution  is  usually  used  to  clean  up  a 
sample  before  using  a  chromatographic  technique.  The  separation  properties  of  the 
components  in  a  mixture  are  constant  under  constant  conditions.  [249,268-271]  SPE  is  a  well- 
known  method  for  rapid  sample  preparation  in  which  a  solid  stationary  phase  is  typically 
packed  into  a  syringe  barrel  and  used  to  selectively  extract,  concentrate,  and  purify  target 
analytes  prior  to  analysis  by  HPLC  or  GC[272].  SPE  methods  usually  have  four  steps  in 
which  (i)  the  cartridge  is  conditioned,  (ii)  the  sample  for  analysis  is  loaded  on  the  cartridge, 
(iii)  the  cartridge  is  washed  to  remove  as  many  impurities  as  possible  and  then  (iv)  the 
analytes  of  interest  are  eluted  and  collected  for  analysis. 
It  is  an  increasingly  useful  sample  preparation  technique.  Many  of  the  problems  associated 
with  liquid  /liquid  extraction  (LLE),  such  as  incomplete  phase  separations,  can  be  avoided 
using  SPE.  Other  disadvantages  of  using  LLE  include  incomplete  recoveries,  use  of 
expensive  and  specialised  glassware,  and  disposal  of  large  quantities  of  organic  solvents. 
SPE  is  more  efficient  than  liquid  /  liquid  extraction  and  yields  quantitative  extractions  that 
are  easy  to  perform.  It  is  rapid  and  can  be  automated  so  solvent  use  and  lab  times  are 
reduced.  SPE  is  used  most  often  to  prepare  liquid  samples  and  extract  semivolatile  or 
nonvolatile  analytes,  but  it  can  also  be  used  with  solids  that  are  pre-extracted  into  solvents. 
SPE  products  are  excellent  for  sample  extraction,  concentration,  and  cleanup.  They  are 
available  in  a  wide  variety  of  chemistries,  adsorbents,  and  size.  Selecting  the  most  suitable 
product  for  each  application  and  sample  is  important.  [273-278 
There  are  many  types  of  SPE  including  cartridges  which  are  more  efficient,  have  fewer 
steps,  and  work  with  acidic  and  basic  drugs  and  which  are  especially  suitable  for  forensic 
laboratories.  [2791 
. 
The  method  is  not  ideal  and  an  improved  extraction  procedure  would  be  desirable  which 
gave  a  single  fraction  containing  all  drugs  which  was  clean  enough  to  be  analysed  by  GC- 
MS.  Recent  developments  in  SPE  have  included  the  introduction  of  new  techniques  such 
as  microextraction  techniques  [2801  and  also  new  types  of,  polymeric  sorbent,  including 
molecularly  imprinted  polymers  [281,2821 Chapter  Five  Page  88 
In  this  study,  a  new  sorbent,  strataTM  X  polymeric  reversed  phase  sorbent  for  polar  and 
non-polar  compounds  was  investigated  as  a  replacement  for  the  Certify  sorbent.  [2831  The 
SPE  strataTM  X  procedure  was  developed  for  the  isolation  of  acidic,  neutral  and  basic  drugs 
from  whole  blood.  The  sorbent  in  strataTM  X  is  composed  of  a  styrene  divinylbenzene 
polymer  that  has  hydrophilic,  hydrophobic  and  pi-pi  retention  mechanisms.  Full  details  of 
the  composition  of  strataTM  X  have  not  been  released  by  the  manufacturer,  Phenomenex, 
but  it  has  substituents  on  a  carbon  chain  as  shown  inFigure  5-2  (b). 
H  -bonding  site 
O 
N 
ý 
(a)  strata  TM  X  cartridge 
pi-pi 
interaction 
(b)  Structure  of  strataTM  X  polymer 
Figure  5-2:  -  strataTM  X 
StrataTM  X  (Figure5-  2a)  uses  a  novel  surface  chemistry  in  the  sorbent  and  offers 
significant  advantages  over  the  traditional  silica-based  SPE  products.  The  selectivity  of 
the  strataTMX  resin  provides  high  and  reproducible  recoveries  for  a  wide  range  of  acidic, 
neutral  and  basic  compounds,  simplifying  the  sorbent  selection  process  for  method 
development.  Not  only  is  development  simple  but  the  unique  surface  properties  of  the  resin 
remain  "conditioned"  even  if  it  accidentally  runs  dry  during  the  extraction,  a  condition  that 
would  significantly  impair  silica-based  sorbents. 
StrataTM  X  has  been  used  for  extraction  of  drugs  from  different  types  of  biological  samples 
including  tissues,  plasma  and  urine  and  seemed  like  a  good  alternative  to  the  silica-based 
sorbent  Certify.  [zsa-287 
This  chapter  describes  work  carried  out  to  develop  the  extraction  step  of  the  proposed 
unified  method  and  the  validation  of  the  whole  method,  including  the  extraction, 
derivatisation  and  GC-MS  analysis  steps.  Three  versions  of  a  possible  unified  method 
were  investigated  based  on  different  types  of  derivatising  agent  as  described  in  Chapter  4. Chapter  Five  Page  89 
These  investigations  were  carried  out  using  the  same  test  standards  as  described  in  Chapter 
4.  The  final  test  of  the  method  was  to  apply  it  to  case  samples. 
5.2  Method  Validation  -  Introduction 
Method  validation:  this  term  consists  of  two  parts.  Firstly,  "method":  this  is  a 
procedure  for  the  analysis  of  a  specific  analyte.  Secondly,  "validate":  to  support  or 
corroborate  on  a  sound  or  authoritative  basis.  E2881  Method  validation  is  a  way  of  testing  a 
particular  analytical  method  to  see  if  it  is  acceptable  for  its  intended  purpose.  [2891 
Methods  which  have  been  validated  by  one  laboratory  need  to  be  validated  before  they  are 
implemented  in  another  laboratory.  Commercial  methods  also  need  to  be  checked  even  if 
the  manufacturer's  recommended  procedures  are  followed.  Validation  is  also  needed  if 
any  method  is  modified  or  used  for  a  new  application,  for  example,  a  method  for  the 
analysis  of  urine  specimens  should  be  validated  if  used  for  blood.  Minor  changes  do  not 
need  re-validation,  for  example,  changing  the  column  in  a  gas  chromatograph  for  another 
of  the  same  type. 
The  validation  of  a  method  follows  a  standardised  set  of  experimental  tests  which  produce 
data  relating  to  accuracy,  precision,  linearity,  limit  of  detection,  limit  of  quantification  and 
recovery.  [2901  Guidelines  have  been  published  by  several  organisations.  [291-2931 
Definitions  of  these  terms  are  as  follows.  [2941  Accuracy  is  the  ability  of  a  method  to  get  the 
true  result.  For  quantitative  tests  the  accuracy  expresses  the  closeness  of  agreement 
between  the  true  value  and  the  value  obtained  by  applying  the  test  procedure  a  number  of 
times. 
Precision  is  the  closeness  of  agreement  between  independent  test  results  obtained  under 
specified  conditions.  In  this  study  precision  was  measured  Intra-day  and  Inter-day. 
Precision  is  usually  affected  by  the  analyte  concentration  and  so  should  be  measured  at 
different  concentrations.  In  this  study  three  different  concentrations  were  used.  Precision 
is  usually  expressed  in  terms  of  the  percentage  relative  standard  deviation  of  the  test 
results. 
Linearity  is  defined  as  the  range  of  concentrations  of  analyte  for  which  the  procedure 
provides  test  results  that  are  in  direct  correlation  to  amount  of  analyte  in  the  sample.  This Chapter  Five  Page  90 
is  determined  from  the  calibration  curve  and  values  of  R2  where  R2  is  the  correlation 
coefficient  between  X  and  Y  in  the  graph. 
LOD  is  defined  as  the  lowest  amount  of  analyte  in  a  sample  that  can  be  detected,  but  not 
necessarily  quantified.  J2951  usually  the  limit  of  detection  is  evaluated  as  the  amount  of 
analyte  that  gives  a  signal-to-noise  ratio  of  3.  Alternatively,  it  is  equivalent  to  the  blank 
reading  plus  3  times  the  standard  deviation  of  the  noise  or  standard  error  of  the  regression 
line.  The  following  equation  was  used: 
LOD  =  YB  +  3Sy/x  Equation  5-1 
where  YB  is  the  intercept  on  the  Y-axis  (equivalent  to  the  blank  reading)  and  Sy/x  is  the 
standard  error  of  the  calibration  linear  regression  line. 
Similarly,  The  LOQ  is  the  smallest  amount  of  analyte  in  a  sample  that  can  be  quantified 
with  suitable  precision  and  accuracy.  [2951  Usually  the  quantitation  limit  is  evaluated  as  the 
quantity  of  analyte  that  gives  a  signal-to-noise  ratio  that  is  equivalent  to  10.  Alternatively, 
it  is  the  blank  reading  plus  10  times  the  standard  deviation  of  the  noise  or  standard  error  of 
the  regression  line. 
. 
Recovery  is  the  percentage  of  the  drug,  metabolite,  or  internal  standard  originally 
in  the  specimen  that  reaches  the  end  of  the  procedure. 
Additional  parameters  have  tended  to  be  added  to  the  list  of  those  required  for  full  method 
validation  [289]  including  selectivity.  Selectivity  was  examined  in  this  project  by  analysing 
negative  control  blood  samples  from  real  cases,  to  determine  if  interferences  were  present. 
In  the  present  study,  these  validation  parameters  were  measured  for  three  possible  versions 
of  a  unified  method  based  on  solid  phase  extraction  with  strataTM  X  followed  by 
derivatisation  with  the  three  reagents  described  in  Chapter  4  and  GC-MS  analysis. 
5.3  General  Experimental  Section 
5.3.1  Introduction 
Drug-free  blood  samples  were  spiked  with  different  amounts  of  drug  mixture  including 
amphetamine,  methamphetamine,  morphine,  benzoylecgonine,  THC-OH  and  THC-COOH 
as  model  compounds.  The  blood  was  then  extracted  by  SPE  using  the  novel  strata  X Chapter  Five  Page  91 
cartridges.  Three  different  derivatisation  methods  were  then  applied  to  the  extracts 
including  PFPA  with  PFP-OH,  PFPA  with  TMS-diazomethane  and  MTBSTFA. 
5.3.2  Preparation  of  drug  mixtures 
a)  All  stock  solutions  were  purchased  or  prepared  at  a  concentration  of  approximately 
O.  lmg/mL  for  spiking  blood  samples.  Less  concentrated  solutions  were  prepared  at 
1  µg/mL  by  dilution  with  methanol. 
A  stock  solution  of  amphetamine  sulphate  (salt)  was  prepared  at  0.11mg/ml;  correcting  for 
amphetamine  free  base  the  concentration  was  0.08mg/ml  =  8Ong/µl.  However  a 
concentration  of  1µg/ml  was  needed,  therefore  100µl  was  taken  from  80ng/µl  stock  and 
900µl  of  methanol  was  added.  This  gave  a  8µg/ml  solution  which  was  diluted  again  by 
taking  500µl  into  a  5ml  mixture  flask  solution  and  making  up  to  volume  with  methanol, 
giving  a  final  concentration  of  0.8µg/ml  =  0.8  ng/µl. 
A  stock  solution  of  methamphetamine  hydrochloride  was  prepared  at  0.105  mg/ml; 
correcting  for  methamphetamine  free  base  the  concentration  was  0.08  mg/ml.  The  same 
dilution  procedure  was  carried  out  as  before,  giving  a  final  concentration  0.8  gg/ml  =  0.8 
ng/.  tl. 
A  stock  solution  of  benzoylecgonine  was  prepared  at  0.105  mg/ml.  50gl  of  this  solution 
was  taken  and  950µl  of  methanol  was  added  to  give  a  solution  of  5.25gg/ml.  250gl  of 
5.25  µg/ml  solution  was  taken  and  4.75m1  of  methanol  added  to  give  a  final  concentration 
of  0.263µg/ml  =  0.263  ng/µl. 
The  concentrations  of  stock  solutions  of  THC-OH  and  THC-COOH  were  100µg/ml.  50µ1 
of  I  OOgg/m1  solution  was  added  to  4.95m1  of  methanol  resulting  in  a  final  concentration  of 
1  µg/ml  =1  ng/gl.  The  final  concentrations  of  working  drug  standards  are  summarized  in 
Table  5-1. Chapter  Five 
Table  5-1:  -  Final  concentrations  of  drug  standards 
Drug  Final  concentration  of  drug 
standards(ng/gl) 
Amphetamine  0.8 
Methamphetamine  0.8 
Benzoylecgonine  0.261 
Morphine  0.91 
THC-OH  1 
THC-COOH  1 
b)  Preparation  of  Internal  Standard  Solutions. 
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Stock  internal  standard  solutions  of  amphetamine-ds,  methamphetamine-d5, 
benzoylecgonine-d3,  cocaine-d3,  THC-OH-d3,  THC-COOH-d3  and  morphine-d3  were 
purchased  at  concentrations  of  100µg/ml  in  methanol.  Each  of  the  stock  solutions  was 
diluted  with  l  Oral  methanol  to  give  standard  solutions  at  1  gg/ml  =1  ng/µl. 
5.3.3  Preparation  of  drug  mixtures  in  blood 
Time  expired  transfusion  blood  supplied  from  a  local  hospital,  which  was  kept  in  the  fridge 
at  4°C,  was  used  to  prepare  drug  standards.  A  drug  mixture  was  prepared  containing 
amphetamine,  methamphetamine,  benzoylecgonine,  cocaine,  THC-OH,  THC-COOH  and 
morphine  with  a  final  concentration  of  approximately  1  µg/ml=ing//µl  of  each  drug  are 
listed  in  Table  5-1. 
Samples  used  for  method  validation  were  prepared  by  adding  lml  blood  to  3.5  ml  buffer 
solution  and  then  adding  standard  solutions  and  100µl  of  deuterated  internal  standard 
solution.  The  blood  standard  was  mixed  thoroughly  and  centrifuged  for  ten  minutes  before 
being  applied  to  the  extraction  cartridge.  Blank  samples  were  prepared  with  and  without 
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5.3.4  Preparation  of  buffer  solution 
A  buffer  is  a  solution  characterized  by  the  ability  to  resist  changes  in  pH  when  limited 
amounts  of  acid  or  base  are  added  to  it.  A  buffer  solution  for  the  study  was  prepared  by 
weighing  6.81g  of  potassium  dihydrogen  orthophosphate  (KH2PO4.  MW  136.09)  into  a 
500m1  beaker  with  450m1  of  distilled  water.  The  pH  was  adjusted  to  pH  6  with  0.1  M 
potassium  hydroxide  solution  and  made  up  to  500m1  with  distilled  water  in  a  volumetric 
flask. 
5.3.5  Extraction  method:  SPE  on  Strata  TM  X 
The  method  used  followed  the  manufacturer's  instructions  and  was  as  follows: 
A-  Conditioning:  prior  to  loading  the  sample,  the  SPE  column  was  washed  and  wetted  with 
1  ml  methanol. 
B-  Equilibration:  in  this  study,  the  SPE  column  was  equilibrated  with  lml  distilled  water. 
C-  Sample  loading:  blood  standards  containing  different  concentrations  of  the  test  drug 
compounds  were  applied  to  the  SPE  columns. 
D-  Washing  out  of  impurities.  5%  methanol  in  distilled  water  was  prepared  by  mixing 
95ml  of  distilled  water  with  5m1  methanol.  1.5  ml  of  this  solution  was  applied  before 
drying  for  30  seconds  at  full  vacuum. 
E-  Elution  was  carried  out  in  one  step  with  1.5m1  of  methanol. 
The  extracts  were  then  evaporated  to  dryness  under  a  stream  of  nitrogen,  without  heating. 
5.3.6  Derivatisation 
Extracts  were  derivatised  with  each  of  the  three  reagents  described  in  Chapter  4  before 
being  analysed  by  GC-MS 
5.3.7  GC-MS  analysis 
Derivatised  extracts  were  analysed  by  GC-MS  using  the  conditions  described  in  Chapter  4, 
Table  4-1.  Data  was  collected  in  the  SIM  mode  using  the  ions  listed  in  Tables  4-2,4-4  and 
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5.3.8  Validation  parameters 
The  parameters  measured  for  each  of  the  three  derivatision  procedures  were:  -  Linearity, 
Intra-day  Precision,  Inter-day  Precision,  Limit  of  Detection,  Limit  of  Quantification  and 
Recovery.  Each  parameter  was  measured  using  5  replicate  standards. 
5.3.9  Application  to  case  samples 
Each  version  of  the  poroposed  unified  method  was  applied  to  real  case  samples  taken  at 
autopsy  and  received  by  the  Section  of  Forensic  medicine  and  Science,  University  of 
Glasgow.  Cases  were  selected  for  analyses  which  were  known  to  be  positive  for  the  drug 
groups  of  interest  which  were  used  as  test  substances  in  this  study,  to  serve  as  positive 
controls.  In  addition,  a  second  group  of  cases  was  analysed  which  had  not  been  found  to 
contain  the  drugs  of  interest  to  serve  as  negative  controls.  These  were  kept  frozen  until 
analysed. 
5.4  Method  Validation  for  Drug  Derivatisation  with  PFPA- 
PFPOH 
5.4.1  Introduction 
These  reagents  produce  pentafluoropropionyl  (acyl)  derivatives  of  amines  and  alcohols  and 
simultaneously  the  anhydride  activates  carboxylic  acids  so  that  PFPOH  will  react  with 
them  to  produce  the  pentafluoropropyl  ester  derivatives.  The  following  paragraphs 
describe  the  validation  procedures  carried  out. 
5.4.2  Linearity 
Five  replicate  analyses  were  carried  out  at  each  concentration  and  linearity  was  determined 
from  the  calibration  curve  and  values  of  R2  where  R2  is  the  correlation  coefficient  between 
X  and  Y  in  the  graph.  Calibration  curves  for  the  target  analytes  were  linear  over  a 
concentration  range  of  16-80  ng/ml  of  blood  for  amphetamine  and  methamphetamine, 
4.55-22.75  ng/ml  of  blood  for  morphine,  5.25-26.25  ng/ml  of  blood  benzoylecgonine  and 
20-100  ng/ml  blood  for  THC-OH,  THC-COOH.  The  correlation  coefficient  (R)  values Chapter  Five  Page  95 
are  listed  in  Table  5-2,  and  curves  (averaged  values  of  5  replicates)  are  shown  below  in 
Figure  5-3  to  Figure  5-8. 
Table  5-2:  -Summary  of  Values  of  correlation  coefficient  (R2)  for  all  compounds  analysed  as 
the  PFP-PFP-OH  derivatives 
Compound  R2  Values 
Amphetamine  0.9966 
Methamphetamine  0.9947 
Morphine  0.9992 
Benzoylecgonine  0.9945 
THC-OH  0.9989 
THC-COOH  0.9934 
Amphetamine 
N 
N 
C 
O 
G 
U) 
F) 
2.5 
2 
1.5 
1 
0.5 
0 
0  20  40 
nglml 
60  80  100 
f  Arrphetanine  PFP 
-Linear  (Arrphetarrine  PFP) 
Figure  5-3:  -  Calibration  curve  for  Amphetamine  analysed  as  the  PFP  derivative Chapter  Five  Page  96 
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Figure  5-4:  -  Calibration  curve  for  Methamphetamine  analysed  as  the  PFP  derivative. 
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Figure  5-5:  -  Calibration  curve  for  Morphine  analysed  as  the  bis-PFP  derivative Chapter  Five  Page  97 
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Figure  5-6:  -  Calibration  curve  for  Benzoylecgonine  analysed  as  the  PFP  ester  derivative 
Figure  5-7:  -  Calibration  curve  for  THC-OH  analysed  as  the  PFP  derivative 
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Figure  5-8:  -  Calibration  curve  for  THC-COOH  analysed  as  the  PFP/PFP  ester  derivative Chapter  Five 
5.4.3  Intra-Day  variation 
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Different  concentrations  for  the  test  drugs  in  the  range  16-80ng/ml  of  blood  for 
amphetamine  and  methamphetamine,  4.55-22.75ng/ml  of  blood  for  morphine,  5.25- 
26.25ng/ml  of  blood  benzoylecgonine  and  20-100ng/ml  blood  for  THC-OH,  THC-COOH 
were  extracted  five  times  to  calculate  the  intra-day  variation  of  the  assay.  Average 
drug/internal  standard  ratios  and  relative  standard  deviations  (%RSD)  were  calculated  for 
each  concentration  as  shown  from  Table  5-3  to  Table  5-6. 
Table  5-3:  -  Intra-Day  variation  for  Amphetamine  and  Methamphetamine  analysed  as  the 
PFP-PFP-OH  derivatives 
Added  Concentration  Average  area  Ratio  (%RSD) 
(ng/ml  of  blood)  Amp/Amp-D3  Meth/Meth-D5 
16  0.2  (22.3)  0.01  (5.8) 
48  0.9  (10.4)  0.03  (10.9) 
80  1.6  (10.3)  0.05  (6.8) 
Table  5-4:  -  Intra-Day  variation  for  Morphine  analysed  as  the  bis-PFP  derivative 
Added  Concentration  (ng/ml  of  blood)  Average  area  Ratio  Mor/Mor-D3  (%RSD) 
4.6  0.05  (3.0) 
13.7  0.1  (8.1) 
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Table  5-5:  -  Intra-Day  variation  for  Benzoylecgonine  analysed  as  the  PFP  ester  derivative 
Added  Concentration  (ng/ml  of  blood)  Average  area  Ratio  Bze/Bze-D3  (%RSD) 
5.3  0.07  (10.8) 
15.8  0.13  (4.8) 
26.3  0.21  (7.2) 
Table  5-6:  -  Intra-Day  variation  for  THC-OH  and  THC-COOH  analysed  as  the  PFP/PFP  ester 
derivatives 
Added  Concentration  Average  area  Ratio  (%RSD) 
(ng/ml  of  blood)  THC-OH  /THC-D3  THC-COOH/THC-COOH-D3 
20  0.4  (6.5)  0.14  (15.6) 
60  0.7  (4.8)  0.61  (10.3) 
100  1.3  (6.2)  1.3  (16.5) 
5.4.4  Inter-Day  variation 
A  set  of  calibration  standards  in  blood  containing  six  drugs  was  extracted  five  times  during 
different  days  with  the  same  concentration  as  before  (16-80ng/ml  of  blood  for 
amphetamine  and  methamphetamine,  4.55-22.75ng/ml  of  blood  for  morphine,  5.25- 
26.25ng/ml  of  blood  benzoylecgonine  and  20-100ng/ml  blood  for  THC-OH,  THC-COOH). 
Calibration  curves  were  constructed  and  the  concentration  of  each  standard  was  measured 
using  the  calibration  curve,  based  on  the  ratio  of  analyte  to  internal  standard.  The  inter-day 
variation  for  each  test  substance  was  measured  and  these  values  are  displayed  in  Table  5-7 
to  Table  5-10. Chapter  Five  Page  100 
Table  5-7:  -  Inter-Day  variation  for  Amphetamine  and  Methamphetamine  analysed  as  the  PFP 
derivatives 
Added  Concentration 
(ng/ml  of  blood) 
Mean  Measured  Concentration  (%RSD) 
Amp  Meth 
16  15.9  (6.9)  16.8  (27.0) 
48  47.7  (5.4)  40.6  (12.9) 
80  80.4  (2.5)  81.0(5.1) 
Table  5-8:  -  Inter-Day  variation  for  Morphine  analysed  as  the  bis-PFP  derivative 
Added  Concentration  -Morphine 
(ng/ml  of  blood) 
Mean  Measured  Concentration  (%RSD) 
4.6  4.5  (12.3) 
13.6  14.1  (10.3) 
22.7  23.0  (2.4) 
Table  5-9:  -  Inter-Day  variation  for  Benzoylecgonine  analysed  as  the  PFP  ester  derivative 
Added  Concentration  -Benzoylecgonine 
(ng/ml  of  blood) 
Mean  Measured  Concentration  (%RSD) 
5.3  5.5  (3.9) 
15.8  15.3  (0.8) 
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Table  5-10:  -  Inter-Day  variation  for  THC-OH  and  THC-COOH  analysed  as  the  PFP/PFP  ester 
derivatives 
Added  Concentration  Mean  Measured  Concentration  (%RSD) 
(ng/ml  of  blood)  THC-OH  THC-COOH 
20  21.2  (8.5)  19.8  (21.4) 
60  58.4  (7.5)  60.9  (9.0) 
100  103.5(l.  9)  98.4(3.1) 
5.4.5  Recovery 
The  recovery  of  the  method,  using  strata  X,  was  calculated  using  spiked  blood  samples 
at  three  different  concentrations.  Each  concentration  was  extracted  five  times  without 
internal  standard  present.  Two  unextracted  standards  were  also  prepared  at  each 
concentration  without  internal  standard  and  were  kept  in  the  fridge  throughout  the 
extraction.  Before  blowing  down  the  samples  under  a  stream  of  nitrogen,  l00µl  of 
internal  standard  was  added  to  each  vial  including  the  unextracted  standards.  The  recovery 
calculated  was  obtained  from  the  peak  area  ratio  of  the  extracted  standard  divided  by  the 
peak  area  ratio  of  the  unextracted  standard,  multiplied  by  100.  Recovery  for  all  the  drugs 
is  summarized  in  Table  5-11  and  Figure5-9. Chapter  Five  Page  102 
Table  5-11:  -  Recovery  of  six  drugs  analysed  as  PFPA-PFP-OH  derivatives 
Analyte  Concentration  n  /ml 
Recovery 
% 
16  74 
Amphetamine  48  89 
80  89 
16  23 
Methamphetamine  48  15 
80  18 
4.6  96 
Morphine  13.7  60 
22.8  71 
5.3  86 
Benzoylecgonine  15.8  91 
26.3  95 
20  62 
THC-OH  60  49 
100  44 
20  61 
THC-COOH  60  58 
100  59 
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Figure  5-9:  -  Recoveries  of  drugs  from  blood  using  StrataTmX  and  analysed  as  the  PFP-PFP- 
OH  derivatives 
5.4.6  Limit  of  Detection  (LOD) 
Blood  was  spiked  to  give  concentrations  of  20,15,10,5,2.5,1  and  0.5  ng/ml  bloods  for 
amphetamine,  methamphetamine,  morphine,  benzoylecgonine,  THC-OH  and  THC-COOH. 
Five  replicates  were  analysed  at  each  concentration.  The  equation  of  the  line  was Chapter  Five  Page  103 
calculated  for  each  drug  using  Microsoft  Excel.  The  regression  analysis  program  within 
Microsoft  Excel  was  also  used  to  calculate  Sy/x  for  each  drug.  [2951  Equation  5-2  was  then 
applied  to  find  the  limit  of  detection  based  on  Equation  5-1 
LOD  =  intercept  +  (3  x  standard  error)  Equation  5-2 
Rearranging  the  equation  of  the  line  for  x  gives  the  following: 
Y=  mx  +b  Equation  5-3 
Answer  equation  (2)  applied  in  Equation  (3)  for  getting  limit  of  detection  as 
x=  y-b/m  Equation  5-4 
5.4.7  Limit  of  Quantitation  (LOQ) 
As  presented  before,  Equation  5-5  was  then  applied  to  find  the  limit  of  quantitation  and 
rearranging  the  equation  of  the  line  from  x  Equation  5-3  for  finding  limit  of  quantitation. 
LOQ  =  Ys  +  10Sy/x  Equation  5-5 
The  limits  of  detection  and  quantitation  were  calculated  and  are  shown  below  in  Table  5- 
12. 
Table  5-12:  -  Limits  of  Detection  and  Limits  of  Quantitation  of  the  six  drugs  analysed  as  the 
PFP-PFP-OH  derivatives 
Drugs  LOD  (ng/ml)  LOQ  (ng/ml) 
Amphetamine  1.2  4.0 
Methamphetamine  0.8  2.7 
Morphine  0.8  2.6 
Benzoylecgonine  0.4  1.5 
THC-OH  1.7  5.8 
THC-COOH  3.7  12.4 Chapter  Five  Page  104 
5.4.8  Application  to  real  case  samples 
The  developed  method  was  applied  to  51  cases  samples  of  which  36  samples  had 
previously  been  found  to  be  positive  for  drugs  of  abuse.  Case  results  are  summarized 
below  in  Table  5-13  and  Table  5-14. 
Table  5-13:  -  Results  of  GC/MS  for  drug-positive  cases  analysed  as  PFPA-PFP-OH 
derivatives 
Case  No  Drug  Concentration  (mg/L) 
Amp  Meth  Mor  Cocaine  Bze  THC  THC-COOH 
Blank  -  -  -  -  -  -  - 
1  0.28  -  -  -  -  -  - 
2  -  -  0.5  -  -  -  - 
3  -  -  0.34  -  -  -  - 
4  -  -  1.74  -  -  -  - 
5  -  -  -  -  0.3  -  - 
6  0.02  -  -  -  -  -  - 
7  -  -  0.7  -  -  - 
8  -  -  0.01  -  -  -  - 
9  -  -  0.46  -  -  -  - 
10  -  -  0.11  -  -  -  - 
11  -  -  0.32  -  -  -  - 
12  -  -  0.15  -  -  -  - 
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14  -  -  -  -  0.07  -  - 
15  -  -  -  -  0.1  -  - 
16  -  -  -  -  0.03  -  - 
17  -  -  -  -  -  0.09  0.23 
18  -  -  0.02  -  -  -  - 
19  0.001  -  -  -  -  -  - 
20  -  -  0.39  -  -  -  - 
21  -  -  0.39  -  -  -  - 
22  -  -  0.001  -  -  -  - 
23  -  -  0.31  -  -  -  - 
24  -  -  0.94  -  -  -  - 
25  -  -  0.56  -  -  -  - 
26  -  -  0.19  -  -  -  - 
27  -  -  0.22  -  -  -  - 
28  -  -  0.18  -  -  -  - 
29  -  -  0.34  -  -  -  - 
30  -  -  0.34  -  -  -  - 
31  -  -  0.423  -  -  -  - 
32  -  -  -  -  -  - 
33  -  -  -  -  -  -  - 
34  -  -  -  -  -  -  - Chapter  Five 
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Table  5-14:  -  Results  of  GC/MS  analysis  of  extracts  containing  other  drugs  using  PFP/PFP- 
OH  reagent 
Case  No  Drug  Concentration  (mg/L) 
Drugs  Amitrip  Metha  Code  Propox  Dothi  Indo  Fluox  Bupre  Parcet 
Blank  -  -  -  -  -  -  -  -  - 
1  1.4  -  -  -  -  -  -  -  - 
2  -  0.84  -  -  -  -  -  -  - 
3  -  -  0.1  -  -  -  -  -  - 
4  -  -  0.3  -  -  -  -  -  - 
5  -  -  -  0.2  -  -  -  - 
6  -  -  -  2.2  -  -  -  -  - 
7  -  -  -  0.3  -  -  -  -  - 
8  -  -  -  0.01  -  -  -  -  - 
9  -  -  -  -  2.5  -  -  - 
10  -  -  0.1  -  -  -  -  -  - 
11  -  -  0.02  -  -  -  -  -  - 
12  -  -  0.014  -  -  -  -  -  - 
13  -  -  -  -  -  0.02  -  -  - Chapter  Five  Page  107 
14 
15 
2.3 
2.8 
(Amitrip  =  Amitriptyline,  Metha  =  Methadone,  Code  =  Codeine,  Propox  =  Propoxyphene, 
Doth  =  Dothiepin,  Indo  =  Indomethacin,  Fluox  =  Fluoxetine,  Bupre  =  Buprenorphine, 
Parcet  =  Paracetamol) 
5.4.9  Discussion 
This  version  of  the  proposed  unified  method  was  validated  using  PFP-OH-PFPA  as  the 
derivatising  agent.  The  validation  parameters,  including  linearity,  precision,  recovery, 
limit  of  detection  and  limit  of  quantification  were  measured  and  are  summarised  in  Table 
5-15  below. 
Table  5-15:  -  Recovery,  intra  and  inter-day  assay  precision  with  PFPA-PFP-OH  at  different 
concentration 
Compound-  Product  Concentration 
n  ml 
Recovery 
%  n=5 
Intra-day 
RSD%(n=5 
Inter-day 
RSD%  n=5 
16  74  22.3  6.9 
Amphetamine-PFP  48  89  10.4  5.4 
80  89  10.3  2.5 
16  23  5.8  27.0 
Methamphetamine-PFP  48  15  10.9  12.9 
80  18  6.8  5.1 
4.55  96  3.0  12.3 
Morphine-PFP  13.65  60  8.1  10.3 
22.75  71  13.5  2.4 
5.25  86  10.8  3.9 
Benzoylecgonine-PFP 
ester 
15.75  91  4.8  0.8 
26.25  95  7.2  1.6 
20  62  6.5  8.5 
THC-OH-PFP  60  49  4.82  7.5 
100  44  6.2  1.9 
20  61  15.6  21.4 
THC-COOH  PFP  ester  60  58  10.3  9.0 
100  59  16.5  3.1 Chapter  Five  Page  108 
The  intra-  and  inter-day  precision  were  evaluated  at  low,  medium  and  high  concentrations 
for  five  replicates  and  the  %  RSD  was  subsequently  calculated.  The  %RSD  values  were 
mostly  within  the  suggested  acceptable  limit  of  15%  (20%  at  the  LOQ)  J2891  Intra-day  assay 
%RSDs  ranged  from  0.3  to  22.3  %.  The  highest  intra-day  %RSD  was  22.3%  for 
amphetamine  in  blood  at  a  concentration  of  16  ng  /ml  while  the  lowest  %RSD  was  3%  for 
morphine  at  4.55  ng/ml  blood.  The  inter-day  assay  %RSDs  ranged  from  0.8  to  27  %.  The 
highest  inter-day  %RSD  was  with  methamphetamine  while  lowest  %RSD  was  with 
Benzoylecgonine  at  15.8  ng/ml  blood  as  shown  in  Table  5-15. 
Calibration  curves  prepared  with  with  six  standards  including  blank  experiments  showed 
that  the  response  was  linear  (R2  >  0.99)  for  all  the  analyzed  compounds  which  is 
acceptable  for  the  analysis  of  biological  specimens.  Also,  although  there  was  matrix 
interference  observed  using  the  StrataX  SPE  cartridge,  good  calibration  graphs  were 
obtained. 
Benzoylecgonine  produced  the  lowest  detection  limit  whereas  THC-COOH  produced  a 
higher  detection  limit.  The  limits  of  detection  and  quantitation  were  listed  in  Table  5-12. 
Two  conclusions  can  be  made  from  these  results.  Firstly,  the  derivatisation  procedure 
worked  well  with  both  amines  and  carboxylic  acids  in  the  same  extract  so  it  fulfils  the 
requirements  of  a  unified  procedure.  Secondly,  the  detection  limits  for  THC-COOH  and 
benzoylecgonine  reflect  the  fragmentation  patterns  seen  in  their  mass  spectra.  The  selected 
ions  for  both  compounds  are  the  base  peaks  in  their  mass  spectra.  However,  the 
percentage  of  the  ion  current  carried  by  the  base  peak  ion  of  benzoylecgonine  is  larger  than 
that  for  THC-COOH,  i.  e.  the  mass  spectrum  of  the  latter  shows  more  ions,  and  so  the 
sensitivity  is  expected  to  be  better  for  benzoylecgonine.  The  detection  limits  for  THC-OH 
and  THC-COOH  would  need  to  be  improved  if  the  method  was  used  routinely  since  the 
recommended  cut-off  level  for  THC  in  oral  fluid  is  4  ng  /ml. Chapter  Five  Page  109 
The  recovery  ranged  between  15-96  %.  The  lowest  recovery  was  with  methamphetamine 
and  the  highest  with  morphine.  The  reason  for  the  poor  recovery  of  methamphetamine  is 
not  clear,  as  more  polar  compounds  such  as  amphetamine,  and  less  polar  compounds  such 
as  THC-OH  had  higher  recoveries.  Possible  reasons  may  relate  to  failure  of  the  chemical 
derivatisation  step  for  the  secondary  amine  or  else  loss  of  methamphetamine  during  the 
evaporation  step.  Comparison  with  the  recovery  of  methamphetamine  measured  using 
other  reagents,  for  example  the  PFPA-methyl  ester  (Figure  5-10)  shows  that  the  recovery  is 
good  and  that  the  loss  of  methamphetamine  must  have  occurred  outside  the  extraction  step 
itself.  However,  the  limit  of  detection  and  limit  of  quantification  of  methamphetamine 
were  acceptable. 
Comparison  of  recovery  of  Methamphetamine  analysed  as 
PFP  and  PFP/Methyl  ester 
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Figure  5-10:  -  Recovery  of  methamphetamine  from  blood  using  Strata  TMX  and  analysed  after 
derivatisation  with  PFPA-PFP-OH  and  PFPAIMethyl  ester 
The  validated  method  was  applied  to  blood  samples  collected  from  Forensic  Medicine  and 
Science  at  the  University  of  Glasgow.  In  general  the  method  worked  very  well  with 
strata"'  X.  However  there  was  a  great  deal  of  interference  in  the  GC-MS  analysis  that 
could  potentially  obscure  the  analyte  peaks.  Because  of  the  interferences  observed  using 
the  strata  TM  X  SPE  cartridge,  washing  of  the  SPE  cartridge  with  more  than  1.5  ml  of  5% 
methanol  in  distilled  water  could  perhaps  resolve  this  problem  Figure  5-11.  The  method Chapter  Five  Page  110 
was  found  to  be  able  to  detect  and  quantify  both  basic  and  acidic  drugs  including  drugs  of 
abuse  and  prescribed  drugs. 
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Figure  5-11:  -TIC  Chromatogram  blank  for  Strata  TM  X  SPE  (A)  with  I  ml  methanol  (B)  with  1.5 
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5.4.10  Conclusion 
This  version  of  the  method  showed  promise  as  a  unified  procedure  for  general  use  because 
of  its  ability  to  detect  and  meaure  both  acidic  and  basic  drugs.  StrataTM  X  also  was  able  to 
extract  both  of  these  types  of  analyte  from  whole  blood,  although  with  different 
efficiencies  and  with  co-extracted  interferences,  but  nevertheless  with  acceptable  limitis  of 
quantification. 
5.5  Method  validation  for  drug  derivatisation  with  PFPA 
and  TMS-diazomethane 
5.5.1  Introduction 
These  derivatising  agents  produce  pentafluoropropionyl  (acyl)  derivatives  of  alcohols  and 
amines,  as  for  the  PFPA-PFPOH  reagent  but  the  pentafluoropropyl  esters  are  replaced  with 
the  methyl  ester  function.  In  principle,  it  would  not  be  necessary  to  repeat  the  validation 
parameters  for  drugs  which  lack  a  carboxylic  acid  group.  However,  the  possibility  arises 
that  changes  in  the  reaction  conditions  might  affect  other  drugs  in  unexpected  ways  and 
changes  in  the  products  obtained  might  also  affect  both  the  subsequent  gas 
chromatography  and  mass  spectrometry.  For  this  reason,  the  same  set  of  drug  standards 
was  used  to  model  the  analytical  method,  allowing  direct  comparison  with  the  other 
versions  of  the  procedure.  The  following  paragraphs  describe  the  validation  procedures 
carried  out. 
5.5.2  Linearity 
Standards  in  blood  were  prepared  and  each  concentration  was  extracted  five  times  and 
calibration  graphs  of  each  compound  were  produced.  The  concentration  ranges  were  the 
same  as  listed  in  Paragraph  5.4.2.  As  seen  before,  the  calibration  curves  of  peak  area  ratio 
against  the  concentration  of  the  target  analyte  were  linear  and  these  are  shown  in  Figure 
5-12  to  Figure  5-17.  The  correlation  coefficient  (R2)  values  are  listed  in  Table  5-16. Chapter  Five  Page  112 
Table  5-16:  -  Correlation  coefficient  (R2)  for  calibration  curves  for  all  compounds  analysed  as 
the  PFP/methyl  ester  derivatives 
Compound  R-  Values 
Amphetamine  0.9888 
Methamphetamine  0.9089 
Morphine  0.9995 
Benzoylecgonine  0.9862 
THC-OH  0.9966 
THC-COOH  0.9994 
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Figure  5-12:  -  Calibration  curve  for  Amphetamine  analysed  as  the  PFP  derivative 
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Figure  5-13:  -  Calibration  curve  for  Methamphetamine  analysed  as  the  PFP  derivative Chapter  Five 
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Figure  5-14:  -  Calibration  curve  for  Morphine  analysed  as  the  bis-PFP  derivative 
Benzoylecgonine 
"  Benzoyiecgonine  PFP/TMS 
-Linear  (Benno  1ecgonine 
PFP/TMS) 
Figure  5-15:  -  Calibration  curve  for  Benzoylecgonine  analysed  as  the  methyl  ester  derivative 
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Figure  5-16:  -  Calibration  curve  for  THC-OH  analysed  as  the  PFP  derivative Chapter  Five 
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Figure  5-17:  -  Calibration  curve  for  THC-COOH  analysed  as  the  PFP/methyl  ester  derivative 
The  calibration  curves  obtained  in  this  validation  work  were  similar  to  those  obtained  with 
the  PFP-PFPOH  reagent  except  for  amphetamine  and  methamphetamine.  For  both  of 
these,  the  blank  showed  significantly  positive.  The  amphetamine  curve  was  however,  a 
reasonable  straight  line  whereas  for  methamphetamine  the  blank  reading  reduced  the 
correlation  coefficient  to  0.9089.  Excluding  the  blank  results  in  a  better  linear  correlation 
with  an  R2  value  of  0.9675. 
5.5.3  Intra  -day  variation 
Using  the  same  procedure  as  for  PFPA-PFP-OH  derivatives,  five  sets  of  blood  standards 
were  extracted  and  analysed  as  PFPA-methyl  derivatives.  The  main  potential  disadvantage 
of  this  reagent  is  that  benzoylecgonine  is  converted  to  cocaine  so  information  on  extent  of 
metabolism  in  casework  samples  would  be  lost.  The  average  area  ratios  were  calculated 
and  are  displayed  from  Table  5-17  to  Table  5-20. 
Table  5-17:  -  Intra-day  variation  for  Amphetamine  and  Methamphetamine  analysed  as  the 
PFP  derivatives 
Concentration  Average  area  Ra  tio  (%RSD,  n=5) 
(ng/ml  of  blood)  Amp/Amp-d3  Meth/Meth-d5 
16  0.6(1.5)  0.3(6.0) 
48  1.0  (1.4)  0.8  (3.2) 
80  1.3  (4.4)  1.14  (1.4) Chapter  Five  Page  115 
Table  5-18:  -  Intra-day  variation  for  Morphine  analysed  as  the  PFP  derivative 
Concentration 
(n  ml  of  blood) 
Average  area  Ratio  Mor/Mor-d3 
(%RSD,  n=5 
4.6  0.03  (0.4) 
13.7  0.1  (1.1) 
22.8  0.12  (0.74) 
Table  5-19:  -  Intra-day  variation  for  Benzoylecgonine  analysed  as  its  methyl  ester 
Concentration 
(ng/ml  of  blood) 
Average  area  Ratio  Bze/Bze-d3 
(%RSD,  n=5 
5.3  2.25  (10.2) 
15.8  5.91  (10.6) 
26.8  11.7  (10.4 
Table  5-20:  -  Intra-day  variation  for  THC-OH  and  THC-COOH  analysed  as  their  PFP/methyl 
ester  derivatives 
Concentration 
(ng/ml  of  blood) 
Average  area  Ratio 
(%RSD,  n=5) 
THC-OH/THC-OH-d3  THC-COOH/THC-COOH-d3 
20  0.59  5.6  0.21  8.6 
60  1.6  (5.1  0.64  3.2) 
100  2.4  (3.7  0.9(7.2) 
The  within-day  variations  as  shown  by  the  %RSD  are  mostly  less  than  10%,  with 
benzoylecgonine  lying  between  10  and  11  %RSD.  These  are  all  within  the  suggested 
limits  for  precision.  [289] 
5.5.4  Inter  -  day  variation 
The  blood  standards  used  to  obtain  the  linearity  curve  were  each  extracted  five  times 
during  one  month  for  all  the  drugs  and  the  average  concentrations  were  calculated  using 
the  calibration  curves  and  these  are  displayed  from  Table  5-21  to  Table  5-24.  The 
concentrations  were  the  same  as  those  used  previously. Chapter  Five  Page  116 
Table  5-21:  -Inter-day  variation  for  Amphetamine  and  Methamphetamine  analysed  as  their 
PFP  derivatives 
Concentration 
(ng/ml  of  blood) 
Mean  Measured  Concentration  (%RSD,  n=5) 
Amp  Meth 
16  15.7  (2.4)  15.7  (4.8) 
48  48.7  (1.8)  48.4  (1.0) 
80  79.8  (1.6)  79.4  (1.6) 
Table  5-22:  -Inter-day  variation  for  Morphine  analysed  as  the  bis-PFP  derivative 
Concentration  -Morphine 
(ng/ml  of  blood) 
Mean  Measured  Concentration 
(%RSD,  n=5) 
4.6  4.7  (2.4) 
13.7  13.6  (1.9) 
22.8  22.7  (0.6) 
Table  5-23:  -  Inter-day  variation  for  Benzoylecgonine  analysed  as  the  methyl  ester  derivative 
Concentration  -Benzoylecgonine 
(ng/ml  of  blood) 
Mean  Measured  Concentration 
(%RSD,  n=5) 
5.3  5.4  (10.5) 
15.8  15.6  (2.9) 
26.26  26.43  (1.6) Chapter  Five  Page  117 
Table  5-24:  -Inter-day  variation  for  THC-OH  and  THC-COOH  analysed  as  the  PFPlmethyl  ester 
derivatives 
Concentration  Mean  Measured  Concentration  (%RSD,  n=5) 
(ng/ml  of  blood)  THC-OH  THC-COOH 
20  19.8  (5.9)  20(5.1) 
60  60.3  (4.2)  59.4  (1.4) 
100  99.5  (0.84)  99.5  (1.3) 
5.5.5  Recovery 
Recoveries  of  drugs  by  the  method  were  calculated  using  spiked  blood  samples  with  low, 
medium  and  high  concentrations  (Table  5-25,  Figure  5-18). 
Table  5.25:  -  Recovery  for  six  drugs  analysed  as  the  PFP/methyl  ester  derivatives 
Analyte  Concentration  n  /ml 
Recovery 
% 
16  99 
Amphetamine  48  92 
80  95 
16  62 
Methamphetamine  48  86 
80  90 
4.55  88 
Morphine  13.65  91 
22.75  87 
5.25  85 
Benzoylecgonine  15.75  85 
26.25  83 
20  66 
THC-OH  60  50 
100  56 
20  56 
THC-COOH  60  60 
100  68 Chapter  Five  Page  118 
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Figure  5-18:  -  Recoveries  of  drugs  from  blood  using  Strata  TMX 
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It  is  noted  that  the  recovery  of  methamphetamine  in  this  set  of  tests  was  much  better  than 
in  the  previous  set. 
5.5.6  Limit  of  Detection  and  Limit  of  Quantification 
The  methods  used  for  obtaining  the  LOD  and  LOQ  were  the  same  as  mentioned  in 
Sections  5.4.6  and  5.4.7  and  the  results  are  shown  below  in  Table  5-26. 
Table  5-26:  -  LOD  and  LOQ  for  Test  Drugs  analysed  as  the  PFP/methyl  ester  derivatives 
Drugs  LOD  (ng/ml)  LOQ  (ng/ml) 
Amphetamine  0.6  2.1 
Methamphetamine  0.6  2.1 
Morphine  0.3  1.1 
Benzoylecgonine  0.3  1.2 
THC-OH  1.3  4.3 
THC-0OOH  1.4  4.7 Chapter  Five  Page  119 
The  LOD  and  LOQ  values  show  some  small  improvements  compared  to  the  first  set  of 
tests.  The  LOQ  of  THC-COOH,  however,  is  better  when  it  is  analysed  as  the  PFP  acyl 
/methyl  ester  derivative. 
5.5.7  Application  to  real  case  samples 
46  case  samples  were  analysed  with  the  PFPA/TMS-diazomethane  reagent  of  which  36 
samples  were  previously  found  to  be  positive  for  some  drugs  of  abuse  (Table  5-27  and 
Table  5-28).  These  cases  were  not  related  to  the  cases  mentioned  in  Table  5-13  and  5-14. 
Table  5-27:  -  Results  of  GC/MS  for  cases  analysed  using  the  PFP/TMS  diazomethane  reagent 
Case  No  Drug  Concentration  (mg/L) 
Amp  Meth  Mor  CocaineBze  THC  THCCOOH 
Blank  -  -  -  -  -  - 
1  0.32  -  -  -  -  - 
2  -  -  0.5  -  -  - 
3  -  -  0.24  -  -  - 
4  -  -  0.11  -  -  - 
5  -  0.54  -  -  - 
6  -  -  0.18  -  -  - 
7  -  0.36  -  - 
8  0.01  -  -  -  - 
9  0.13  -  -  -  - 
10  0.01  -  -  -  -  - 
11  0.02  -  -  -  -  - Chapter  Five  Page  120 
12  0.014  -  -  -  -  - 
13  -  -  -  0.007  -  - 
14  -  -  -  0.11  -  - 
15  -  -  -  0.11  -  - 
16  -  -  -  0.022  -  - 
17  -  -  -  0.01 
18  -  -  0.32  -  -  - 
19  -  0.26  -  -  - 
20  -  -  0.1  -  -  - 
21  -  -  0.5  -  -  - 
22  -  -  0.04  -  -  - 
23  -  -  0.1  -  -  - 
24  -  -  0.2  -  -  - 
25  -  -  0.1  -  -  - 
26  -  -  0.5  -  -  - 
27  -  -  0.41  -  -  - 
28  -  -  0.1  -  -  - 
29  -  -  0.2  -  -  - 
30  -  -  0.2  -  -  - 
31  -  -  0.4  -  -  - 
32  -  -  0.4  - Chapter  Five  Page  121 
33 
34 
35 
36 
0.4 
0.54 
0.2 
0.01 
Table  5-28:  -  Results  of  GCIMS  analysis  of  extracts  containing  other  drugs  using  PFP/TMS 
diazomethane  reagent 
Drugs  Amitrip  Metha  Code  Propox  Dothi  Indo  Fluox  Bupre  aracet 
Blank  -  -  -  -  -  -  -  - 
1  0.3  -  -  -  -  -  - 
2  2.4  -  -  -  -  -  -  - 
3  -  0.2  -  -  -  -  -  - 
4  -  -  0.03  -  -  -  -  - 
5  -  -  0.6  -  -  -  -  - 
6  -  -  -  0.8  -  -  -  - 
7  -  -  -  2.5  -  -  -  - 
8  -  -  -  -  -  -  -  - 
9  -  -  -  -  -  -  -  - 
10  -  -  -  -  -  -  -  - 
(Amitrip  =  Amitriptyline,  Metha  =  Methadone,  Code  =  Codeine,  Propox  =  Propoxyphene, 
Doth  =  Dothiepin,  Indo  =  Indomethacin,  Fluox  =  Fluoxetine,  Bupre  =  Buprenophine, 
Parcet  =  Paracetamol) Chapter  Five  Page  122 
5.5,8  Discussion 
The  validation  parameters  including  linearity,  precision,  recovery,  limit  of  detection,  and 
limit  of  quantification  were  evaluated  as  described  previously  and  recoveries  and  precision 
are  summarised  in  Table  5-29. 
The  RZ  values  of  calibration  curves  were  >_0.99  for  morphine  and  the  cannabinoids  but  for 
amphetamine,  methamphetamine  and  benzoylecogonine  RZ  S  0.98).  The  interference 
effects  on  amphetamine  and  methamphetamine  appeared  to  come  from  SPE  using  Strata  - 
TmX  and  from  the  TMS-diazomethane  reagent  so  the  intercepts  for  amphetamine  and 
methamphetamine  were  high. 
The  intra-day  and  inter-day  precision  were  evaluated  at  low,  medium  and  high 
concentrations  for  five  replicates.  Intra-day  assay  %RSDs  ranged  from  0.4  to  10.6  % 
while  the  inter-day  assay  RSDs  ranged  from  0.64  to  10.5  %.  The  highest  intra-day  %RSD 
was  10.8%  for  Benzoylecgonine  at  a  concentration  of  15.8  ng/ml  blood  while  the  lowest 
%RSD  was  0.4%  for  morphine  at  a  concentration  of  4.6  ng/ml  blood.  A  similar  pattern 
was  seen  for  inter-day  precision:,  the  highest  inter-day  %RSD  was  10.5%  for 
benzoylecgonine  at  a  concentration  of  5.3  ng/ml  blood  while  lowest  %RSD  was  0.64%  for 
morphine  at  a  concentration  of  22.8  ng/ml  as  shown  in  Table  5-29.  It  is  noted  that  some 
intra-day  precisions  are  worse  than  for  the  corresponding  inter-day  values,  although  they 
mostly  lie  in  the  same  range.  These  variations  may  represent  basic  problems  in 
reproducibility  of  the  SPE  procedure,  of  the  derivatisation  procedure  (due  to  impurities  in 
the  TMS-diazomethane  reagent)  or  else  of  the  GC-MS  instrument.  Comparing  this 
derivatisation  procedure  with  the  previous  one,  it  can  be  seen  that  there  are  some 
differences  in  precision  between  the  methods  for  the  test  substances  but  neither  is  clearly 
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Recoveries  ranged  between  50  and  99%.  The  lowest  recovery  was  for  THC-OH  and  the 
highest  was  for  amphetamine.  As  noted  earlier,  the  recovery  of  methamphetamine  was 
higher  in  this  series  of  tests  than  in  the  first  set. 
Morphine  and  benzoylecgonine  produced  the  lowest  detection  limits  and  THC-COOH 
produced  the  highest  detection  limit.  The  limits  of  detection  and  quantitation  are  listed  in 
Table  5-26. 
Table  5-29:  -  Accuracy,  intra-  and  inter-day  assay  precision  for  the  test  substances  analysed 
at  different  concentrations  with  PFPA-TMS-diazomethane  derivatisation 
Compound- 
Product 
Concentration 
(ng/ml) 
Recovery  % 
(n=5) 
Intra-day 
RSD% 
n=5 
Inter-day 
RSD%  (n=5) 
16  99  1.5  2.4 
Amphetamine-PFP  48  92  1.4  1.8 
80  95  4.4  1.6 
16  62  6.02  4.8 
Methamphetamine- 
PFP 
48  86  3.2  1.03 
80  90  1.4  1.6 
4.6  88  0.4  2.4 
Morphine-bis-PFP  13.7  91  1.1  1.9 
22.8  87  0.74  0.6 
5.25  85  10.2  10.5 
Benzoylecgonine- 
Methyl  ester 
15.8  85  10.6  2.9 
26.8  83  10.4  1.6 
20  66  5.63  5.9 
THC-OH-PFP  60  50  5.13  4.2 
100  56  3.7  0.84 
20  56  8.6  5.12 
THC-COOH 
PFP/Methyl  ester 
60  60  3.2  1.41 
100  68  7.16  1.33 
The  validated  method  was  applied  to  blood  samples  collected  from  Forensic  Medicine  and 
Science  at  the  University  of  Glasgow.  In  general  the  method  worked  well  with  this 
derivatising  reagent.  However  as  found  in  the  first  set  of  tests,  there  were  interferences  in 
the  GC-MS  analyses  due  to  the  StrataTM  X  cartridges  and  also  due  to  the  TMS- Chapter  Five  Page  124 
diazomethane  reagent.  However,  the  method  was  found  to  be  able  to  detect  and  quantify 
both  basic  and  acidic  drugs  including  drugs  of  abuse  and  prescribed  drugs. 
5.5.9  Conclusion 
This  version  of  the  method  also  showed  promise  as  a  unified  procedure  for  general  use 
because  of  its  ability  to  detect  and  meaure  both  acidic  and  basic  drugs.  This  derivatisation 
procedure  would  be  very  useful  if  a  pure  form  of  the  TMS-diazomethane  solution  could  be 
prepared.  The  limits  of  quantification  for  cannabinoids  would  need  to  be  improved  if  the 
method  was  to  be  used  routinely. 
5.6  Method  validation  for  drug  derivatisation  with 
MTBSTFA 
5.6.1  Introduction 
The  third  version  of  the  proposed  unified  method  was  validated  as  before,  using  the  same 
approach  to  the  measurement  of  the  validation  parameters.  Neither  methamphetamine  nor 
morphine  could  be  detected  as  their  TBDMS  derivatives,  as  noted  in  Chapter  4. 
5.6.2  Linearity 
Using  the  procedure  as  before,  each  drug  concentration  in  blood  was  extracted  five  times 
and  the  calibration  curves  for  the  target  analytes  were  prepared.  These  were  found  to  be 
linear.  The  correlation  coefficient  (R2)  values  are  listed  in  Table  5-30,  and  the  curves  are 
shown  below  in  Figure  5-19  to  Figure  5-22.  The  ions  for  these  derivatives  used  for  GC- 
MS-SIM  were  at  high  mass  values  and  were  selective,  so  there  was  no  interference  in  the 
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Table  5-30:  -  Correlation  coefficients  (R2)  for  all  compounds  analysed  as  TBDMS  derivatives. 
Compound  R-  Values 
Amphetamine  0.9995 
Benzoylecgonine  0.9971 
THC-OH  0.999 
THC-COOH  0.9976 
Amphetamine 
f  Amphetanine-  TBDMCS 
Linear  (Amphetamne-TBDIv1CS) 
0  20  80  100 
Figure  5-19:  -  Calibration  curve  for  Amphetamine-TBDMCS  derivative 
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Figure  5-20:  -  Calibration  curve  for  Benzoylecgonine-TBDMCS  derivative Chapter  Five 
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f  THC-OH-TBDMCS 
Linear  (THC-OH-TBDMCS) 
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Figure  5-21:  -  Calibration  curve  for  THC-OH-TBDMCS  derivative 
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Figure  5-22:  -  Cailbration  curve  for  THC-COOH-TBDMCS 
5.6.3  Intra  -Day  Variation 
The  set  of  calibration  curve  standards  containing  all  six  drugs  was  extracted  five  times 
during  one  day  and  the  results  of  GC-MS  analysis  are  displayed  in  Table  5-31  to  Table 
5-33. 
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Table  5-31:  -  Intra-Day  variation  for  Amphetamine  analysed  as  the  TBDMS  derivative 
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Concentration  (ng/ml  of  blood)  Average  Area  Ratio  of  Amp/Amp-d5 
(%RSD,  n=5) 
16  0.07  (8.9) 
48  0.5  (6.4) 
80  0.97  (10.3) 
Table  5-32:  -  Intra-Day  variation  for  Benzoylecgonine  analysed  as  the  TBDMS  derivative 
Concentration  (ng/ml  of  blood)  Average  area  Ratio  Bze/Bze-d3 
(%RSD,  n=5) 
5.3  0.32  (10.7) 
15.75  0.9  (6.7) 
26.25  0.42  (10.3) 
Table  5-33:  -  Intra-Day  variation  for  THC-OHITHC-COOH  analysed  as  the  TBDMS  derivatives 
Concentration 
(ng/ml  of  blood) 
Average  area  Ratio  ( 
THC-OH 
%RSD,  n=5) 
THC-COOH 
20  0.21  (5.2)  0.15  (1.0) 
60  0.7  (1.9)  0.52  (1.9) 
100  1.2  (10.3)  0.86  (10.0) Chapter  Five  Page  128 
5.6.4  Inter-Day  Variation 
The  average  area  ratios  were  calculated  for  five  sets  of  drug  standards  which  were 
extracted  five  times  over  a  period  of  1  week  and  are  displayed  in  Table  5-34  to  Table  5-36. 
Table  5-34:  -  Inter-  Day  variation  for  Amphetamine  analysed  as  the  TBDMS  derivative 
Concentration  -Amp  (ng/ml  of  blood)  Mean  Concentration  (%RSD,  n=5) 
16  16.3  (4.1) 
48  50.3  (12.6) 
80  79.9  (2.2) 
Table  5-35:  -  Inter-  Day  variation  for  Benzoylecgonine  analysed  as  the  TBDMS  derivative 
Concentration  Bze  (ng/ml  of  blood)  Mean  Concentration  (%RSD,  n=5) 
5.3  5.5  (12.0) 
15.75  15.3  (8.4) 
26.25  25.9  (2.7) 
Table  5-36:  -  Inter-  Day  variation  for  THCITHC-COOH 
Concentration  Mean  Concentration  (%RSD,  n=5) 
(ng/ml  of  blood)  THC-OH  THC-COOH 
20  19.2  (9.36)  18.1  (5.3) 
60  58.4  (6.48)  57.8  (7.5) 
100  101.2  (2.45)  99.5  (3.3) Chapter  Five 
5.6.5  Recovery 
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The  recoveries  of  the  method  for  drugs  extracted  from  spiked  blood  samples  at  low, 
medium  and  high  concentrations  were  measured  as  before.  The  results  are  shown  below  in 
Table  5-37  and  Figure  5-23. 
Table  5-37:  -  Recovery  for  test  substances  analysed  as  MTBSTFA  derivatives 
Analyte 
Concentration 
(n  /ml) 
Recovery 
% 
16  90 
Amphetamine  48  85 
80  64 
5.25  85 
Benzoylecgonine  15.75  56 
26.25  80 
20  65 
THC-OH  60  56 
100  62 
20  64 
THC-COOH  60  72 
100  73 
Recovery 
Amp  Benzo  THC-OH  THC-COOH 
ng/mI 
Figure  5-23:  -  Recoveries  of  drugs  from  blood  using  strata  TM  X  and  analysed  as  the  TBDMS 
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5.6.6  Limits  of  Detection  and  Quantification 
The  method  for  obtaining  the  LOD  and  LOQ  was  described  in  Sections  5.4.5  and  5.4.6. 
The  results  for  the  test  substances  analysed  as  the  TBDMS  derivative  are  shown  below  in 
Table  5-38. 
Table  5-38:  -  Limits  of  detection  and  quantitation  for  TBDMS  derivatives 
Drug  LOD  (ng/ml)  LOQ  (ng/ml) 
Amphetamine  3.3  10.8 
Benzoylecgonine  1.9  4.9 
THC-OH  7.3  24.4 
THC-COOH  5.9  19.8 
5.6.7  Application  to  real  cases 
The  developed  method  was  applied  to  26  case  samples  of  which  16  cases  were  previously 
found  to  be  positive  for  drugs  of  a  buse.  These  were  collected  from  Forensic  Medicine  and 
Science,  University  of  Glasgow.  They  are  summarised  below  in  Table  5-39.  No 
prescription  drugs  were  detected  in  any  of  the  blood  samples  using  this  derivatising  reagent 
and  all  these  cases  different  from  other  cases. 
Table  5-39:  -  Results  of  GC/MS  for  cases  analysed  with  MTBSTFA  derivatisation 
Case  No  Drug  Concentration  (mg/L) 
Amp  Meth  Mor  Cocaine  Bze  THC  THC- 
COOH 
Blank  -  -  -  -  -  -  - 
1  0.54  -  -  -  -  -  - 
2  0.43  -  -  -  -  - Chapter  Five  Page  131 
3  0.7  -  -  -  -  -  - 
4  0.9  -  -  -  -  -  - 
5  -  -  -  -  -  -  0.02 
6  -  -  -  -  -  -  0.01 
7  -  -  -  -  -  -  0.04 
8  -  -  -  -  -  0.03 
9  -  -  -  -  0.35  -  - 
10  -  -  -  -  0.11  -  - 
11  -  -  -  -  -  -  - 
12  -  -  -  -  -  - 
13  -  -  -  -  0.02  -  - 
14  -  -  -  -  0.023  -  - 
15  -  -  -  -  0.03  -  - 
16  -  -  -  -  -  - 
5.6.8  Discussion 
The  validation  parameters  including  linearity,  precision,  recovery,  limit  of  detection  (LOD) 
and  limit  of  quantification  (LOQ)  were  evaluated as  for  the  other  two  derivatising  reagents 
and  the  recoveries  and  precision  measurements  are  summarised  in  Table  5-40. 
The  MTBSTFA  reagent  produced  R2  Z0.99  for  all  analytes  and  the  GC-MS  analyses  were 
less  affected  by  interferences  than  the  previous  reagent.  The  intra-  and  inter-day  precisions 
were  evaluated  at  low,  medium  and  high  concentrations  for  five  replicates.  Intra-day  assay 
%RSDs  ranged  from  1  to  10.7%.  The  highest  intra-day  %RSD  was  for  benzoylecgonine  at Chapter  Five  Page  132 
a  concentration  of  5.3  ng/ml  blood  while  the  lowest  %RSD  was  for  THC-OH  at  a 
concentration  of  4.55  ng/ml  blood.  However,  the  inter-day  assay  %RSDs  ranged  from 
2.45  to  12.6  %.  The  highest  inter-day  %RSD  was  for  amphetamine  at  a  concentration  of 
48  ng/ml  while  the  lowest  %RSD  was  for  amphetamine  at  80  ng/ml  blood  as  shown  in 
Table  5-40. 
The  recovery  ranged  between,  56  and  90  %.  The  lowest  recovery  was  for  benzoylecgonine 
at  a  concentration  of  15.75  ng/ml  blood  and  the  highest  was  for  amphetamine  at  a 
concentration  of  16  ng/ml  blood. 
The  limits  of  detection  and  quantitation  are  listed  Table  5-38  which  show  that 
benzoylecgonine  produced  the  lowest  detection  limit  and  THC-OH  gave  the  highest 
detection  limit. 
Table  5-40:  -  Accuracy,  intra  and  inter-day  assay  precision  with  MTBSTFA  at  different 
concentration 
Compound- 
Product 
Concentration(ng/ml)  Recovery 
%(n--5) 
Intra-day 
RSD%(n=5 
Inter-day 
RSD%  n=5 
16  90  8.9  4.1 
Amphetamine-  48 
TBDMS 
85  6.4  12.6 
80  64  10.3  2.2 
5.25  85  10.7  12 
Benzoylecgonine-  15.75 
bis-TBDMS 
56  6.7  8.4 
26.25  80  10.3  2.7 
20  65  5.2  9.36 
THC-OH-  TBDMS  60  56  1.9  6.5 
100  62  10.3  2.5 
20  64  1.0  5.3 
THC-COOH-  60 
TBDMS 
72  1.9  7.5 
100  73  10  3.3 
The  method  was  applied  to  blood  samples  collected  from  Forensic  Medicine  and  Science 
at  the  University  of  Glasgow.  Drugs  of  abuse  were  detected  but  no  prescription  drugs  were 
found  in  any  of  the  samples. Chapter  Five  Page  133 
5.6.9  Conclusion 
The  TBDMS  derivatives  gave  good  linearity  for  the  4  test  compounds.  However,  this 
derivative  was  found  to  be  unsuitable  for  methamphetamine  and  morphine,  which  could 
not  be  detected.  These  compounds  were  used  as  model  compounds  which  represented  the 
behaviour  of  other  drugs  with  similar  functional  groups  and  so  it  can  be  concluded  that 
many  other  drugs  and  metabolites  would  not  be  detected  using  this  reagent.  Also,  the 
limits  of  detection  and  quantification  were  too  high  with  this  reagent  for  the  method  to  be 
usable  in  routine  toxicology. 
5.7  General  Discussion  and  Conclusions 
Analytical  chemistry  is  a  very  important  field  particularly  when  applied  to  forensic 
toxicology  in  which  gas  chromatography-mass  spectrometry,  extraction  and  derivatisation 
techniques  are  used.  This  study  looked  into  the  effects  of  different  chemical  derivatisation 
procedures  on  separation  and  identification  of  illicit  drugs  such  as  amphetamine, 
methamphetamine,  morphine,  benzoylecgonine,  THC-OH  and  THC-COOH.  A  single 
method  was  used  for  the  extraction  of  these  drugs  from  whole  blood  and  three  different 
methods  were  used  for  derivatisation. 
Extraction  procedures  are  used  to  clean  up  the  sample  by  removing  interfering  substances 
and  concentrating  the  drug  for  injection  into  the  GC-MS  instrument.  Solid  phase 
extraction  was  used  in  this  case.  There  are  different  types  of  solid  phases  available 
depending  on  what  kind  of  drug  needs  to  be  extracted,  acidic,  basic  or  neutral.  If  drugs  of 
different  types  are  to  be  extracted  simultaneously  then  two  fractions  can  be  eluted  from  the 
solid  phase  cartridge,  one  for  acidic  drugs  and  one  for  basic  drugs.  This  can  be  time 
consuming. 
The  aim  of  this  study  was  to  find  a  single  extraction  method  for  the  simultaneous 
extraction  of  acidic  and  basic  drugs.  Solid  phase  extraction  cartridges  produced  by 
Phenomenex,  called  StrataTmX  were  investigated.  The  disadvantage  of  using  StrataTmX 
was  that  the  eluate  was  relatively  dirty  so  investigation  into  the  use  of  more  solvents  in  the 
washing  steps  to  remove  more  impurities  was  carried  out:  the  original  method  used  1.5  ml 
methanol  but  because  of  the  problem  with  interferences,  the  volume  was  increased  to  2  ml 
methanol. 
Using  a  microwave  instead  of  a  conventional  heating  block  was  used  to  assist 
derivatisation.  It  required  less  time  to  achieve  complete  derivatisation.  Special  heat Chapter  Five  Page  134 
resistant  vials  and  caps  were  required  as  the  normal  caps  used  melted  in  the  microwave. 
The  microwave  temperature  is  mentioned  in  section  5.2.8.  The  temperature,  power  and 
time  of  irradiation  were  investigated.  The  time  for  derivatisation  was  varied  from  1  to  5 
minutes.  It  was  found  that  using  3  or  5  minutes  at  the  high  power  setting  affected  the 
integrity  of  the  caps  and  sample  was  lost.  One  and  two  minutes  were  similar  but  high 
temperature  and  to  keep  the  elute  by  prevention  evaporate  under  high  temperature.  The 
optimum  time  was  found  to  be  1  minute  at  the  high  power  setting.  A  disadvantage  of  using 
the  microwave  was  that  the  distribution  of  power  was  uneven  and  therefore  it  was 
important  to  distribute  the  vials  in  a  circle  as  shown  in  Figure  4-16. 
A  validated,  sensitive  and  specific  method  for  the  extraction  and  quantification  of  drugs 
abuse  in  blood  is  presented.  For  this  project  three  different  reagents  were  compared. 
Acylation  with  PFP-OH/PFPA  was  applied  with  6  drugs  which  have  different  functional 
groups.  Amphetamine  had  problems  due  to  evaporation,  as  it  is  volatile,  so  it  is 
recommended  that  the  evaporation  to  dryness  stage  should  be  carried  out  slowly  without 
heating  to  prevent  loss  of  analyte.  Methylation  and  acylation  with  PFPA-TMS- 
diazomethane  was  considered  better  than  the  acylation  reaction  because  the  reagent  gave 
good  reactions  and  improved  the  shape  of  chromatographic  peaks.  However  the  best 
sequence  for  addition  of  the  reagents  is  first  to  put  PFPA  then  TMS-diazomethane  for 
safety  reasons.  Silylation  with  MTBSTFA  was  only  successful  with  amphetamine, 
benzoylecgonine,  THC-OH  and  THC-COOH  but  did  not  work  with  morphine  and 
methamphetamine,  which  formed  derivatives  but  these  had  poor  fragmentation  patterns 
and  bad  chromatographic  peak  shapes.  However  the  sample  can  be  injected  directly  to 
GC/MS  without  the  need  to  use  ethyl  acetate  like  the  other  reagents. 
It  is  important  to  know  the  chemical  structure  and  functional  groups  of  the  analyte  to  be 
derivatised  when  choosing  a  derivatising  agent.  No  single  reagent  was  optimum  for  every 
analyte.  Amphetamine  gave  optimum  results  with  PFPA/PFP-OH  whereas 
methamphetamine,  morphine,  benzoylecgonine,  THC-OH  and  THC-COOH  gave  optimum 
results  with  TMS-diazomethane/PFPA.  However,  using  acylation-methylation  gave  the 
best  sensitivity  and  improved  chromatography. 
Finally,  the  derivatistion  and  validation  of  methods  for  different  drugs  containing  different 
functional  groups  was  interesting  because  the  reactions  are  dependent  on  both  function 
groups  and  reagents.  Amphetamine,  methamphetamine,  benzylecgonine,  THC-OH  and Chapter  Five  Page  135 
THC-COOH  derivatised  well  and  gave  good  validation  results  with  PFPA-PFP-OH  and 
PFPA-trimethylsilyl-diazomethane  derivatisation.  However,  derivatisation  of 
amphetamine,  benzoylecgonine  and  THC-OH  was  optimum  with  MTBSTFA.  Morphine 
and  methamphetamine  did  not  derivatise  with  MTBSTFA.  PFPA-trimethylsilyl- 
diazomethane  as  the  derivatising  reagent  was  best  for  morphine  and  THC-COOH.  Table 
5-41  summarises  the  validation  parameters  for  each  drug  for  each  of  the  three 
derivatisation  reagents. 
Table  5-41:  Validation  parameters  for  each  drug  according  to  the  three  derivatising  reagents 
PFPA/PFPOH  PFPA-ME  TBDAZS 
Linearity  R 
AMP  0.9966  0.9888  0.9995 
MA  0.9947  0.9089 
MOR  0.9992  0.9995 
- 
BZE  0.9945  0.9862  0.9971 
THC  0.9989  0.9966  0.999 
THCOOH  0.9934  0.9994  0.9976 
Precision,  I  ntra  day,  %RSD* 
AMP  22.3-10.3  1.5-4.4  8.9-10.3 
MA  5.8-6.8  6.0-1.4  - 
MOR  3.0-13.5  0.4-0.74  - 
BZE  10.8-7.2  10.2-10.4  10.7-10.3 
THC  6.5-6.2  5.6-3.7  5.2-10.3 
THCOOH  15.6-16.5  8.6-7.2  1.0-10.0 
Precision,  I  nter  day,  %RSD* 
AMP  6.9-2.5  2.4-1.6  4.1-2.2 
MA  27-5.1  4.8-1.6  - 
MOR  12.3-2.4  2.4-0.64  - 
BZE  3.9-1.6  10.5-1.6  12-2.7 
THC  8.5-1.9  5.9-0.84  9.4-2.5 
THCOOH  21.4-3.1  5.1-1.3  5.3-3.3 
Recovery  %* 
AMP  74-89  99-95  90-64 
MA  23-18  62-90  - 
MOR  96-71  88-87  - 
BZE  86-95  85-83  85-80 
THC  62-44  66-56  65-62 
THCOOH  61-59  56-68  64-73 
LOD  n  /ml 
AMP  1.2  0.6  3.3 Chapter  Five  Page  136 
MA  0.8  0.6 
_ 
MOR  0.8  0.3 
_ 
BZE  0.4  0.3  1.9 
THC  1.7  1.3  7.3 
THCOOH  3.7  1.4  5.9 
LO  n  /ml 
AMP  4  2.1  10.8 
MA  2.7  2.1  - 
MOR  2.6  1.1 
- 
BZE  1.5  1.2  4.9 
THC  5.8  4.3  24.4 
THCOOH  12.4  4.7  19.8 
*  Parameters  measured  at  different  concentrations  are  given  as  ranges, 
from  the  lowest  to  the  highest  concentration  values. 
The  summary  table  allows  the  effect  of  the  derivatisation  method  to  be  compared.  Each  of 
the  derivatising  methods  gave  acceptable  linearities,  although  the  MTBSTFA  reagent  did 
not  work  with  methamphetamine  or  morphine.  However,  for  all  of  the  other  measured 
parameters,  the  PFPA/TMS-diazomethane  combination  gave  generally  better  results  for 
each  of  the  test  compounds  and  this  combination  warrants  further  investigation,  especially 
with  respect  to  developing  an  analytical  grade  of  the  TMS-diazomethane  reagent. Chapter  Six  Page  137 
6  Gamma-Hydroxybutyric  Acid  and  Beta- 
Hydroxybutyric  Acid 
6.1  Introduction 
This  study  concerned  a  specific  application  of  derivatisation  techniques  to  compounds  of 
interest  in  forensic  toxicology,  although  for  different  reasons,  as  described  below.  These 
had  previously  been  measured  individually  but  not  simultaneously. 
The  full  chemical  name  of  GHB  is  gamma-hydroxybutyrate  (4-hydroxybutyrate)  and  for 
BHB  the  extended  chemical  name  is  (beta-hydroxybutyrate,  3-hydroxybutyrate).  These 
isomers  are  normal  components  of  mammalian  metabolism;  they  occur  naturally  in  every 
cell  in  the  human  body  and  are  most  properly  considered  nutrientsý296,297].  BHB  is  one  of 
the  ketone  bodies  which  will  affect  GHB  metabolism  when  they  reach  elevated 
concentrations.  High  concentrations  could  significantly  inhibit  the  metabolism  of 
GHBE2981.  GHB  is  a  metabolite  of  the  inhibitory  neurotransmitter,  gamma-aminobutyric 
acid  (GABA)  and  is  an  endogenous  compound  found  in  central  nervous  system  (CNS)  and 
peripheral  tissues.  At  moderate  doses,  GHB  induces  a  state  of  relaxation,  euphoria  and 
. 
[29  disinhibition  similar  to  alcohol  83°°1 
GHB  was  first  synthesized  in  196013011  by  the  French  researcher  Dr.  Henry.  He  was 
interested  in  exploring  the  effects  of  GABA  on  the  brain,  because  little  or  no  GABA 
crosses  the  blood-brain  barrier.  His  laboratory  synthesized  GHB,  which  substitutes  a 
hydroxyl  group  for  an  amino  group.  This  difference  allows  GHB  to  cross  the  blood-brain 
barrier  where  some  of  it  is  metabolized  into  GABA.  GHB  was  initially  used  as  an 
anaesthetic  to  aid  in  surgery  because  of  its  ability  to  induce  sleep  and  reversible  coma  [301, 
303].  In  the  late  1980's,  GHB  was  marketed  and  sold  in  the  health  food  industry  as  a  growth 
hormone  stimulator  to  help  body  builders  promote  muscle  mass  and  maintain  weight  [304]. 
People  take  GHB  because  it  helps  to  fight  stress  and  depression,  induces  deep  sleep, 
relieves  anxiety,  enhances  sexual  feelings  and  enhances  athletic  performance  [3011.  As  an 
anti-depressant  GHB  is  typically  dissolved  in  water,  so  it  appears  as  an  odourless, 
colourless  and  nearly  tasteless  liquid  and  it  is  therefore  easily  dissolved  in  alcoholic 
beverages.  Sometimes  the  substance  is  available  as  a  powder,  or  in  capsule  form.  GHB 
has  more  than  30  common  street  or  slang  names  such  as  soap,  liquid  x,  Gamma  OH,  salt Chapter  Six  Page  138 
water,  Georgia  home  body,  Grievous  bodily  harm,  Great  Hormones  at  Bedtime,  G-caps, 
GGHBA,  Easy  lay,  Oxy-sleep,  Natural  sleep  500.  In  recent  years,  GHB  has  gained  a 
reputation  as  an  illicit  drug  and  has  become  a  popular  drug  of  abuse  E305-31  11  when  used 
alone  or  in  combination  with  other  substances,  as  when  mixed  with  alcohol  and  other  drugs 
to  increase  its  euphoric  effects.  GHB  is  also  one  of  the  drugs  reputedly  used  in  drug- 
facilitated  assault  and  drug-facilitated  sexual  assault,  more  popularly  referred  to  as  "date 
rape,  "  [312] 
. 
GHB  is  a  naturally-occurring  substance  that  is  present  in  small  amounts  in  every  cell  in  the 
body  but  is  found  in  greater  concentrations  in  kidney,  heart,  skeletal  muscles  and  brown  fat 
tissues.  However  liver,  lung,  blood,  brain  and  white  fat  have  low  concentrations  and  it  is 
an  endogenous  compound  found  in  central  nervous  (CNS)  and  peripheral  tissues  that  has 
been  hypothesized  to  have  a  role  as  a  neurotransmitter.  GHB  has  been  used  as  an 
anaesthetic  and  as  a  treatment  for  sleep  disorders,  alcohol  withdrawal  (alcoholism),  and 
narcolepsy.  GHB  and  BHB  are  both  very  important,  especially  BHB,  which  is  thought  to 
be  responsible  for  many  cases  of  sudden  death,  and  therefore  more  information  will  be 
given  below.  BHB  is  considered  to  be  one  of  the  ketone  bodiest3131  (Figure  6-1)  which  are 
normally  present  in  urine  and  blood,  but  in  very  low  concentrations.  Ketone  bodies  consist 
.  of  the  three  substances  acetoacetate,  beta-hydroxybutyrate  and  acetone,  31a,  31sß  ý297 
OH  00 
H  CýCH  33 
Figure  6-1  Ketone  Bodies 
The  body  typically  uses  glucose  for  energy  and  it  supplies  the  tissues.  Glucose,  under  the 
influence  of  insulin,  is  converted  to  glycogen  and  body  fat.  However,  when  there  are 
excess  ketone  bodies  available  for  energy,  more  than  is  required  by  the  tissues,  they  cannot 
be  converted  into  fat  and  so  accumulate  in  the  blood,  and  are  excreted  in  the  urine.  This 
process  is  known  as  ketosis.  Ketone  production  results  from  the  breakdown  of  body  fats 
Figure  6-1.  When  fats  are  absorbed  through  the  walls  of  the  small  intestine,  the  glycerol  is 
separated  from  the  fatty  acids,  and  the  fatty  acids  are  broken  into  pieces  in  the  liver.  The 
pieces  are  known  as  ketone  bodies.  The  excretion  of  the  excess  ketones  in  the  urine  is 
important  because  the  presence  of  large  amounts  of  ketone  bodies  in  the  blood  threatens  to Chapter  Six  Page  139 
upset  the  acid-alkaline  balance  of  the  blood,  and  thereby,  the  balance  in  the  tissues  [3161  - 
Actually,  BHB  and  acetoacetate  chemically  are  not  ketones:  they  are  considered  to  be 
physiologically  equivalent  to  ketones  because  they  are  readily  interconverted  in  the  body 
Therefore  acetone  is  a  true  ketone,  and  the  more  general  term  is  "ketone  bodies".  Ketones 
are  by-products  of  fatty  acid  metabolism  which  are  increased  in  diabetes,  alcoholic 
ketoacidosis  and  starvation13171  Metabolism  occurs  in  the  liver  mitochondria.  Ketone 
bodies  are  oxidized  by  most  tissues  except  those  of  the  liver  [3181  to  provide  an  energy 
source  from  stored  lipids  at  times  of  low  carbohydrate  availability.  Therefore  normal 
glucose  concentrations  inhibit  ketone  body  synthesis,  and  the  ketone  bodies  only  begin  to 
be  synthesized  in  high  concentrations  as  serum  glucose  concentration  falls  (Figure  6-2) 
[3191 
Fatty  Acid 
(extracellular) 
-Fatty  Acid 
ýý  (intracellular)  I 
Synthesis  I 
Mitochondria 
ý 
Energy' 
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Ketone  Bodies 
(Export  Energy) 
Figure  6-2:  -  The  cells  produce  ketone  bodies  for  energy. 
6.2  GHB  and  BHB  in  the  body 
6.2.1  Chemistry,  synthesis  and  pharmacokinetics  of  GHB 
GHB's  chemical  name  is  gamma-hydroxybutyrate  (4-hydroxybutrate,  the  sodium  salt 
being  sodium  oxybutyrate)  Figure  6-3.  It  consists  of  four  carbons  and  is  a  small  polar 
molecule,  soluble  in  water  and  a  short  chain  fatty  acid  13011.  It  is  formed  primarily  from  the 
precursor  aminobutyric  acid  by  the  enzyme  monoamine  oxidase. Chapter  Six  Page  140 
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Figure  6-3:  -  Chemical  structures  of  GABA  and  GHB 
OH 
The  properties  of  GHB  include  its  having  a  neuromodulatory  role  in  the  brain  and  the 
ability  to  induce  several  pharmacological  and  behavioural  effects.  Following  oral 
ingestion,  GHB  is  rapidly  absorbed  from  the  gastrointestinal  tract  and  transported  by  the 
portal  circulation  to  the  liver  where  most  of  it  gets  metabolized  to  carbon  dioxide  and 
water  by  first-pass  metabolism  pathways.  A  certain  amount  crosses  the  blood-brain 
barrier.  GHB  overdose  has  been  reported  to  result  in  coma,  cardiorespiratory  depression, 
seizures  and  death13011.  GHB  has  a  half-life  of  20-53  min,  which  appears  to  increase  with 
higher  doses.  Because  the  drug  is  rapidly  eliminated  from  the  body,  GHB  exposure  is 
difficult  to  document. 
The  simplest  way  to  produce  GHB  is  by  the  hydrolysis  of  the  corresponding  lactone  (a 
cyclic  intramolecular  ester)  to  the  desired  hydroxy  acid.  Ester  hydrolysis  can  be  done  in 
two  ways:  an  acid  catalyzed  reaction  or  a  base  catalyzed  reaction.  The  base  catalyzed 
reaction  is  preferred,  because  the  reaction  is  not  reversible,  unlike  the  acid  catalyzed  one, 
and  therefore  higher  yields  are  obtained.  Alkaline  hydrolysis  gives  the  sodium  salt  of 
GHB.  The  free  acid  is  not  stable  and  will  immediately  cyclize  into  gamma  -butyrolactone 
again.  The  reaction  proceeds  equimolarly  (the  number  of  moles  of  each  substance  that 
reacts),  and  there  are  no  by  products  produced  in  this  reaction,  such  as  hydrogen  gas  or 
water  Figure  6-4' 
00 
+  NaOH  HO 
O-  Na+ 
Figure  6-4:  -  Chemistry  and  Synthesis  Sodium  Gamma-Hydroxy  Butyrate  (NaGHB). Chapter  Six  Page  141 
GHB  is  formed  in  the  brain  from  GABA,  derived  in  turn  from  succinic  semialdehyde 
(SSA)  via  a  specific  succinic  semialdehyde  reductase  (SSR,  Figure  6-5).  GHB  can  be 
reconverted  back  to  SSA  via  GHB  dehydrogenase,  and  GHB  can  be  converted  back  to 
GABA.  Succinic  semialdehyde  can  also  be  metabolized  by  succinic  semialdeyde 
dehydrogenase  (SSADH)  to  succinic  acid.  Mutant  mice  in  which  the  SSADH  enzyme  is 
t3o11  deleted  display  high  levels  of  GHB  and  GABA 
OH 
H2N  GABA  transaminase 
0 
0 
GABA 
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Figure  6-5:  -  GABA  metabolism  to  GHB  in  body 
When  GHB  became  illegal  in  the  United  States  of  America,  drug  users  started  looking  for 
similar  chemicals.  Gamma-butyrolactone  (GBL)  and  1.4-butanediol  (1,4-BD)  are  two 
such  analogues  of  GHB.  The  body  will  convert  them  to  GHB  where  GBL  is  metabolized 
to  GHB  via  lactonase  while  1.4-BD  is  first  metabolized  to  gamma-hydroxybutyraldehyde 
via  alcohol  dehydrogenase,  then  to  GHB  via  aldehyde  dehydrogenase  (Figure  6-6). 
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Figure  6-6:  -  Metabolism  of  1,4  BD  to  GHB  in  the  body. 
6.2.2  Chemistry  and  pharmacokinetics  of  BHB 
Beta-hydroxybutyrate  and  other  ketone  bodies  are  synthesized  from  acetyl  CoA  (Figure 
6-7)  and  this  occurs  in  hepatic  mitochondria.  The  thioester  bond  which  links  the  acyl 
group  to  coenzyme  A  has  a  large  negative  standard  free  energy  of  hydrolysis,  therefore  an 
acyl  group  attached  to  COA  in  this  manner  is  considered  to  be  activated. 
glucose 
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ý\ 
amino  acids 
Fatty  acids-------  Acetyl  CoA  ketone  bodies------ 
phospholipids 
eicosanoids 
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Figure  6-7:  -  Major  metabolic  sources  of  acetyl  CoA. 
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Acetoacetate  is  produced  in  a  three  step  process.  However,  it  can  be  reduced  to  beta- 
hydroxybutyrate,  and  acetone  also  arises  in  small  amounts  as  a  biologically  inert  side 
product.  When  mobilization  of  fatty  acids  from  adipose  tissue  is  high,  hepatic  beta- 
oxidation  will  occur  at  a  high  rate  and  so  will  synthesis  of  ketone  bodies  from  the  resulting 
acetyl  CoA.  The  first  step  is  the  formation  of  acetoacetyl  CoA  in  a  reversal  of  the  thiolase 
step  of  beta  oxidation  (Figure  6-8). 
0 
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CH3  -C  -CoA  +  CH3 
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Figure  6-8:  -  First  step  is  formation  of  acetoacetate-CoA 
In  the  second  step,  a  third  molecule  of  acetyl  CoA  condenses  with  the  acetoacetyl  CoA, 
forming  3-hydroxy-3-methlglutaryl  CoA  (HMG  CoA)  in  a  reaction  catalyzed  by  HMG 
CoA  synthase  Figure  6-9. 
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Figure  6-9:  -  Second  step  is  formation  of  3-hydrox-3-methlglutaryl-CoA  (HMG  CoA) 
In  the  third  step  HMG  CoA  is  cleaved  to  yield  acetoacetate  (ketone  body)  in  a  reaction 
catalyzed  by  HMG  CoA  lyase.  One  molecule  of  acetyl  CoA  is  also  produced  (Figure 
6-10).  Subsequently  acetoacetate  can  be  reduced  to  beta-hydroxybutyrate  by  beta- 
hydroxybutyrate  dehydrogenase  in  a  reaction  requiring  NADH.  The  extent  of  this  reaction 
depends  on  the  state  of  the  NAD  pool  of  the  cell:  when  it  is  highly  reduced,  most  or  all  of 
the  ketones  can  be  in  the  form  of  beta-hydroxybutyrate  (Figure  6-11).  Some  acetoacetate 
spontaneously  decarboxylates  to  yield  acetone.  The  odour  of  acetone  can  be  smelled  on  the 
[320)  breath  of  individuals  with  severe  ketosis  (Figure  6-10  to  Figure  6-12) 
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Figure  6-10:  -  Third  step  is formation  of  acetoacetate  and  acetyl  CoA 
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Figure  6-11:  -  Fourth  step  is  formation  of  B-hydroxybutyrate 
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Figure  6-12:  -  Formation  of  acetone  from  acetoacetate  by  decarboxylation 
6.2.3  Toxicity 
Gamma-hydroxybutyric  acid  is  readily  absorbed  after  oral  administration  and  rapidly 
metabolised  in  the  liver  by  oxidative  enzymes.  Conversion  to  gamma-butyrolactone  can 
occur  and  elimination  is  rapid,  via  the  kidneys,  with  urine  recovery  virtually  complete 
within  8  hours  of  administration.  Only  negligible  amounts  of  the  parent  drug  are  recovered 
unchanged  in  urine  (<5%)  and  after  12  hours,  the  drug  is  not  detectable.  Effects  of  GHB Chapter  Six  Page  145 
including  drowsiness,  euphoria,  dizziness,  nausea,  visual  disturbances  and 
unconsciousness,  are  usually  manifested  by  15  minutes  after  administration  and  persist  for 
about  3  hours  on  average.  Serious  adverse  reactions  have  included  hypotension, 
bradycardia,  respiratory  depression,  seizures,  coma  and  possibly  death.  In  many  forensic 
cases  alcohol  abusers  were  found  dead  and  the  cause  of  death  could  not  be  ascertained.  In 
order  to  examine  the  possible  role  of  ketoacidosis  for  the  cause  of  death  the  concentration 
of  ketone  bodies  (acetone,  acetoacetate  and  D-ß-hydroxybutyrate)  have  to  be  determined  in 
postmortem  blood  specimens  [3213.  However,  beta-hydroxbutyrate  is  not  detected  by  the 
screening  test  for  ketones  which  detects  only  acetoacetic  acid.  Because  beta- 
hydroxybutyrate  is  stable  and  also  is  usually  present  at  concentrations  higher  than  the  other 
ketones,  it  provides  a  more  sensitive  test  to  use  when  monitoring  the  treatment  of  diabetic 
ketoacidosis.  The  mechanism  of  these  deaths  is  obscure  but  could  be  related  to  a  critical 
[322,3231  fall  in  blood  pH  to  around  pH  7 
6.2.4  Methods  of  Analysis  of  GHB  and  BHB 
There  are  several  methods  for  the  detection  of  GHB  and  BHB  in  blood  samples  by  gas 
chromatography  mass  spectrometry  (GC/MS)J324,3251  These  have  been  used  to  investigate 
the  relationship  between  GHB  and  depression  of  the  central  nervous  system  where  effects 
were  obsered  similar  to  alcohol  as  well  as  induced  relaxtion  and  tranquillity,  libido 
enhancement  and  euphoria  , 
[326,327] 
The  blood  samples  were  analysed  by  GC/MS  using  liquid-liquid  extraction  or  solid  phase 
extraction  and  disilyl-derivatisation  with  or  without  conversion  to  the  gamma- 
butyrolactone  (GBL).  [324,328,329]  Gamma  hydroxybutyrate  (GHB)  is  naturally  present  in 
both  blood  and  urine  but  the  role  of  GHB  remains  unclear.  [330,331]  Some  authors  extract 
GHB  from  urine  because  GHB  remains  in  urine  longer  than  blood.  Of  these  papers  the 
post-mortem  blood  GHB  concentration  range  was  13.8-86.3  mg/l.  [332-336] 
BHB  has  also  been  analysed  by  headspace  gas  chromatography  following  conversion  to 
acetone,  (337,338]  One  paper  reports  a  method  to  analyse  both  of  them  in  urine  but  not  blood, 
using  a  single  method,  based  on  solvent  extraction  and  silylation  before  GC-MS  J3391  LC- 
MS  methods  have  also  been  published  for  GHB  either  as  the  free  acid  [3401  or  as  its  n-butyl 
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6.2.5  Aims 
Gamma-hydroxybutric  acid  is  a  central  nervous  system  depressant  that  has  been  abused 
recreationally  for  its  purported  euphoric  and  relaxant  effects  and  for  the  purposes  of  drug- 
facilitated  sexual  assault  due  to  its  sedative  and  amnesic  affects  at  high  doses.  The 
dramatic  increase  in  the  abuse  of  GHB  and  association  in  criminal  investigation  over  the 
past  decade  has  created  the  need  for  forensic  laboratories  to  develop  analytical  methods  to 
detect  GHB.  The  4-hydroxy  isomer  of  GHB  is  also  of  forensic  interest.  In  some  cases  it 
may  be  difficult  for  the  forensic  pathologist  to  assign  a  cause  of  death  for  a  known  alcohol 
abuser  who  has  been  found  dead,  and  alcoholic  ketoacidosis  has  been  implicated.  One 
diagnostic  test  for  ketoacidosis  is  to  measure  the  concentration  of  beta-hydroxybutyric  acid 
in  blood.  Therefore  it  is  beneficial  to  have  a  GC/MS  method  which  can  be  used  in  the 
forensic  lab  for  the  determination  of  physiological  concentrations  of  beta-hydroxbutyrate 
in  postmortem  blood,  so  creating  a  method  for  measuring  both  GHB  and  BHB  at  the  same 
time  with  the  same  instrumental  conditions.  The  aims  of  this  study  were  to  evaluate  the 
reagents  for  derivatisation,  evaluate  microwave  assisted  derivatisation  and  evaluate 
suitable  chromatographic  analytic  procedures,  and  so  to  develop  a  method  for  the 
simultaneous  quantification  of  GHB  and  BHB  in  blood. 
6.3  Experimental  Section 
6.3.1  Chemicals  and  reagents 
N,  O-Bis  (trimethylsilyl)  trifluoroacetamide  with  1%  Trimethylchlorosilane  (BSTFA  +  1% 
TMCS,  Figure  6-13),  is  a  silylation  reagent.  It  has  some  desirable  properties  such  as 
reacting  faster  and  more  completely  than  other  reagents  because  of  the  presence  of  the 
trifluoroacetyl  group;  it  has  high  volatility,  as  do  its  by-products;  it  results  in  separation  of 
early  eluting  peaks,  has  excellent  solubility  in  organic  solvents  and  the  addition  of  TMCS 
.  catalyzes  reactions  of  hindered  functional  groups  in  secondary  alcohols  and  amines[342] 
The  reagent  was  purchased  from  Fluka.  Methanol  was  purchased  from  VWR  International 
Ltd.  Ammonia  solution,  NH4OH,  and  potassium  dihydrogen  orthophosphate  were 
purchased  from  BDH  Laboratory  supplies. Chapter  Six  Page  147 
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Figure  6-13:  -  Chemical  structure  of  BSTFA 
6.3.2  Standards 
The  drug  standards  used  were  GHB,  1  mg/ml  in  methanol  and  GHB-d6,  lmg/ml  in 
methanol,  as  the  internal  standard  for  GHB  and  BHB.  Both  were  produced  by  Cerilliant 
and  supplied  in  the  UK  by  LGC  Promochem.  Beta-hydroxybutyric  acid  sodium  salt  was 
obtained  from  Fluka. 
6.3.3  Preparation  of  standard  solutions  of  GHB 
GHB  working  standard,  100µg/ml  (O.  lmg/ml)  in  methanol,  was  prepared  from  the  stock 
lmg/ml  solution  by  diluting  100µl  of  the  stock  solution  with  900µl  of  methanol.  The 
internal  standard  was  GHB-d6,100µg/ml,  prepared  from  the  stock  solution.  25µl  of 
internal  standard  solution  was  added  to  each  sample.  Blood  standards  were  prepared  by 
adding  different  amounts  of  GHB  and  GHB-d6  to  blood  as  indicated  in  Table  6-1. 
Table  6-1:  -  Preparation  of  different  concentrations  of  GHB 
Working  Standard  Volume 
(µ1) 
Whole  Blood  Volume  (µl)  Concentration 
(gg/ml) 
10  200  5 
20  200  10 
40  200  20 
60  200  30 
80  200  40 
100  200  50 Chapter  Six 
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1.0052g  of  BHB  was  weighed  into  1L  deionised  water.  This  gave  a  free  BHB 
concentration  of  8.3mg/ml.  The  concentration  range  used  for  analysis  was  from  0-2  mg/L, 
therefore  12.05  ml  of  an  8.3  mg/ml  solution  was  added  to  50  ml  flask  and  made  up  to 
volume  with  blank  blood,  resulting  in  a  BHB  working  solution  with  a  concentration  of 
2  mg/ml  Table  6-2.251l  of  internal  standard  solution  was  added  to  each  sample. 
Table  6-2:  -  Preparation  of  different  concentrations  of  BHB 
Number  Standard  in  Blood 
(ml) 
Blank  Blood 
(ml) 
Concentration 
(mg/ml) 
1  10  0  2 
2  7.5  2.5  1.5 
3  5  5  1 
4  2.5  7.5  0.5 
5  1  9  0.2 
6  0.5  9.5  0.1 
6.3.5  Extraction  method  based  on  SPE  clean  screen 
Solid  phase  extraction  (SPE)  was  carried  out  using  Clean  Screen  GHB®  cartridges 
(200mg/3m1,  Figure  6-14),  supplied  by  United  Chemical  Technologies  Inc  (UCT 
CSGHB203)  which  contained  phenyl  and  propylsulphonic  acid  substituents.  The 
extraction  mechanism  of  Clean  Screen  was  efficient,  robust  and  clean.  When  a  sample  is 
loaded  onto  the  column  at  pH6,  many  functional  groups  present  in  the  sample  are  ionized. 
This  creates  repulsion  between  the  column  and  many  sample  borne  interferences,  thereby 
reducing  the  likelihood  of  their  adsorbing  onto  the  column.  The  SPE  column  can  then  be 
washed  with  water  or  weak  aqueous  buffers  at  or  below  pH6  without  risking  loss  of  the 
analytes.  Many  compounds  of  intermediate  polarity  and  potential  interferences  will  also 
remain  on  the  column.  The  majority  of  these  potential  interferences  can  be  removed  by 
using  a  methanol  wash.  Anionic  analytes  bound  to  the  column  can  be  eluted  after  another 
drying  step.  The  drying  steps  are  necessary  to  remove  water  which  would  have  prevented 
water  immiscible  elution  solvents  from  optimally  interacting  with  the  analytes.  To  elute 
the  anionic  analytes,  an  organic  solution  with  a  high  pH  between  11  and  12  should  be  used. Chapter  Six  Page  149 
A  methylene  chloride-isopropanol-ammonium  hydroxide  mixture  will  simultaneously 
disrupt  these  ionic  interactions  and  successfully  elute  the  desired  compound. 
Figure  6-14:  -  UCT-GHB-SPE  Solid  Phase  Extraction 
6.3.6  Instrumental  method 
The  GC  was  equipped  with  a  fused  silica  capillary  column  (HP-5,30  in  x  0.32  mm  i.  d., 
0.25µm  film  thickness)  from  J&W  Scientific.  The  injection  port  was  operated  in  the 
splitless  mode  at  280°C,  with  the  purge  being  initiated  at  0.5  minutes.  The  initial  oven 
temperature  was  65°C  for  0.5  minute  at  which  time  a  15°C/min  ramp  was  instituted  until 
reaching  a  final  temperature  of  300°C.  The  mass  spectrometer  was  operated  using  the 
same  conditions  listed  in  Table  4-1. 
The  ions  used  for  selected  ion  monitoring  are  given  in  Table  6-3.  Representative  SIM  and 
full  scan  chromatograms  and  the  mass  spectrum  for  GHB  are  given  in 
Figure  6-15  and  Figure  6-16.  The  fragmentation  pattern  of  GHB  as  its  TMS  derivative  is 
explained  in  Figure  6-17.  Corresponding  diagrams  for  BHB  are  given  in  Figures  6-18  to  6- 
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Table  6-3:  -  selected  Ions  used  for  GC-MS  SIM 
Target  analyte  Retention  time  Selected  Ions 
(m/z) 
Internal 
standard 
Selected 
Ions(m/z) 
GHB  4.78  117,233  GHB-d6  239 
BHB  4.13  191,233  GHB-d6  239 
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6.3.7  Method  validation  for  GHB 
6.3.7.1  Linearity 
Linearity  was  determined  for  the  concentration  range  of  0  to  50µg/200µ1  blood.  The 
calibration  curve  for  the  target  analyte  was  linear  and  had  a  linear  correlation  coefficient 
(R2)  equal  to  0.9993  as  shown  in  Figure  6-20 
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Figure  6-20:  -  Calibration  curve  for  GHB 
6.3.7.2  Recovery 
f  GHB-BSTFA 
-Linear  (GHB-BSTFA) 
The  recovery  of  GHB  from  spiked  blood  samples  was  determined  as  described  earlier  in 
Chapter  5.  Recoveries  for  the  analyte  were  in  the  range  44-76%  (Table  6-4,  Figure  6-21  ). 
Table  6-4:  -  Recovery  of  GHB  from  blood  using  Clean  Screen  GHB  cartridges 
Concentration  (  ml)  GHB  %  Recovery 
10  44 
30  49 
50  76 Chapter  Six  Page  156 
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Figure  6-21:  -  Recovery  of  GHB  from  blood  using  Clean  Screen  GHB  cartridges 
6.3.7.3  Limits  of  Detection  and  Quantitation 
The  methods  for  determining  limits  of  detection  and  quantitation  of  GHB  from  spiked 
blood  samples  have  already  been  described  in  Chapter  5  (Paragraph  5.4.6  and  5.4.7). 
Blank  blood  was  spiked  with  GHB  to  give  concentrations  of  1,2.5,5,10  and  20µg/ml. 
These  were  extracted  as  described  previously.  The  detection  limit  was  evaluated  as  the 
amount  of  analyte  that  gives  a  signal-to-noise  ratio  of  3  times  the  background  noise.  The 
limit  of  quantitation  was  evaluated  as  the  signal-to-noise  ratio  that  is  equivalent  to  10  times 
the  noise  (Table  6-5). 
Table  6-5:  -  Limit  of  Detection  and  Quantitation  for  GHB 
GHB  (µg/ml) 
LOD 
LOQ 
6.3.7.4  Inter-Day  Precision 
0.4 
1.30 
The  calibration  curve  standards  were  extracted  five  times  during  different  days  and  the 
inter-day  variation  at  each  concentration  was  assessed  and  is  displayed  below  in  Table  6-6. Chapter  Six  Page  157 
Table  6-6:  -  Inter-Day  precision 
Concentration  GHB  (  ml  Mean  concentration  (%RSD) 
5  5.1  (10.6) 
10  10.0  (18.3) 
20  19.7  11.8 
30  30.1  2.9 
40  39.9  (0.9 
50  50.0  0.4 
6.3.7.5  Intra-  Day  Precision 
The  average  area  ratios  (drug/internal  standard  ratio)  and  relative  standard  deviations  were 
calculated  after  the  linearity  curve  standards  were  extracted  five  times  to  determine  the 
intra-day  variation  of  the  assay  over  the  calibration  range  and  this  is  displayed  in  Table 
6-7. 
Table  6-7:  -  Intra-Day  Precision 
Concentration  in  blood 
(  ml 
m/z  233/239 
GHB/GHB-d6  (RSD 
5  0.8(9.7) 
10  1.3(6.3) 
20  4.7  (9.6 
30  6.3  10.5 
40  6.5  (9.8) 
50  7.6(8.8) 
6.3.8  Method  validation  for  BHB 
6.3.8.1  Linearity 
Linearity  was  determined  for  concentration  range  of  0  to  2mg/ml.  The  calibration  curve 
for  the  target  analyte  was  linear  and  the  linear  correlation  coefficient  (R)  was  0.9988 
(Figure  6-22). Chapter  Six  Page  158 
Figure  6-22:  -  Calibration  Curve  for  BHB 
6.3.8.2  Recovery 
The  method  for  determining  the  recovery  of  the  analyte  from  spiked  blood  samples  has 
already  been  described  in  Chapter  5.  Recoveries  for  the  analyte  were  in  the  range  47-89% 
(Table  6-8,  Figure  6-23). 
Table  6-8:  -  Recovery  of  BHB  from  blood  samples 
Concentration  (m  ml)  Recovery  % 
0.1  47 
1  84 
2  89 
Figure  6-23:  -  Recovery  of  BHB  from  blood  using  Clean  Screen  GHB  cartridges Chapter  Six  Page  159 
6.3.8.3  Limits  of  Detection  and  Quantitation 
Limit  of  detection  and  quantitation  of  the  method  for  spiked  blood  samples  were  measured 
as  described  previously  in  Chapter  5.  Blank  blood  was  spiked  with  BHB  to  give 
concentrations  of  0.0025,0.005,0.01,0.02,0.06  mg/ml.  these  were  extracted  as  described 
previously.  The  limit  of  detection  was  evaluated  as  the  concentration  of  analyte  that  gave  a 
signal-to-noise  ratio  of  3  times  the  noise.  The  limit  of  quantitation  was  evaluated  as  the 
concentration  of  analyte  that  gave  a  signal-to-noise  ratio  that  was  equivalent  to  10  or  else  it 
is  blank  reading  plus  10  times  the  standard  deviation  of  the  noise  or  standard  error  of  the 
calibration  curve  (Table  6-9). 
Table  6-9:  -  Limits  of  Detection  and  Quantitation 
BHB  (mg/ml) 
LOD  0.001 
LOQ  0.004 
6.3.8.4  Intra-Day  precision 
The  average  area  ratio  and  relative  standard  deviations  were  calculated  for  each 
concentration  and  are  displayed  in  Table  6-10 
Table  6-10:  -  Intra-Day  precision 
Concentration  in  blood  (mg/ml)  m/z  233/239 
BHB/GHB-d6  SD 
0.1  4.3(8.5) 
0.2  6.2  9.7) 
0.5  16.2  (7.8 
1  26.2  7.1 
1.5  27.1(0.4) 
6.3.8.5  Inter-Day  Precision 
The  set  of  standards  used  for  the  calibration  curve  was  extracted  five  times  during  different 
days  and  the  inter-day  variation  was  assessed  and  is  displayed  in  Table  6-11. Chapter  Six  Page  160 
Table  6-11:  -  Inter-Day  precision 
Concentration  in  blood  (mg/ml)  m/z  233/239 
BHB/GHB-d6  (RSD 
0.1  0.13  8.1 
0.2  0.21  10.9 
0.5  0.46  6.0) 
1  0.1  (4.0 
1.5  1.5  (0.94) 
6.4  Application  to  Case  Samples 
The  developed  method  was  applied  to  89  forensic  autopsy  case  samples  which  were 
collected  from  Forensic  Medicine  and  Science,  University  of  Glasgow.  The  samples  were 
kept  frozen  until  analysed  by  GC/MS. 
These  real  case  samples  were  subdivided  into  four  groups:  the  first  group  contained  cases 
which  did  not  have  a  history  of  alcohol  abuse  (i.  e.  not  known  to  be  alcoholics)  and  which 
had  a  negative  alcohol  result.  The  second  group  were  not  known  to  be  alcoholics  but  had  a 
positive  alcohol  result.  The  third  group  had  a  history  of  alcohol  abuse  but  had  a  low  blood 
alcohol  concentration  (less  than  200/100ml)  at  the  time  of  death.  The  fourth  group  had  a 
history  of  alcohol  abuse  and  had  a  high  blood  alcohol  concentration  at  the  time  of  death. 
The  results  of  the  analyses  of  case  samples  are  given  in  Table  6-12. 
Table  6-12:  -  Results  of  GC/MS  analysis  of  cases  for  GHB/BHB 
Case 
Number 
BHB  Concentration 
(mg/ml) 
GHB  Concentration 
(mg/L) 
Group 
Blank  - 
1  0.4  76  Non-alcoholic,  Neg  alc 
2  0.4  101  Non-alcoholic,  Neg  alc 
3  0.3  72  Non-alcoholic,  Neg  ale 
4  1.1  236  Non-alcoholic,  Neg  alc 
5  0.3  91  Non-alcoholic,  Neg  alc 
6  0.33  207  Non-alcoholic,  Neg  alc 
7  0.3  123  Non-alcoholic,  Neg  alc 
8  0.4  123  Non-alcoholic,  Neg  alc 
9  0.4  189  Non-alcoholic,  Neg  alc 
10  0.34  65  Non-alcoholic,  Neg  alc Chapter  Six  Page  161 
11  0.42  211  Non-alcoholic,  Neg  alc 
12  0.4  312  Non-alcoholic,  Neg  alc 
13  0.34  89  Non-alcoholic,  Neg  alc 
14  0.4  150  Non-alcoholic,  Neg  alc 
15  0.32  81  Non-alcoholic,  Neg  alc 
16  0.31  237  Non-alcoholic,  Neg  alc 
17  0.31  88  Non-alcoholic,  Neg  alc 
18  0.31  56  Non-alcoholic,  Neg  alc 
19  0.3  102  Non-alcoholic,  Neg  alc 
20  0.34  112  Non-alcoholic,  Neg  alc 
21  0.34  24  Non-alcoholic,  Neg  alc 
22  0.42  100  Non-alcoholic,  Neg  alc 
23  0.42  185  Non-alcoholic,  Neg  alc 
24  0.4  143  Non-alcoholic,  Neg  alc 
25  0.4  88  Non-alcoholic,  Neg  alc 
26  0.34  9  Non-alcoholic,  Neg  alc 
27  0.35  103  Non-alcoholic,  Neg  alc 
28  0.38  93  Non-alcoholic,  Neg  alc 
29  0.35  285  Non-alcoholic,  Neg  alc 
30  0.4  72  Non-alcoholic,  Neg  alc 
31  0.4  236  Non-alcoholic,  Neg  alc 
32  0.34  84  Non-alcoholic,  Neg  alc 
33  0.33  126  Non-alcoholic,  Neg  alc 
34  0.37  187  Non-alcoholic,  Neg  alc 
35  0.32  24  Non-alcoholic,  Neg  alc 
36  0.31  186  Non-alcoholic,  Neg  alc 
37  1.3  251  Non-alcoholic,  Pos  alc 
38  1.1  256  Non-alcoholic,  Pos  alc 
39  0.6  138  Non-alcoholic,  Pos  alc 
40  0.3  242  Non-alcoholic,  Pos  alc 
41  0.4  509  Non-alcoholic,  Pos  alc 
42  1.5  123  Non-alcoholic,  Pos  alc 
43  0.49  509  Non-alcoholic,  Pos  alc 
44  0.4  177  Non-alcoholic,  Pos  alc 
45  0.4  310  Non-alcoholic,  Pos  alc Chapter  Six  Page  162 
46  0.5  182  Non-alcoholic,  Pos  alc 
47  0.4  145  Non-alcoholic,  Pos  alc 
48  0.3  210  Non-alcoholic,  Pos  alc 
49  0.63  161  Non-alcoholic,  Pos  alc 
50  0.36  44  Non-alcoholic,  Pos  alc 
51  0.38  75  Non-alcoholic,  Pos  alc 
52  0.34  55  Non-alcoholic,  Pos  alc 
53  0.38  98  Non-alcoholic,  Pos  alc 
54  0.4  132  Non-alcoholic,  Pos  alc 
55  0.31  216  Non-alcoholic,  Pos  alc 
56  0.39  131  Non-alcoholic,  Pos  alc 
57  0.37  186  Non-alcoholic,  Pos  alc 
58  0.4  216  Non-alcoholic,  Pos  alc 
59  0.36  147  Non-alcoholic,  Pos  alc 
60  0.35  144  Non-alcoholic,  Pos  alc 
61  0.39  226  Non-alcoholic,  Pos  alc 
62  0.31  34  Non-alcoholic,  Pos  alc 
63  0.4  216  Non-alcoholic,  Pos  alc 
64  0.36  40  Non-alcoholic,  Pos  ale 
65  0.35  86  Non-alcoholic,  Pos  alc 
66  0.38  83  Non-alcoholic,  Pos  alc 
67  0.37  172  Alcoholic,  Low  alc 
68  0.37  218  Alcoholic,  Low  alc 
69  0.39  411  Alcoholic,  Low  alc 
70  0.35  53  Alcoholic,  Low  alc 
71  0.76  243  Alcoholic,  Low  alc 
72  0.4  103  Alcoholic,  Low  alc 
73  0.3  91  Alcoholic,  Low  alc 
74  0.4  54  Alcoholic,  Low  alc 
75  0.4  253  Alcoholic,  Low  alc 
76  0.38  348  Alcoholic,  Low  alc 
77  1.5  123  Alcoholic,  Low  alc 
78  0.35  123  Alcoholic,  Low  alc 
79  0.35  118  Alcoholic,  Low  alc 
80  2.2  118  Alcoholic,  High  alc Chapter  Six  Page  163 
81  4.2  169  Alcoholic,  High  alc 
82  5.7  97  Alcoholic,  High  alc 
83  3.5  172  Alcoholic,  High  alc 
84  0.87  255  Alcoholic,  High  alc 
85  0.49  190  Alcoholic,  High  alc 
86  7.15  137  Alcoholic,  High  alc 
87  0.36  186  Alcoholic,  High  alc 
88  0.37  38.2  Alcoholic,  High  alc 
89  6.4  76.9  Alcoholic,  High  alc 
Analyses  of  the  data  for  these  cases  was  carried  out  by  regression  analysis,  looking  for  any 
correlation  between  blood  alcohol  and  either  BHB  or  GHB  or  between  BHB  and  GHB,  and 
also  using  the  Student's  t-test  to  test  for  the  occurrence  of  any  significant  differences 
between  the  four  groups  (two-tailed  test,  unequal  variance).  No  significant  correlations 
were  found  between  alcohol  concentration  and  either  BHB  or  GHB  concentration  in  blood 
or  between  BHB  and  GHB  concentrations  in  blood  (Figure  6-18,  Figure  6-19).  The 
significance  level  did  not  increase  by  selecting  either  alcoholics  or  non-alcoholics  for  this 
analysis. 
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Figure  6-18:  -  Scatter  plot  of  blood  alcohol  concentration  versus  blood  BHB  concentration. Chapter  Six  Page  164 
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Figure  6-19:  -  Scatter  plot  of  blood  alcohol  concentration  versus  blood  GHB  concentration. 
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Figure  6-20:  -  Scatter  plot  of  blood  BHB  concentration  versus  blood  GHB  concentration. Chapter  Six  Page  165 
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Figure  6-21:  -  GHB  and  BHB  combined  with  alcohol 
   GHB 
.  BHB 
By  contrast,  t-test  results  indicated  significant  differences  between  some  of  the  groups 
(Table  6-13  and  6-14).  At  least  in  the  cases  used  for  this  study,  the  alcoholics  group  with 
high  blood  alcohol  concentrations  has  significantly  higher  BHB  concentrations  than  the 
other  groups. 
Table  6-13:  -  Statistical  summary  of  the  four  groups: 
Group  N  BHB  GHB 
Average 
(µ  ml) 
Std  Dev  Average 
(µ  ml) 
Std  Dev 
1  36  0.37  0.131  130  73.6 
2  30  0.48  0.284  174  113 
3  13  0.49  0.324  178  111 
4  10  3.81  2.51  152  57 Chapter  Six  Page  166 
Table  6-14:  -  P-values  from  T-test  comparison  of  the  four  groups: 
BHB 
Group  1  vs  Group  2  0.060 
Group  1  vs  Group  3  0.229 
Group  1  vs  Group  4  0.006* 
Group  2  vs  Group  3  0.912 
Group  2  vs  Group  4  0.007* 
Group  3  vs  Grou  4  0.007* 
GHB 
Group  I  vs  Group  2  0.065 
Group  1  vs  Group  3  0.153 
Group  1  vs  Grou  4  0.363 
Group  2  vs  Group  3  0.920 
Group  2  vs  Grou  4  0.446 
Group  3  vs  Grou  4  0.492 
*  Statistically  significant  (p<O. 
6.5  Discussion 
GHB  and  BHB  were  derivatised  by  silylation  using  BSTFA/TMCS.  In  the  silylation 
process  a  trimethylsilyl  (TMS)  group  replaces  each  active  hydrogen  of  GHB  and  BHB 
creating  one  method  for  determination  of  GHB  and  BHB  by  GC/MS  in  a  single  run[61'  3431 
However,  the  same  internal  standard  and  ion  at  m/z  239  was  used  for  both  GHB  and  BHB 
which  might  reduce  accuracy  and  precision  for  BHB  and  also  the  same  ion  (m/z  233)  was 
used  for  both  BHB  and  GHB,  which  creates  the  potential  for  confusion  or  mistaken 
identity  if  the  retention  time  window  is  not  carefully  monitored. 
The  fragmentation  and  derivatisation  of  GHB  and  BHB  are  very  similar  (Figure  6-17), 
because  BHB  has  a  similar  structure  to  GHB.  The  retention  times  of  GHB  and  BHB  were 
4.78,4.13,  respectively.  The  quantification  ions  were  m/z  233  and  239  for  the  analytes 
GHB  and  BHB  and  Internal  standard,  respectively.  The  base  peak  at  m/z  147  cannot  be 
used  because  the  ion  appears  as  a  fragment  in  the  mass  spectrum  of  both  the  drug  and  the 
internal  standard.  In  addition,  this  ion  is  considered  non-selective,  because  it  contains  only 
parts  of  the  derivative  molecule  coming  from  the  derivatising  reagent. Chapter  Six  Page  167 
It  has  been  discussed  previously  (section  6.1  and  6.2)  that  GHB  and  BHB  are  naturally 
produced  in  the  body  in  small  quantities.  The  human  body  produces  BHB  in  times  of 
starvation,  or  if  the  individual  is  a  diabetic  in  order  to  produce  energy  in  place  of  glucose. 
Another  theory  proposes  that  there  is  a  relationship  between  alcohol  and  BHB 
concentrations.  Table  6-12  shows  four  classification  groups  for  alcohol  levels.  These 
involve  non-alcoholic  subjects  with  negative  and  positive  alcohol  concentrations  and 
alcoholic  subjects  with  low  or  high  alcohol  concentrations.  It  was  noted  that  when  alcohol 
levels  were  high,  the  BHB  levels  were  also  high.  When  BHB  levels  are  high,  there  is  some 
indication  that  GHB  levels  are  affected,  in  that  the  higher  the  BHB  levels,  the  lower  the 
GHB  levels.  However  this  did  not  reach  statistical  significance.  [343,3441 
6.6  Conclusion 
In  the  method  developed,  SPE  was  used  to  extract  both  GHB  and  BHB  from  blood 
samples,  followed  by  BSTFA  /TMCS  derivatisation  and  then  1µl  in  GC/MS.  This  method 
was  effective  and  was  found  to  be  a  simple,  fast  and  sensitive  procedure  for  determination 
of  GHB  and  BHB.  The  silylation  derivatisation  method  with  microwave  was  carried  out 
and  improved  the  chromatography.  There  is  a  relationship  between  alcohol  level  and  BHB 
concentration  in  the  body.  Where  the  alcohol  level  becomes  high  the  BHB  will  also  be 
high.  In  non-alcoholics  with  either  positive  or  negative  alcohol  levels  the  concentration  of 
BHB  was  less  than  1.  Smg/ml.  However,  with  high  alcohol  levels,  the  BHB  concentration 
was  more  than  0.49  mg/ml.  There  is  some  evidence  for  a  relationship  between  GHB  and 
BHB  where  each  concentration  affects  the  other,  but  in  a  normal  situation  the  body  keeps 
the  balance  by  controlling  the  production  mechanism. Chapter  Seven  Page  168 
7  Benzodiazepines 
7.1  Introduction 
Benzodiazepines,  sometimes  called  "benzos",  are  based  on  the  fusion  of  a  benzene  ring 
and  a  7-membered  diazepine  ring.  They  are  believed  to  act  on  the  gamma-aminobutyric 
acid  (GABA)  receptor  GABAA.  Receptors  for  benzodiazepines  are  located  throughout  the 
central  nervous  system,  including  the  cerebral  cortex,  cerebellum,  hippocampus,  striatum 
and  spinal  cord,  so  benzodiazepines  offer  a  clinical  therapy  of  primary  importance  in 
treating  neurological  disorders  such  as  anxiety,  sleep  disturbance,  muscle  spasms  and 
cp11epSi  163-165,176,177,345-3481 
(3a91  drugs. 
The  benzodiazepines  are  a  particularly  large  family  of 
They  can  be  taken  orally  or,  when  abused,  oral  formulations  can  be  ground  up  for 
injection.  They  are  used  as  anticonvulsants,  anxiolytics,  hypnotics  or  muscle  relaxants 
with  different  durations  of  action  114S].  Since  Sternbach  synthesised  the  first  benzodiazepine 
in  1955  by  an  unexpected  ring  extension  of  a  quinazoline-3-N-oxide  derivative,  a  number 
of  structurally  similar  compounds  have  been  marketed  by  drug  companies. 
Chlordiazepoxide  was  the  first  medical  benzodiazepine,  introduced  in  1961  and  followed 
in  1963  by  diazepam  and  in  1965  by  oxazepam.  More  than  fifty  of  these  drugs  are 
presently  marketed  for  clinical  use  throughout  the  world.  Thirty-five  are  subject  to 
international  control  under  the  1970  United  Nations  Convention  on  Psychotropic 
Substances.  The  most  significant  benzodiazepines  in  the  last  decade  have  been  diazepam, 
lorazepam,  alprazolam,  temazepam,  chlordiazepoxide  and  lormetazepam 
Benzodiazepines  are  strongly  associated  with  opioid  users  and  with  drug-related  deaths, 
and  are  one  of  the  main  drug  classes  found  in  poisoning-related  hospital  admissions. 
These  drugs  are  frequently  encountered  in  clinical  and  forensic  toxicology  and  they  have 
featured  in  an  increasing  number  of  misuse  situations  over  the  past  years  [146,1821 
Large  doses  are  rarely  fatal  unless  other  drugs  are  taken  concomitantly,  because  of  their 
relative  safety.  Benzodiazepines  and  benzodiazepine-like  substances  such  as  zopiclone 
are  frequently  abused.  Analysis  of  benzodiazepines,  their  active  metabolites  and 
benzodiazepine-like  substances  in  blood  samples  may  be  indicated  in  many  forensic  cases 
such  as  driving  under  the  influence  of  drugs,  cases  of  date  rape  or  violent  crime  and  cases 
in  which  the  cause  of  death  is  unknown.  These  include  the  1,4-benzodiazepines  such  as Chapter  Seven  Page  169 
diazepam,  temazepam  and  oxazepam  and  the  often  more  potent,  diazolo-  and  triazolo  - 
groups  represented  by  alprazolam,  midazolam,  triazolam.  In  high  doses  benzodiazepines 
can  cause  persons  to  exhibit  classical  features  of  central  nervous  system  (CNS)  depressant 
drugs  such  as  nystagmus,  ataxia,  slurred  speech  and  impaired  divided  attention  skills[178, 
179,350J 
Benzodiazepine  abuse  is  a  large  problem  in  poly  drug  users.  They  are  often  used  to  reduce 
anxiety,  help  sleep  or  counter  the  negative  effects  of  other  drugs.  They  are  addictive  and 
can  cause  significant  withdrawal  symptoms.  Short  term  prescribing  of  benzodiazepines 
may  have  some  benefit  in  supporting  drug  users  to  control  their  intake  of  other  drugs  when 
first  coming  into  treatment  and  to  stabilise  their  lives[161'  179]  Consequently,  toxicologists 
need  to  be  able  to  detect  these  drugs  in  biological  specimens  and  to  understand  their 
toxicology.  The  most  commonly  encountered  benzodiazepines  are  diazepam  and  its  three 
metabolites  N-desmethyldiazepam,  temazepam  and  oxazepam.  The  derivatisation 
procedure  for  each  of  these  drugs  with  three  different  reagents  was  investigated. 
7.2  Chemistry 
Benzodiazepines  (Figure  7-1)  are  based  on  the  fusion  of  a  benzene  ring  with  the  diazepine 
ring.  The  subsequent  molecule  as  a  benzodiazepine  is  characterized  by  two  nitrogen  atoms 
on  the  diazepine  ring.  These  nitrogen  atoms  are  usually  in  the  1  and  4  positions  of  the  ring, 
according  to  the  numbering  convention  of  atoms  around  the  molecule.  Differences  in  the 
benzodiazepines  are  based  on  the  presence  of  additional  substituents  at  the  1,2,3,5  and  7 
positions  of  the  molecule  (refer  to  Table7-1).  Variations  in  these  substituents  lead  to  a 
change  in  their  pharmacological  potencies  and  efficacies,  variations  in  the  physiochemical 
properties  and  of  course  variations  in  the  ring.  1105J  A  number  of  modifications  in  the 
benzodiazepine  ring  structure  have  resulted  in  a  number  of  new  compounds  with  similar 
pharmacological  activities,  but  differences  in  lipophilicity,  basicity  and  chemical  reactivity. 
These  differences  are  also  responsible  for  the  different  response  of  benzodiazepines  to 
analytical  methods  (Figure  7-2)[35". Chapter  Seven 
Figure  7-1:  -  General  benzodiazepine  structure 
Table  7-1:  -  Chemical  structures  of  selected  1,4-benzodiazepines 
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Benzodiazepine  Trade  name  R,  R2  R3  R4  R5 
Diazepam  Valium  -CH3  -H  -H  -H  -CI 
Nordiazepam  Calmday  -H  -H  -H  -H  -CI 
Temazepam  Restoril, 
Levanxol 
-CH3  -H  -OH  -H  -CI 
Oxazepam  Adumbran, 
Praxiten 
-H  -H  -OH  -H  -CL 
Clonazepam  Ritrovil  -H  -H  -H  -CI  -NO2 
Flunitrazepam  Rohypnol  -CH3  -H  -H  -F  -NO2 
Nitrazepam  Mogadon  -H  -H  -H  -H  -NO2 Chapter  Seven  Page  171 
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Figure  7-2:  -  Structures  of  some  benzodiazepines 
7.3  Pharmacokinetics  of  benzodiazepines 
OH 
LORMETAZEPAM 
Benzodiazepines  have  important  pharmacokinetic  differences  with  respect  to  speed  of 
onset  and  duration  of  action  and  all  benzodiazepines  are  metabolized  in  the  liver  through 
oxidation,  glucuronidation,  or  nitrogen  reduction  and  are  eliminated  by  the  kidneys.  The 
rate  of  onset  of  action  depends  on  the  mode  of  administration,  the  dissolution  of  the 
formulation,  the  rapidity  of  absorption,  and  the  rate  of  entry  into  the  brain.  Diazepam  is 
rapidly  absorbed  after  oral  use  and  enters  the  brain  quickly  thus  promptly  relieving  anxiety. 
Given  intravenously,  it  can  rapidly  stop  repeated  epileptic  seizures.  N-Desmethyldiazepam 
is  absorbed  more  slowly  than  diazepam.  Oxazepam  is  quite  slowly  absorbed  and  takes 
some  time  to  penetrate  the  brain.  Lorazepam  is  also  slow  to  enter  the  brain  but  it  can  be 
used  intravenously  to  sedate  during  investigative  or  minor  surgical  procedure. 
The  hepatic  metabolism  of  drugs  can  be  phase  I,  mainly  oxidation  and  de-alkylation,  and 
phase  H,  conjugation  to  form  glucuronides,  and  sulfates  compounds.  Benzodiazepines  can 
undergo  both  phase  I  and  phase  II  metabolism  (diazepam,  chordiazepoxide  and Chapter  Seven  Page  172 
flurazepam)  or  phase  II  alone  (lorazepam,  oxazepam,  and  temazepam).  Drugs  metabolized 
via  phase  II  processes  alone  are  better  tolerated  than  phase  I-  phase  II  drugs  by  patients 
such  as  alcoholics  with  liver  impairment.  In  addition,  phase  I  metabolism  slows  with  age 
so  that  the  elderly  are  more  likely  to  suffer  adverse  effects  when  taking  phase  I-  phase  II 
drugs  than  phase  II  only  drugs.  The  elimination  half  lives  of  benzodiazepines  vary  greatly, 
and  usually  lengthen  in  the  aged  patient  for  two  essential  reasons:  firstly,  the  volume  of 
distribution  is  increased  and  secondly,  the  clearance  rate  is  decreased.  N- 
desmethyldiazepam  (nordiazepam)  is  the  major  active  metabolite  of  diazepam  (Figure  7-3) 
It  has  a  prolonged  half-life,  over  100  hours,  consequently  it  accumulates  over  the  first 
month  of  treatment,  reaching  higher  plasma  concentrations  than  the  parent  compound, 
diazepam.  N-desmethyldiazepam  is  also  the  major  metabolite  of  clorazepate,  prazepam, 
ketazolam,  halazepam,  medazepam  and  to  some  extent  chlordiazepoxide.  In  contrast  to 
these  long-lasting  drugs,  lorazepam,  oxazepam,  temazepam  and  lormetazepam  have  half- 
lives  of  about  6-24  hours.  As  the  body  eliminates  much  of  each  dose  between  each 
administration,  these  compounds  are  suitable  for  acute,  short-lived  anxieties,  fluctuating 
levels  of  anxiety,  and  for  insomnia  (Table  7-2) 
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Figure  7-3:  -  Metabolic  pathway  of  diazepam Chapter  Seven  Page  173 
Table  7-2:  -  Pharmacokinetic  data  of  some  of  benzodiazepines  of  interest 
Benzodiazepine 
(MW) 
Half- 
life(h) 
Key  active 
metabolite 
pKa  Vd  (LJkg)  Protein 
binding 
(%) 
Diazepam  (284)  20-50  Nordiazepam  3.4  0.7-2.6  98 
Nordiazepam  (270)  50-99  Oxazepam  3.5,12.0  -  97 
Oxazepam  (286)  4-15  None  1.7,11.6  0.7-1.6  97 
Temazepam  (300)  5-15  Oxazepam  1.3  0.8-1.0  96 
7.4  Methods  of  analysis  of  benzodiazepines:  previous 
work 
A  large  number  of  papers  have  been  published  on  methods  of  analysis  of  benzodiazepines. 
HPLC  methods  and  more  recently  LC-MS  based  methods  have  generally  been  preferred 
because  of  chromatography  problems  in  GC  based  methods.  Benzodiazepines  have 
nevertheless  been  analysed  by  GC/MS.  J236,352,3531  Several  papers  describe  methods  for 
diazepam  and  its  metabolites.  Some  of  these  papers  discuss  analysis  of  whole  blood 
samples  and  others  the  analysis  of  hair  using  liquid  -  liquid  or  solid  phase  extraction.  [354] 
One  paper  describes  derivatisation  using  a  silylating  reagent  such  MTBSTFA,  MSTFA  or 
BSTFA  containing  1%  TMCS.  The  target  range  concentrations  were  25-6000  ng/ml  of 
diazepam  and  oxazepam  when  analysed  as  TBDMS  derivatives.  [236] 
7.5  Aims 
As  explained  in  previous  chapters,  chemical  derivatisation  is  very  useful  for  modifying 
compounds  to  produce  a  new  compound  which  is  suitable  for  analysis  using  GC/MS. 
Benzodiazepines  are  a  very  important  class  of  drug  to  analyse,  therefore  when  analysing  by 
GC-MS  the  best  derivatising  reagent  needs  to  be  assessed  and  an  evaluation  made  of Chapter  Seven  Page  174 
microwave  assisted  derivatisation.  However,  as  mentioned  above,  GC-MS  has  not  been 
successfully  applied  to  benzodiazepine  analysis  because  many  of  them  are  thermally 
unstable  and  do  not  chromatograph  well  by  gas  chromatographic-based  techniques.  For 
this  reason,  derivatisation  procedures  mentioned  in  Chapter  5  were  applied  to  the  most 
frequently-encountered  benzodiazepines  in  the  UK,  diazepam  and  its  three  metabolites  and 
this  pilot  study  was  aimed  at  an  initial  investigation  of  derivatisation  methods  which  might 
extend  the  range  of  benzodiazepines  which  could  be  analysed  by  GC-MS.  As  before,  these 
compounds  were  used  as  model  substances  as  an  indicator  of  the  applicability  of  the 
derivatisation  methods  to  benzodiazepine  screening  by  GC-MS  within  a  general  STA 
procedure.  Diazepam  itself  has  no  available  derivatisation  sites  but  was  included  to  assess 
whether  the  derivatisation  conditions  would  result  in  molecular  changes  to  the  parent 
substances. 
7.6  Derivatisation  procedures 
7.6.1  Reagents 
Refer  to  Chapter  4  and  5 
7.6.2  Drug  standards  and  internal  standards 
The  drug  standards  and  internal  standards  used  were  diazepam,  diazepam-d5,  N- 
desmethyldiazepam,  nordiazepam-ds,  temazepam,  temazepam-ds  oxazepam,  and 
oxazepam-d5.  Stock  standard  solutions  were  obtained  at  a  concentration  of  100gg/ml  in 
methanol,  supplied  by  Cerilliant. 
7.6.3  Preparation  of  drug  mixtures  and  internal  standard 
solutions 
A  mixed  drug  solution  containing  a  concentration  of  1  µg/mL  of  each  drug  was  prepared 
by  taking  100µl  of  lOOpgImL  solution  and  making  up  to  lOmL  with  methanol.  The 
internal  standard  solution  was  prepared  similarly  using  the  deuterated  standards. Chapter  Seven  Page  175 
7.6.4  Method  and  Results 
Preparation  of  buffers  and  spiked  standards,  and  extraction,  instrumentation  and 
derivatisation  procedures  were  the  same  as  in  Chapter  4  and  5.  The  chromatograms  and 
mass  spectra  of  the  test  compounds  are  given  in  Figures  7-  4  to  7-9  and  the  fragmentation 
reactions  of  some  derivatives  are  given  in  Figures  7-10  to  7-14. 
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7.6.5  Discussion 
+ 
This  study  was  aimed  at  giving  some  information  about  GC-MS  behaviour  of  diazepam 
and  its  metabolites  with  three  derivatising  reagents.  These  reactions  were  conducted  under 
the  same  GC-MS  conditions  and  derivatisation  methods  and  extraction  already  mentioned 
in  Chapters  4  and  5.  Table  7-3  shows  the  retention  times  and  ions  selected  to  identify  the 
derivatised  benzodiazepines. 
The  solid  phase  extraction  (SPE)  required  fewer  steps  and  worked  with  acidic  and  basic 
drugs,  which  are  especially  suitable  for  forensic  laboratories.  The  SPE  cartridge  called 
StrataTMX  employs  a  novel  surface  chemistry  in  the  sorbent,  offering  significant 
advantages  over  the  traditional  silica-based  SPE  products. 
Generally,  temazepam  and  oxazepam  reacted  with  PFPA  and  MTBSTFA.  The  molecular 
ions  for  temazepam  PFP  and  TBDMCS  were  m/z  446  and  m/z  414  respectively.  The  ions 
and  fragmentation  patterns  with  PFP-OH  and  TMS-diazomethane  were  the  same  because 
the  same  reaction  had  occurred  with  both  reagents.  These  ions  gave  fragmentation  patterns 
as  shown  in  Figure  7-10  and 
Figure  7-11.  Temazepam  derivatives  had  base  peaks  at  m/z  271  and  m/z  357  which  were 
assigned  to  the  fragments  [C15H12N2C1O]'  and  [C20H22N2C1O2]  +,  using  PFP  and 
TBDMCS,  respectively.  Oxazepam  has  two  different  functional  groups  (-OH)  and  (-NH) Chapter  Seven  Page  186 
so  during  derivatisation  the  protons  in  these  groups  were  replaced  by  (C3F50)  and 
(SiC(CH3)5)  respectively.  The  molecular  ions  for  oxazepam  PFP  and  TBDMCS  were  at 
m/z  578  and  m/z  514  and  the  fragmentation  patterns  are  shown  in  Figure  7-12  and  Figure 
7-13.  The  base  peaks  at  m/z  472  and  m/z  457  were  as  signed  to  the  fragment 
[C2oH7F7N204]  +  and  [C25H34SiC1O2N2]  +,  respectively.  The  molecular  ion  for  nordiazepam 
(desmethyldiazepam)  with  MTBSTFA  was  at  m/z  384  and  the  fragmentation  pattern  is 
shown  in  (Figure  7-14).  It  has  a  base  peak  at  m/z  327,  assigned  to  the  fragment  [C16H12Si 
CLO2N2]  +.  The  PFP  and  MTBSTFA  (TBDMCS)  derivatives  of  temazepam  by  loss  of 
(C3F502)  and  (SiC  (CH3)50)  consecutively  share  the  ion  at  m/z  283. 
Table  7-3:  -  Retention  times  and  selected  ion  data  for  diazepam  and  its  metabolites  with 
different  derivatising  reagents 
Compound  Active  group  Reagent  Retention  Time 
(min) 
Ions 
monitored 
Diazepam  -  PFPA-PFP-OH  14.13  256,283,284 
Nordiazepam  -NH-  PFPA-PFP-OH  - 
Oxazepam  -NH-,  -OH-  PFPA-PFP-OH  14.71  472,473,232 
Temazepam  -OH-  PFPA-PFP-OH  14.43  271,282,283 
Diazepam  -  PFPA-TMS  14.13  256,283,284 
Nordiazepam  -NH-  PFPA-TMS  -  - 
Oxazepam  -NH-,  -OH-  PFPA-TMS  14.78  472,473,232 
Temazepam  -OH-  PFPA-TMS  14.78  271,282,283 
Diazepam  -  MTBSTFA  14.13  256,283,284 
Nordiazepam  -NH-  MTBSTFA  16.43  327,328,329 
Oxazepam  -NH-,  -OH-  MTBSTFA  16.25  457,459,383 
Temazepam  -OH-  MTBSTFA  17.82  357,385,283 
-=  underivatived 
As  expected,  diazepam  did  not  react  with  any  of  the  derivatising  reagents  nor  was  it 
affected  structurally  by  any  of  them.  The  mass  spectrum  in  Figure  7-9  is  given  as  one Chapter  Seven  Page  187 
example  of  the  reaction  product,  in  this  case,  with  PFP-PFP-OH  reagent,  which  is  the  mass 
spectrum  of  unchanged  diazepam. 
The  acylation  derivatisation  reagent  used  for  diazepam  and  its  three  metabolites  is  one  of 
the  most  commonly  used  acylation  reagents.  This  reagent  reacts  with  alcohols,  amines  and 
phenols  to  produce  derivatives  with  good  chromatographic  peak  shapes.  Nordiazepam  was 
the  exception  and  did  not  work  as  well  with  this  reagent,  most  likely  because  of  the 
secondary  amine  group.  However,  temazepam  and  oxazepam  both  gave  derivatives.  The 
spectrum  of  temazepam-PFP  derivative  has  a  base  peak  corresponding  to  loss  of  the 
derivatised  hydroxyl  group.  There  is  no  clear  interpretation  of  the  mass  spectrum  of 
oxazepam  bis-PFP  derivative  and  the  proposed  fragmentation  pathway  in  Figure  7-12  is 
tentative. 
The  methylation  (esterification)  reagent  only  reacts  with  carboxylic  acid  (-COOH)  groups 
and  was  not  expected  to  react  with  any  of  the  benzodiazepines,  which  was  confirmed 
experimentally.  However,  it  was  important  to  evaluate  this  reagent  with  these  common 
benzodiazepine  structures  because  the  diazepine  ring  could  in  theory  open  and  react  with 
the  derivatising  agents.  This  mixture  produced  good  peak  shapes  for  all  drugs  except  for 
oxazepam  which  can  be  explained  by  the  presence  of  secondary  amine  groups.  As 
expected,  desmethyldiazepam  did  not  react  with  the  acylating  reagent  in  this  mixture 
either,  also  as  a  result  of  the  secondary  amine  group. 
MTBSTFA  reagent  had  enhanced  reactivity  as  a  result  of  its  ability  to  silylate  carboxyls, 
hydroxyls,  thiols  and  primary  and  secondary  amines;  hence  it  reacted  with  diazepam  and 
its  three  metabolites  and  improved  the  chromatography.  The  mass  spectra  showed  the 
expected  M-57  ions  due  to  loss  of  the  tertiary  butyl  group,  and  this  reaction  produced  the 
base  peak  in  the  mass  spectrum  of  desmethyldiazepam.  [236] 
7.7  Conclusion 
Derivatisation  procedures  with  three  different  reagents  for  some  common  benzodiazepines, 
including  temazepam,  oxazepam,  diazepam  and  nordiazepam,  were  investigated.  The 
extraction  of  diazepam  and  its  three  metabolites  in  blood  is  presented.  These  drugs  have 
different  functional  groups  such  as  NH  and  OH,  so  generally  the  best  derivatisation  method 
suitable  for  these  functional  groups  used  acylation  or  silylation  reagents.  PFPA-PFP-OH Chapter  Seven  Page  188 
and  PFPA-  TMS  did  not  work  with  nordiazepam,  but  MTBSTFA  did  however  work  well 
with  nordiazepam.  Overall,  the  silylation  derivatisation  method  gave  the  best  sensitivity 
and  most  improved  chromatography  for  all  analytes.  During  the  course  of  the  work  for  this 
study,  a  literature  publication  appeared  for  the  analysis  of  benzodiazepines  in  biological 
samples  based  on  the  methyl-tertiary-butylsilyl  derivative.  The  results  of  this  study  were 
similar  to  those  obtained  in  the  present  work  except  that  different  retention  times  were 
obtained  for  the  derivatives.  [2361  As  mentioned  earlier  in  Section  4.2.2,  the  authors  of  that 
study  found  the  derivatives  to  be  reliable,  sensitive  and  reproducible  for  the  analysis  of 
benzodiazepines  in  biological  samples. Chapter  Eight  Page  189 
8  Conclusions  and  Further  Work 
8.1  Conclusions 
The  use  of  blood  in  forensic  toxicology  was  investigated  by  developing  a  reliable  method 
of  derivatisation  for  multiple  drugs  based  on  the  model  compounds  amphetamine, 
methamphetamine,  morphine,  benzoylecgonine,  THC-OH  and  THC-COOH,  GHB,  BHB, 
and  some  commonly-encountered  benzodiazepines. 
The  aim  of  this  project  was  to  develop  a  suitable  analytical  method  for  the  qualitative  and 
quantitative  analysis  of  drugs  in  blood  using  derivatisation  prior  to  gas  chromatography- 
mass  spectrometry.  Derivatisation  is  very  important  for  modifying  a  compound  to  produce 
a  new  substance  which  has  different  properties  from  the  original  compound  and  which  is 
suitable  for  GC-MS.  Different  derivatisation  reagents  and  procedures  were  investigated 
with  the  various  analytes  mentioned  earlier.  Prior  to  derivatisation  a  simple  and  rapid  solid 
phase  extraction  was  developed  using  a  novel  mixed-mode  sorbent.  This  extraction 
procedure  was  used  for  both  acidic  and  basic  drugs. 
The  first  part  of  the  study  was  the  investigation  of  different  derivatising  reagents  including 
PFPA  plus  PFP-OH,  PFPA-TMS  and  MTBSTFA  with  different  drugs  of  abuse.  These 
were  analysed  by  gas  chromatography-mass  spectrometry.  The  method  gave  good 
recoveries  for  the  target  drugs  and  the  method  validation  parameters  were  acceptable. 
The  second  part  of  the  study  concerned  a  particular  application  of  derivatisation  reactions 
and  was  the  investigation  of  the  analysis  in  autopsy  blood  of  GHB  and  BHB,  which  are 
both  endogenous  to  the  human  body.  A  small  amount  of  blood  (0.2mL)  was  used  with  the 
solid  phase  extraction  procedure  developed  earlier.  The  extraction  was  found  to  be  simple, 
efficient,  robust,  clean  and  fast.  The  derivatising  reagent  which  gave  the  best  results  was 
silylation  by  BSTFA  with  TMCS  as  catalyst.  This  reagent  showed  excellent  solubility  and 
derivatised  faster  and  more  completely  than  any  other  reagent.  The  SPE  procedure  worked 
very  well  with  BHB,  with  recoveries  shown  in  Table  6-8.  The  method  was  simple  and 
efficient;  recoveries  were  good  resulting  in  a  very  sensitive  procedure  for  qualitative  and 
quantitative  analysis. Chapter  Eight  Page  190 
Finally  a  derivatisation  procedure  for  benzodiazepines  was  investigated.  Benzodiazepines 
as  a  class  encompass  a  wide  variety  of  drugs  and  therefore  it  is  a  very  important  class  of 
drug  for  analysis.  Different  derivatisation  procedures  were  applied  to  diazepam  and  its 
three  metabolites,  nordiazepam,  temazepam  and  oxazepam.  These  compounds  have 
different  functional  groups  and  by  using  different  reagents  with  them  the  best 
fragmentation  patterns  produced  from  each  analyte  and  those  which  gave  the  most 
sensitivity  were  found.  Some  of  these  reagents  did  not  work  with  analytes,  for  example, 
nordiazepam  did  not  react  with  PFPA-PFP-OH  or  PFPA-TMS  but  worked  well  with 
MTBSTFA.  Silylation  with  BSTFA  containing  TMCS  gave  the  best  sensitivity  and 
chromatography. 
Generally,  when  more  information  is  obtained  about  an  unknown  sample  this  will  help  to 
select  the  best  and  most  suitable  derivatisation  reagent  for  the  target  drugs  because 
different  classes  and  function  groups  have  different  requirements.  GC-MS  parameters  are 
very  important  to  obtain  stable,  reproducible  sensitivity  during  analyses.  Selection  of  an 
SPE  cartridge  suitable  for  volume  of  samples  is  also  important  to  avoid  loss  of  any  sample 
during  the  extraction  step. 
8.2  Further  work 
This  study  has  worked  well  with  blood  analysis  including  many  of  drugs  of  abuse,  but 
there  are  still  many  aspects  of  analysis  of  blood  which  have  not  yet  been  done.  There  are 
many  drugs  included  in  the  benzodiazepine  group  and  more  investigation  into  the 
relationship  with  derivatisation  reagents  is  still  needed.  Also,  the  derivatisation  chemistry 
used  is  very  important  in  obtaining  clean,  quantitative,  reactions  and  the  selection  of 
suitable  reagents  for  use  with  different  types  of  drug  needs  further  investigation,  especially 
with  respect  to  drugs  containing  a  wider  range  of  functional  group  types. 
The  derivatisation  and  extraction  procedures  developed  here  could  be  applied  to  other 
sample  matrices,  including  urine,  hair  or  nail.  The  investigation  into  the  use  of  alternative 
catalysts  may  help  to  analyse  a  wider  range  of  drugs. Chapter  Nine  Page  191 
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Appendix  1:  Publication  in  support  of  this  thesis 
COMPARISON  OF  CIIEIIIICAL  DERIVATIVES  FOR  SYSTEMATIC 
TOXICOLOGICAL  ANALYSIS  OF  AUTOPSY  BLOOD  USING  GAS 
CHROMATOGRAPHY  -  MASS  SPECTROMETRY 
Tareq  AL-Ahmadi  (") 
, 
R.  A.  Anderson 
Forensic  Medicine  and  Science,  University  of  Glasgow,  Glasgow  G12  8QQ,  UK. 
Abstract 
Aims:  Different  derivatisation  techniques  have  been  developed  for  drug  analysis  in  whole 
blood  using  GC-MS.  The  method  was  validated  for  six  drugs  of  abuse  and  their 
metabolites. 
Method:  A  mixed  standard  stock  solution  was  prepared  to  give  a  final  concentration  of 
I  gg/ml  for  each  analyte  and  this  was  used  to  spike  whole  blood.  Solid  phase  extraction 
(SPE)  was  carried  out  using  the  polymeric  phase  Phenomenex  Strat-X  (60  mg/3ml 
cartridges  containing  33µm  particles).  Blank  blood  (iml)  was  mixed  with  internal 
standard  solution  and  different  concentrations  of  mixed  standard  stock  solution,  and 
phosphate  buffer  (pH  6,3.5ml).  This  was  centrifuged  for  10  minutes  and  transferred  to 
SPE  columns.  The  extracts,  in  methanol,  were  evaporated  to  dryness  and  derivatised 
using  three  different  methods:  (a)  acylation-esterification  with  PFPA/  PFP-OH  (2:  1  v/v, 
150  µl);  (b)  acylation-methylation  with  PFPA/  trimethylsilyldiazomethane  (TMS)  (5:  1 
v/v,  120  µl);  (c)  silylation  with  MTBSTFA  containing  1%  TBDMSCI  (30  µl).  Reaction 
vials  were  heated  with  a  microwave  oven  for  one  minute.  After  derivatisation,  vials  for 
methods  (a)  and  (b)  were  cooled  to  room  temperature  and  evaporated  to  dryness  under  a 
stream  of  nitrogen.  The  derivatised  extracts  were  reconstituted  in  50µl  of  ethyl  acetate 
prior  to  analysis  by  GC-MS.  Extracts  derivatised  by  method  (c)  were  analysed  directly. 
A  Thermo-Finnigan  Trace  GC-MS  instrument  was  used  in  selected  ion  monitoring  (SIM) 
mode  except  method  (c)  which  used  full  scan  mode.  The  GC  was  equipped  with  an  HP5 
column  (30m  x  0.32  mm  x  0.25µm)  from  J&W  scientific  and  split/splitless  injection  port 
at  280°C.  The  oven  temperature  was  at  100°C  for  2  min,  programmed  at  12°C/min  to 
300°C.  Ions  monitored  for  quantitative  analysis  were  as  follows  : 
Derivative  Amp  MA  MOR  BZE  THC  THC-COOH 
PFPA/PFP- 
OH  118  204  414  82  417  459 
PFPA/TMS  118  204  414  82  417  489 
MTBSTFA  158  172  341  282  371  515 
The  method  was  subsequently  applied  to  35  forensic  autopsy  case  samples. 
Results:  Recoveries  for  all  drugs  of  interest  were  found  to  be  over  70%.  Limits  of 
detection  (LOD)  were  calculated  as  3  times  the  standard  error  of  the  regression  line  plus 
the  intercept.  LOD's  in  blood  ranged  from  0.4  ng/ml  to  3.7  ng/ml  with  PFPA/PFP-OH, 
0.3ng/ml  to  1.4ng/ml  with  PFPA/TMS  and  with  MTBSTFA  were  from  1.9  ng/ml  to 
7.3  ng/ml.  Limits  of  quantification  (LOQ)  were  calculated  as  10  times  the  standard  error. 
They  were  12.4  ng  /ml  with  PFPA/PFP-OH,  :!  4.7  ng/ml  with  PFPA/TMS  and  19.8 
ng/ml  with  MTBSTFA  of  blood.  The  case  samples  analysed  were  found  to  contain 
various  drugs  of  abuse  and  prescription  drugs.  The  different  derivatisation  techniques 
gave  varying  results;  however  acylation-methylation  gave  the  best  sensitivity  and 
chromatography. 242 
Conclusion:  A  validated,  sensitive  and  specific  method  for  the  extraction  and 
quantification  of  drugs  abuse  in  blood  is  presented.  An  alternative  derivatisation  method 
(acylation-methylation)  is  proposed  which  gives  better  sensitivity  and  improved 
chromatography  for  detection  and  quantification  of  drugs  of  abuse  compared  to  silylation 
or  acylation  alone. 
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